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ABSTRACT

Phenylbutazone is a non-steroidal anti-inflammatory drug that
acts by inhibiting prostaglandin synthesis.

Prostaglandins are

associated with crucial aspects of reproduction.

In 5 experiments,

mares were used to test the effects of phenylbutazone on
reproduction.

In all experiments, treatment was 2 g phenylbutazone

or 10 ml physiological saline intravenously(control).
In Experiment I, 9 mares were phenylbutazone-treated for 180
consecutive days and teased.

Ovaries were palpated and cyclicity was

verified by circulating progesterone concentrations.
cycles were evaluated.
control groups.

Thirty-six

Mares were then divided into treatment and

Estrous mares were artificially inseminated.

Non-surgical embryo collection was performed 7 to 8 days
post-ovulation.

Three fertilized ova were collected from control

mares and 1 from a treated mare.

Results suggested that

phenylbutazone had no effect on estrual behavior, cyclicity or
ovulation.
In Experiment II, 8 mares were phenylbutazone-treated daily for
33 days.

Blood samples and corresponding uterine secretions were

obtained daily.

Only purulent samples of uterine secretion were

positive for phenylbutazone.
In Experiment III, 7 mares were placed on a switchback,
experimental design, teased daily and cyclicity was verified by
circulating progesterone concentrations.

On day k post-ovulation,

mares were subjected to uterine biopsy and subsequent estrous
behavior was determined by teasing.

xiii

Days from biopsy to induced

estrus for controls and treatment were significantly different
(P<0.025).

Results of Experiments II and III suggested that

phenylbutazone accumulated in inflamed uterine tissue and inhibited
prostaglandin synthesis.
In Experiments IV & V, 14 mares were teased daily.
mares were mated.

Estrous

Treatment started on the first day of estrus and

continued daily until embryo collection on day 10 post-ovulation.
Embryos (blastocysts) were photographed to evaluate morphological
development, incubated in Dulbecco's phosphate-buffered saline and
then homogenized to determine total protein concentrations.
medium was assayed for prostaglandin synthesis.

Culture

There was no

significant difference between embryos recovered from treated or
control mares for total prostaglandin synthesis.
a reduced concentration of PGF <x, PGE
2

treated mares compared with controls.

2

and PGI

2

There was, however,
in embryos from

Embryos from treated mares

were significantly smaller(P<0.05),but contained more total protein
than control embryos.

Treatment did not affect ovulation, fertiliza

tion or embryo viability.

xiv

INTRODUCTION

Phenylbutazone is a non-steroidal anti-inflammatory drug
widely used in equine medicine.

It is used to restore performance in

competitive horses, to relieve musculoskeletal diseases and to
comfort chronically sore horses, such as brood mares.

Its therapeu

tic effectiveness and toxic parameters have been clearly defined
(Tobin, 1979a).

Non-steroidal anti-inflammatory drugs

(1) inhibit

enzymes that act in the synthesis of prostaglandins and therefore
reduce tissue prostaglandins; (2) normally accumulate in stomach,
kidney, small intestines and inflamed tissues; (3) reduce pain, fever
and swelling in inflamed tissues (Tobin, 1979a).
Phenylbutazone has been shown to inhibit both the cyclooxygenase and hydroperoxidase enzyme systems that are necessary for the
synthesis of prostaglandins from arachidonic acid.

Prostaglandins

actively participate in many crucial reproductive processes.

When

the non-toxic effective dose of phenylbutazone (2 g) is injected
intravenously it takes =30 minutes to transverse the blood-brain
barrier, distribute throughout the horse and to begin blockage of
formation of the prostaglandins (Tobin, 1979a).

In previous studies,

it was assumed that phenylbutazone was potentially capable of
entering uterine tissue interrupting prostaglandin synthesis and
altering normal cyclic function of the corpus luteum.

In previous

investigations in this laboratory, researchers administered 2 g
phenylbutazone intravenously to mares for 8 to 21 days, beginning on
day 14 and day 1 of the estrous cycle, respectively.

Results showed

no significant differences in plasma progesterone profiles and
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interestrous intervals between phenylbutazone-treated and physiologi
cal saline-treated mares.
The viable embryo exerts biochemical signals to the maternal
unit that permit development of a histotrophic uterine environment
through the continued secretion of progesterone from the corpus
luteum.

Conceptus secretory proteins play a role in directing the

embryo to synthesize major arachidonic acid metabolites associated
with bovine conceptus viability, development and implantation
(Thatcher et al., 1989).

There are reports that verify production of

prostaglandins by the harvested embryo in many farm and laboratory
animals; however, there are no reports available for similar stage
embryos for the mare.
Researchers have determined that prostaglandin antagonists
administered to various species inhibited ovulation, luteolysis, ovum
transport, blastocyst hatching, embryo implantation, embryo expan
sion, live birth rate and sharply diminished endometrial prostaglan
din concentration and release (see Table 6).

However, there was no

available information on the viability of the equine embryo in the
mare being administered a non-steroidal anti-inflammatory drug.
The experiments undertaken were designed to substantiate
previous observations and to determine if chronic administration of
phenylbutazone significantly alters fertility in mares.

LITERATURE REVIEW

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

Chemical Properties
Non-steroidal anti-inflammatory drugs (NSAID) are all
aromatic-acidic compounds, sometimes referred to as "aspirin-like"
drugs.

These agents can be subdivided by general chemical structure

into several categories:

salicylates or derivatives of pyrazolon,

fenamic acid, indene or arylalkanoic acids.

These agents have, to

some degree, analgesic, antipyretic and anti-inflammatory activities.
They have been employed in the treatment of arthritis, myositis,
tendonitis and other soft-tissue and osseous inflammatory conditions
(Short and Beadle, 1978).
All NSAID are carboxylic acids with a pKa of =4.5, which gives
a very low water solubility (Snow, 1983).

They are usually formulat

ed as sodium salts, especially for parenteral administration.

Sodium

salt formation also increases the speed of absorption following oral
administration.

Their acidic nature favors accumulation in inflamed

tissues (Snow, 1981), which also tend to be acidic (Tobin, 1981b).
The acidic nature of these drugs causes them to be between 95 and 99%
bound to plasma proteins (Tobin, 1981b).

Meclofenamic acid and

naproxen are over 99% bound to plasma proteins (Snow, 1981).
Although the binding is readily reversible, this property limits
NSAID distribution from plasma to other body fluids and tissues and
has important implications in drug detection and therapy (Higgins and
Lees, 1988).

This is important because the non-protein bound or
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free drug is associated with biological activity.

Prior exposure or

concurrent administration of other drugs that are highly protein
bound can, because of competition for binding sites, lead to higher
free levels of either drug (Snow, 1981).

Since these drugs are

plasma protein bound they do not pass into saliva.

Therefore, saliva

testing is not acceptable for detection of NSAID (Tobin, 1981b).
The first NSAID to be synthesized was acetylsalicylic acid
(aspirin) at the end of the 19th Century and it is still the most
frequently used NSAID in humans.

However, it is not popular for use

in the horse because of its short duration of action.

In 1949,

phenylbutazone (the second oldest NSAID) was introduced as a
therapeutic agent for man and has since become the dominant NSAID
used in the horse (Snow, 1981).

Pharmaceutical companies have

synthesized a large number of NSAID that are available to both human
and equine medicine.
Table 1.
horse

A partial list of these agents is presented in

Only 4 are presently employed for extensive use in the

(1) the fenamic acid derivative, meclofenamic acid (Arque]®;

Snow, 1981); (2) the phenylacetic acid derivative, naproxen
(B\

(Equiproxen ; Snow, 1981); (3) the clonixin acid derivative, flunixin
meglumine (Banamine®; Ciofalo, 1977); (4) the pyrazolone derivative,
phenylbutazone (Butazolidin ; Burns, 1953).

The chemical structures

of these 4 popular equine NSAID are presented in Figure 1.

Of these,

phenylbutazone remains the most popular and widely used in equine
medicine (Tobin, 1979a).

Table

1.

Some non-steroidal anti-inflammatory drugs which all
appear to share the same basic mechanism of action as
phenylbutazone and same general pattern of toxicity

Generic

Proprietary Name

Salicylates

Aspirin

Phenylbutazone

Butazolidin

Oxyphenbutazone

Tandearil

Naproxen

Equiproxen

Meclofenamic Acid

Arquel

Flunixin Meglumine

Banamine

Quinine

-

Indomethacin

Indocin

Tolmetin

Tolectin

Niflumic Acid

Nifluril

Ketoprofen

Orudis

Ibuprofen

Motrin

Ibuprofen

Advil

Mefenamic Acid

Ponstel

Adapted from Tobin (1981b)
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COOH

CH3
c h 2 - c h 2 -c h 2 - c h 3

Flunixin (Banamine )
Phenylbutazone (Butazolidin )

CHi

OOH

C— COOH
N

I

H

CH30
Cl
Naproxen (Equiproxen9 )

Meclofenamic Acid (Arquel9 )

Figure 1. Cheaical structure of non-steroidal antiinflaamatory drugs connonly used in equine nedicine
Adapted fron Booth (1982)

Mechanism of Action
The search for a possible mechanism of action of NSAID was
started by Piper and Vane (Vane, 1971).

They discovered that lungs

could release a previously undetected substance that they called
"rabbit aorta contracting substance".

When isolated perfused lungs

of sensitized guinea-pigs were challenged, rabbit aorta contracting
substance, histamine, slow reacting substance in anaphylaxis,
prostaglandin E

2

and

were released.

The release of rabbit aorta

contracting substance, which could also be provoked by bradykinin and
slow reacting substance in anaphylaxis, was antagonized by aspirin
like drugs, as was the evoked broncho-constriction.

Results of their

experiments suggested that rabbit aorta contracting substance was a
prostaglandin or had a structure intermediate between the prostaglan
din precursor arachidonic acid and PGE

2

or PGF <x (Vane, 1971).
2

Vane (1971) designed experiments to test the possibility that
NSAID inhibit the enzyme(s) which generate prostaglandin.

He

incubated guinea-pig lung homogenate with arachidonic acid aerobical
ly at 37°C and determined an increase in PGE

2

and PGF OC synthesis.
2

To test for inhibition of prostaglandin synthesis, varying amounts of
indomethacin, sodium acetylsalicylate or sodium salicylate were added
to the incubation flasks.
generation of PGF2a

All 3 anti-inflammatory acids inhibited

and PGE ~like activity.
2

In all preparations,

there was a linear relationship between percentage inhibition and log
concentration of indomethacin or aspirin.

On a weight basis, indo

methacin was 23 times more potent than aspirin as an inhibitor of
PGF OC, and on a molar basis 47 times more potent.
2

Aspirin was more

potent than sodium salicylate as an inhibitor of synthesis of PGF <x
2

and PGE ~like activity.
2

Results of Vane's experiments determined

that the 3 NSAID inhibited synthesis of prostaglandins, but not how
the inhibition is brought about.
Since these pioneering reports, the inhibitory action of
aspirin-like drugs on prostaglandin production has been amply con
firmed and demonstrated in almost all laboratory species and many
other biological preparations from tissues throughout the body using
a variety of assay techniques (Ferreira and Vane, 1974).

Results of

experiments conducted by Brune et al. (1976) clearly showed that
acidic NSAID

(1) are effective in almost every biological system,*

(2) reach higher concentrations in inflamed tissue than most others
throughout the body; (3) are found only in similarly high concentra
tions in

absorptive and excretory organs such as stomach, small

intestine and kidney.

How NSAID specifically exert their local

anti-inflammatory action was, however, undetermined.
Mizuno et al. (1982) proposed the specific mechanism of action
of NSAID.

The biosynthesis of the prostaglandin family (Figure 2) is

initiated by the enzyme reaction of fatty acid cyclooxygenase to con
vert arachidonic acid to PGG > followed by the action of prostaglan
2

din hydroperoxidase on PGG

2

to form PGH .
2

The former is a bis-dioxy-

genase reaction, and the latter a peroxidase-like reaction.

Mizuno

et al. (1982) investigated the effects of various NSAID in general on
both cyclooxygenase and hydroperoxidase activity.

When tested by the

assay of the manganese protoporphyrin-assistedproduction of PGG

2

from

arachidonic acid, all the drugs irreversibly inhibited the cyclooxy
genase reaction.

In contrast, none of the drugs except phenylbuta

zone also inhibited the hydroperoxidase reaction.

Aspirin, indometh-

9

Extracellular Fluid
Compartment

Acylhydrolases
Cell
membrane

Triglycerides
Phospholipids

Proteins

Phospholipase A

'Injurious Stimuli
(chemi cal/physi cal)

ARACHIDONIC ACID

Fatty acid
cyclooxygenase

NSAID

PGG,
Prostaglandin
hydroperoxidase

Phenylbutazone

PGH

PGE

2

PGI

Figure 2. Inhibition of prostaglandin biosynthesis by
non-steroidal anti-inflammatory drugs (NSAID)

Adapted from Kindahl (1980), Bell
et al. (1980) and Chand and Eyre (1977)
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acin and flurbiprofen did protect the hydroperoxidase activity from
heat or alkaline pH inactivation.

Results raised the possibility

that NSAID might also affect the binding of enzyme and heme because
heme is a required cofactor of the enzyme in both the cyclooxygenase
and hydroperoxidase reactions.
In summary, the mechanism of action for NSAID is the inhibition
of cyclooxygenase.

Phenylbutazone also inhibits prostaglandin

hydroperoxidase (Mizuno et al., 1982).

The order of anti-inflamma

tory potency of commonly used NSAID as determined in laboratory
animals is meclofenamic acid > indomethacin > naproxen > phenylbuta
zone > acetylsalicylic acid (Snow, 1983).

Pharmacokine tics
All NSAID appear to be metabolized to inactive metabolites
except phenylbutazone.

At therapeutic doses about 10% of phenylbu

tazone is degraded to oxyphenbutazone, that has activity similar to
phenylbutazone and is also used therapeutically.
then excreted in urine and bile.
are secreted in saliva.

The metabolites are

Only negligible amounts of the drug

It is generally considered necessary to

determine appropriate dosage and frequency of dosing to maintain a
therapeutic circulating plasma level of these drugs during treatment
(Snow, 1981).

Because of the high plasma protein binding of NSAID

and low water solubility, their rate of metabolism is the predominant
factor responsible for declining plasma concentrations after adminis
tration (Snow, 1983).

It is probable that therapeutic concentrations

may remain in tissues for a period of time after they are no longer
detectable in blood, which may explain a residual effectiveness after

11
therapy cessation (Snow, 1981).
The plasma half-life following intravenous administration for
meclofenamic acid, naproxen and flunixin meglumine in the horse have
been reported to be 1.0, 4.7 and 1.6 hours, respectively.

For phen

ylbutazone, the plasma half-life is dose dependent, possibly due to
the effect of its active metabolite oxyphenbutazone.
Of the 4 drugs used in the horse, only phenylbutazone and
flunixin meglumine are formulated and available for parenteral
administration, but all 4 are marketed for oral administration in the
form of powders or granules.

Phenylbutazone is also prepared in a

paste form in a multi-dose applicator (Snow, 1983).

Plasma concen

trations of NSAID following oral administration can be highly vari
able (even within one animal) due to breed, age of horse and rela
tionship to feeding time.

Giving the drug on an empty stomach

results in higher peak plasma concentration and a greater bioavaila
bility than when it is given on a full stomach.

Even though these

compounds are acidic, most absorption occurs from the duodenum rather
than the stomach.

Presence of food in the stomach slows gastric

emptying and therefore absorption (Snow, 1981).

Studies also indi

cate that under the same conditions, absorption of phenylbutazone and
meclofenamic acid may be lower in pony breeds than in Thoroughbreds
(Snow, 1983).
In summary of pharmacokinetics, all NSAID are metabloized to
inactive metabolites (except phenylbutazone) and are excreted in
urine and bile.

All preparations are generally administered as a

course of treatment lasting 5 to 10 days.

Increasing peak plasma

concentration is dependent on the rate of drug metabolism, dose rate,
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frequency and route of administration, breed and age of the horse and
relationship to feed and feeding time.

Parenteral administration of

flunixin meglumine may be either intravenous or intramuscular.

Phen

ylbutazone and meclofenamic acid must be given only intravenously
since intramuscular injection causes severe inflammation.

Toxicity
The NSAID all induce gastrointestinal irritation that often
leads to ulceration of mucosal lining of the gastrointestinal tract
from the oral cavity to the large intestine.
due to inhibition of other enzyme systems.

Toxic effects may be
Ferreira and Vane (1974)

proposed that inhibition of prostaglandin biosynthesis may lead to
unwanted side effects in organs that depend upon prostaglandins for
normal physiological function.
acid secretion.

For example, PGE inhibits gastric

A locally released prostaglandin may be a mechanism

to prevent hyperacidity, which can lead to mucosal damage.

Also, the

function of locally released prostaglandins in the stomach may be to
increase blood flow to the mucosa.

Vasoconstriction upon removal of

this effect by NSAID may lead to ischaemia, tissue death and bleed
ing.

This proposed cytoprotection property of locally released

prostaglandins was demonstrated by Robert et al. (1979).

Pretreat

ment with prostaglandins in rats prevented necrosis of the gastric
mucosa when orally given acids, bases and hot water.

Therefore,

toxic doses of phenylbutazone in horses and ponies may decrease pros
taglandin production at the mucosal level and decrease cytoprotec
tion (MacAllister, 1983).
Prolonged bleeding time and inhibition of platelet aggrega
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tion is caused by most NSAID (Tatro et al., 1980).

Non-steroidal

anti-inflammatory drugs also cause varying degrees of nephrotoxicity
with some incidence of papillary necrosis.

Some, like phenylbuta

zone, lead to retention of sodium chloride and water (Ferreira and
Vane, 1974).

In a retrospective study of 16 horses in which renal

papillary necrosis was found at necropsy, it was determined that all
had suffered from a variety of diseases in which dehydration and
NSAID therapy were prominent features (Gunson, 1983).

Papillary

necrosis seen in both kidneys of all horses was not associated with
clinically apparent renal disease.

It was proposed that 2 synergis

tic etiologic factors contributed to equine renal papillary necrosis.
First, blood volume depletion due to dehydration, hemorrhage or water
deprivation resulted in dependence on prostaglandins for renal blood
flow.

Then, antiprostaglandin drugs were able to reduce blood supply

to the now prostaglandin dependent vasa recta and cause ischemia of
the renal papillae.

It was suggested that horses being treated with

NSAID must have sufficient water to balance and avoid hypovolemia.
Clinically, the early signs of toxicity are depression, anorex
ia, weight loss, diarrhea, dehydration and sometimes oral ulceration.
The first indication of toxicity on routine blood biochemistry is a
progressive decline in total plasma proteins and a rise in plasma
urea concentration.

With continued treatment, areas of ulceration

converge and impaired epithelial integrity leads to absorption of
toxins and a terminal shock condition.

Marked ulceration of the

tongue is often noted (Snow, 1981, 1983).
Toxicity studies of 3 NSAID were conducted by Snow et al.
(1983).

Phenylbutazone, meclofenamic acid and naproxen were
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administered at the recommended dose rate and then at twice the
normal dose.

Results determined that at the therapeutic dose rate,

phenylbutazone may cause a protein-losing gastroenteropathy in
ponies; however, the other 2 commonly used NSAID did not exert this
effect at either dose regimen.
Potential toxicity of NSAID in mare milk must be considered by
the equine veterinary clinician.

If a valuable but chronically

arthritic brood mare is maintained at low doses of a NSAID, it must
be certain that concentrations of the drug are passing into the milk.
The NSAID will almost certainly be cleared from the body more slowly
in nursing foals than in adult horses and this will increase
potential toxicity (Higgins and Lees, 1988).

Clinical Use and Efficacy
All NSAID are proposed to be useful in numerous acute and
chronic inflammatory conditions of both soft tissue and skeletal
origin.

It appears that different NSAID are more effective against

some conditions than others.

The 4 commonly used NSAID in equine

medicine vary in efficacy in specific conditions.
Naproxen (Equiproxen ) is recommended for relief of pain,
inflammation and lameness associated with myositis and soft tissue
disease (Tobin, 1979b).

Kilian et al. (1974) induced myositis "tying

up" by injecting lactic acid at 8 sites into the back muscles of
horses.

These horses were treated with naproxen, which resulted in

greatly reduced pain, lameness and tissue swelling.

Jones and Hamm

(1978) induced equine myositis using this model and proposed that
naproxen was superior to phenylbutazone because it gave more rapid
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relief of inflammation and associated lameness.

Hamm (1978) reported

that continuous administration of naproxen in the daily feed during
training and racing season of young colts significantly reduced the
incidence of musculoskeletal injuries and performance days lost to
injuries such as splints, osslets, osteoperiostitis, tendinitis,
tenosynovitis and suspensory desmitis.
Flunixin meglumine (Banamine ) appears to be more potent than
other equine NSAID and superior for rapid relief of equine colic
(Tobin, 1979b).

Vernimb and Hennessey (1977) reported 38% of horses

treated for colic were improved within 15 minutes.

It was reported

that animals were eating by this time with normalization of heart and
respiratory rates and peristalsis

indicated remission of colic and

pain.

obtained in animals affected by

The best results have been

flatulent or spastic colic as compared with those with intestinal
stasis or circulatory impairment.

Houdeshell and Hennessey (1977)

demonstrated that parenteral and oral flunixin meglumine is also safe
and efficacious for alleviation of pain and inflammation associated
with musculoskeletal disorders in the horse.

Flunixin meglumine was

also reported to be efficacious in treating endotoxic shock in ponies
(Turek et al., 1985).
Meclofenamic acid (Arquel )

is an unusual NSAID in that its

onset of action is relatively slow, taking from 36 to
develop (Tobin, 1979b).

96 hours to

It has been demonstrated to be especially

effective in the treatment of acute and chronic equine osteoarthritis
and certain soft tissue inflammatory conditions affecting the loco
motor system such as navicular disease, laminitis and bony tissue
conditions.

The drug accumulates appreciably in synovial fluid,
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without altering the physicochemical properties of synovial fluid.
The tissue containing the most drug is omental fat with other sites
being hair, spleen and articular cartilage.

In comparison, meclofen

amic acid is superior to phenylbutazone in treating equine osteo
arthritis (Riley et al., 1971; Conner et al., 1973).
Phenylbutazone (Butazolidin ) remains the most popular and
widely used NSAID in equine medicine.

It is still the standard

against which other drugs are compared for clinical effectiveness
(Tobin, 1979b).

This may be attributed to

(1) over 30 years of

clinical experience indicating its efficacy in a variety of
conditions; (2) considerably lower costs for treatment, especially
over extended periods of time; (3) low dose rates; (4) minimal
effective blood concentration necessary; (5) establishment of
phenylbutazone "Bute" as a household name (Snow, 1981).

For these

reasons, phenylbutazone was the drug of choice for this study.
Tobin (1979b) summarized that these 4 equine NSAID

(1) are

safe and effective when given at therapeutic doses; (2) they have a
number of broadly similar characteristics in that dosages are
approximately equivalent from drug to drug; (3) their time courses of
action are broadly similar; (4) their detection in blood and urine is
not particularly difficult; but (5) there are subtle differences in
clinical effectiveness against certain conditions, that make specific
NSAID the drugs of choice for specific conditions.
NSAID properties is presented in Table 2.

A summary of

Pharmacological

characteristics of NSAID are summarized in Table 3.
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Table 2.

1.

Summary of non-steroidal anti-inflammatory drug properties

Acidic drugs that accumulate in acidic, inflamed tissues

2.

Highly protein bound in plasma

3.

Easily detected in urine and plasma; undetectable in saliva

4.

Restore normal performance, not a central nervous system
stimulant or depressant

5.

Safe and effective at therapeutic doses

6.

May be used in competitive horses

7.

Inhibit enzymes which form prostaglandins and therefore
reduce tissue pain and inflammation

8.

Reduce fever (antipyretic)

9.

Accumulate in stomach, kidney and gastrointestinal tract
and tend to produce lesions in these tissues if toxic
doses are given
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Table 3.

Pharmacological characteristics of non-steroidal
anti-inflammatory drugs commonly used in equine medicine3

Drug

Route

Phenylbutazone
(Butazolidin® )

IV
Oral

Flunixin meglumine
(Banamine ®)

IV,IM
Oral

Naproxen
(Equiproxen® )

IV
Oral

Meclofenamic acid
(Arquel® )

IV
Oral

?Adapted from Booth (1982)
Gabel et al. (1977)
cMaylin (1977)

Daily dose
(mg/kg)

Detection in
Half-life Urine Plasma
(hours)
(hours) (hours)

2.2 to 4.4
4.4 to 8.8

3.5
6

96b

1.1
1.1

1.6

48

8

5.0
10.0

4

48

48

2.0
2.2

6-8

96°

24c

24-48b
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Use of Non-steroidal Anti-inflammatory Drugs in Competing Horses
Various equestrian federations throughout the world have
determined their own regulations governing the use of NSAID in
competition horses.

The NSAID do not have central nervous system

stimulant or depressant actions and therefore are unlikely to affect
the optimal performance of a horse.

It is accepted that these agents

both by their analgesic and anti-inflammatory activities are able to
improve performance impaired due to tissue damage (Snow, 1981).
The NSAID are included in a group of drugs referred to as drugs
of controlled medication.

The goal of a controlled medication

program is to smooth out the minor health and musculoskeletal
problems that are common to all athletes and to insure that horses
are presented at the starting gate fit to race at their best.

By

allowing specific therapeutic medications to be used, controlled
medication programs avoid driving trainers and veterinarians to more
extreme, difficult and damaging measures such as freezing, denerving,
nerve blocking and intra-articular corticosteroid injections without
rest.

These are the drugs that many racing commissioners in the

1960s and 1970s chose to allow to be used in performance horses under
controlled conditions (Tobin, 1981c).
These drugs are extremely valuable therapeutic agents in
performance horses when properly used.

Under the proper circumstan

ces, NSAID have the ability to enable a horse to perform more
consistently at its innate ability.
great economic importance in racing.

Therefore, these drugs are of
Proponents for the use of NSAID

suggested that if their use were restricted, the number of horses
that race and compete in shows would be markedly reduced (Tobin,
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1981c).
Therapeutic medication consists of administering an agent to a
horse which controls a condition that is interferring with the
performance of that horse.

The justification for this type of

medication is that it allows a horse to run up to its form but not
beyond its innate ability.

Therefore, a horse with joint or muscle

pain may be given a NSAID to control inflammation and pain.

The

horse trainer's and veterinarian's objective is to keep their horses
in the competition.

Proper medication can be a critical factor of

this objective (Tobin, 1981c).
In January, 1989, the American Horse Show Association (AHSA)
Board of Directors unanimously approved a major amendment to the
Medications Rule, placing restrictions on the use of NSAID at AHSA
recognized competitions.
1, 1989.

The ammendment effective date was December

The purpose of the ammendment is to protect the fairness of

competition by preventing abuses of drugs and to safeguard the health
and well-being of horses and ponies by accommodating the treatment of
illness and injury (Lengel, 1989).
This ammendment rules

(1) when a NSAID is needed, either

phenylbutazone or flunixen meglumine should be administered, but not
both; (2) when phenylbutazone is administered, not more than 2 g/450
kg body weight/day should be administered, not closer than 12 hours
prior to competing and not more than 5 successive days; the dose for
a pony is to be reduced accordingly; (3) when flunixen meglumine is
administered, not more than 500 mg/450 kg body weight/day should be
administered, not closer than 12 hours prior to competing and not
more than 5 successive days; the dose for a pony is to be reduced

21
accordingly; (4) if both phenylbutazone and flunixen meglumine were
administered to a horse or pony during the 7 days prior to competing,
then one or both must have been administered no closer than 48 hours
prior to competing, in order to achieve an acceptably low trace level
(Lengel, 1989).
According to international racing jurisdictions, only the
United States and the Rio de Janeiro Jockey Club permit use of NSAID
in racing horses.
among states.

Medication rules regulating use of NSAID vary

Each state that permits horse racing determines its

own regulations.

Some states do not permit any use of NSAID.

In

many states, there is no permitted medication for 2-year-old horses,
but there is restricted use of NSAID in adult horses.

Restrictions

determine the accepted maximum post-race blood and urine levels of
permitted NSAID and the accepted time of administration.

Regulations

may vary between harness racing and runners (Drug Control Service
Policy Review, 1988).
The Louisiana State Racing Commission does not permit any
medication for racing 2-year-olds.

Of the NSAID, only phenylbutazone

and oxyphenbutazone are permitted for use.

Post-race urine and blood

levels for both drugs are 165 yg/ml and 5 yg/ml, respectively,
regardless of time of administration (Louisiana State Racing
Commission, 1986).
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PHENYLBUTAZONE IN HORSES

Introduction
Phenylbutazone was first synthesized in 1946 by H. Stengyl in
Switzerland and was later marketed as Butazolidin® by J.R. Geigy,
A.G., as a therapeutic agent to treat rheumatic diseases (Jeffcott,
1977).

Phenylbutazone was widely used in human medicine until it was

restricted because it caused deaths from aplastic anemia and agranu
locytosis.

However, an extensive veterinary market developed to

treat equine musculoskeletal disorders, colic and inflammation
(Tobin, 1979a).

Phenylbutazone has been approved for use in racing

horses in most American states.

Horses are allowed to be medicated

with phenylbutazone while competing in Federation Equestre Interna
tionale shows providing a limit of 4 pg/ml of plasma (Tobin et al.,
1986).

Phenylbutazone is not a naturally occurring compound

(Schubert, 1967) and is classified as a non-steroidal anti-inflamma
tory drug (Tobin, 1979a).

Chemistry
Chemically, phenylbutazone is a pyrazolidine with 2 nitrogen and
3 carbon atoms.

It has an acidic nature with a pKa of 4.5, making it

soluble in aqueous solutions of pH > 6.0 (therefore also in body
fluids).

It forms colorless crystals which melt at 104.5 to 106.5°C.

It is sparingly soluble in usual organic solvents.

Phenylbutazone is

rather susceptible to oxidation, the first step being the formation
of a hydroxyl group at the 4 position.

It has a well defined ultra

violet light spectrum and infrared absorption (Schubert, 1967).
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Physically, phenylbutazone is a white or light yellow powder
with a bitter taste.

It is poorly soluble in water (Barragry, 1973).

Safety
Phenylbutazone is a safe drug if administered within therapeutic
doses (Tobin et al., 1986).

Finocchio et al. (1970) administered the

clinically recommended dose of 2 g/450 kg phenylbutazone intravenous
ly to 11 Thoroughbreds and determined that hemoglobin concentration,
packed cell volume, serum protein fractionation, serum creatinine
concentration and urine pH, osmolarity and creatine concentration
were not significantly changed from normal values.

Recommended Dose and Route of Administration
The optimal effect can be achieved by 2 g/450 kg (average size
horse) intravenously/day or 4 g/450 kg orally/day.

Daily dosing is

required since the anti-inflammatory effect is not good for more than
about 24 hours (Tobin, 1979a).

The American Association of Equine

Practitioners has recommended that the dose for racing horses be not
greater that 2.2 mg/kg intravenously each day, with the last dose
occurring not more than 24 hours before post time (Tobin et al.,
1986).
First response to the drug can be seen a few hours after
administration.

Optimum effect is variable but occurs approximately

12 hours after administration.

Intravenous injection appears to

speed the onset of action on the average by 2 to 4 hours compared
with oral use.

Onset of action is variable after oral administration

depending on whether the horse eats before or after the drug is
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given.

Optimal clinical effect appears to continue for a variable

time, usually for < 48 hours after the last dose, depending on the
dose and length of treatment course (Gabel et al., 1977).
Researchers determined that clinical efficacy of doubling the
recommended dose of phenylbutazone as a loading dose should be
limited to the first 1 or 2 days of treatment only.

In this treat

ment regimen, overall clinical response was good to excellent with no
overt signs of phenylbutazone toxicity in any horse (Lees et al.,
1983; Taylor et al., 1983a).
Intramuscular injection of phenylbutazone is used in some
countries although it is not recommended.

Intramuscular injections

into the neck region of 2.5 mg/kg phenylbutazone induced heat,
tenderness and swelling around the injection site which persisted up
to 5 days (Sullivan and Snow, 1982).
For standardization and predictability purposes, 2 g of phenyl
butazone intravenously administered daily was chosen for all 5 exper
iments in this study.

Half-life
The half-life of phenylbutazone is highly variable depending
upon dose, dosing regimen, age of recipient and species.

In the

horse, despite its size, phenylbutazone has approximately the same
half-life as in smaller experimental animals.
Usually, the half-life is approximately 3 hours intravenously or
6 hours orally.

If the daily dose is increased and the phenylbuta

zone accumulates in body tissues, the half-life also increases and
toxicity can result (Tobin, 1979a).

An intravenous dose of 4.4 mg/kg
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phenylbutazone results in a plasma half-life of 3 to 4 hours.
bling the dose almost doubles the half-life (Snow, 1983).

Dou

Concurrent

intravenous administration of phenylbutazone and another related
drug, isopyrin (Tomanol ) also results in prolongation of both drugs
due to competition for the metabolizing enzymes responsible for their
degradation (Snow, 1981).
Phenylbutazone exhibits dose-dependent kinetics in the horse.
The elimination half-life increases from 3.5 hours at 4.4 mg/kg body
weight to 8.6 hours at 10 mg/kg.

A possible reason for this could be

accumulation of phenylbutazone in the body when high doses are
administered.

Accumulation of phenylbutazone within the body might

partially explain why doses only 1.5 to 2 times the recommended
maximum can produce a fatal protein-losing enteropathy in ponies
within 10 to 14 days, whereas recommended dose rates seem to be well
tolerated clinically by most horses for months or even years (Lees et
al., 1985).
Maylin (1974) demonstrated an increase in half-life of phenyl
butazone in a daily dosing regimen.

He administered 4.4 mg/kg body

weight phenylbutazone intravenously to horses daily for 4 days.

The

half-life of phenylbutazone in plasma was 5.1, 5.3, 5.5 and 6.1 hours
following the first, second, third and fourth doses, respectively.
Other reports of the half-life of phenylbutazone being dose
dependent include

(1) 3.5 hours with 4.4 mg/kg to 6 hours with 17.8

mg/kg (this may reflect saturation of liver enzymes at high dose
levels); (2) doubling the dose from 2.2 to 4.4 mg/kg phenylbutazone
raised plasma levels by 33%; (3) quadrupling the dose from 2.2 to 8.8
mg/kg phenylbutazone raised the plasma concentration by 300%
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(Gerring, 1981).
Phenylbutazone has demonstrated a wide range in reported halflife among various mammalian species.

Phenylbutazone is metabolized

in man at a very slow rate with a plasma half-life averaging 3 days.
However, in the monkey, dog, rabbit, rat, guinea pig and horse the
drug is rapidly metabolized.

The half-life of phenylbutazone in the

goat and cattle falls in the moderate range (Burns, 1968)(Table A).
In cattle, elimination half-life changes considerably depending on
route of administration.
using a cross-over design.

Three administration routes were compared
The half-life of phenylbutazone was 36,

44 and 51 hours for intravenous, oral and intramuscular administra
tion, respectively (Lees et al., 1988a).
In the horse, the half-life of oxyphenbutazone is approximately
the same as that of the parent drug, phenylbutazone (Gandal et al.,
1969; Barragry, 1973; Lees et_ al., 1986; Gerken and Sams, 1988).

In

comparison, the plasma half-life reported for phenylbutazone in the
horse has ranged from 3.5 to 10.9 hours, increasing with the adminis
tered dose (Soma et al., 1983; Tobin et al., 1986).

The plasma

half-life of oxyphenbutazone has been reported to be 2.8 to 6.0 hours
for doses from 4.4mg/kg to lOmg/kg (Gandal et al., 1969; Lees et al.,
1986b; Gerken and Sams, 1988).

The plasma half-life of phenylbuta

zone is increased in horses following administration of oxyphenbuta
zone.

A similar finding has been reported in other species and

suggests that oxyphenbutazone contributes to the overall effect of
phenylbutazone and inhibits metabolism of phenylbutazone in horses
(Booth, 1982; Lees et al., 1986b).
Urinary pH has little effect on the plasma half-life of
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phenylbutazone, which is determined mainly by hepatic metabolism and
possibly by biliary secretion (Tobin et al., 1986)

Table

4.

Species differences in the elimination of phenylbutazone

Species

Man
Cattle
Goat

Half-life (hours)

72a
31, 36, 39b
15°

Monkey

8a

Dog

6a

Horse

3.5d , 6a

Rat

6a

Guinea Pig

5a

Rabbit

3a

Pig

2e , 6a

? Burns (1968)
De Backer et al. (1980); Lees et al. (1988a); Martin et al. (1984)
Boulos et al. (1972)
Piperno (1968)
e Booth (1982)
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Absorption
Oral administration of phenylbutazone is often the preferred
route because of ease of administration and the irritant action of
the drug when injected intravenously and/or perivascularly.

A

portion of orally administered phenylbutazone is rapidly absorbed
from the stomach via diffusion and ion trapping.

Since phenylbuta

zone is a weak acid of high lipid solubility, its absorption would be
favored by acid conditions in the stomach and early small intestine
of the horse (Traub, 1983; Lees et al., 1986a; Maitho et al., 1986).
Gerring e_t al. (1981) reported detection of phenylbutazone in the
plasma of ponies 10 minutes after oral dosing.

The most rapid ab

sorption appears to occur from the small intestine, that is likely
due to the greater surface area of the intestinal mucosa when com
pared with the gastric mucosa (Traub, 1983).
Variability has been noted when phenylbutazone is administered
orally under similar conditions.

Phenylbutazone absorption is

subject to marked inter- and intra- animal variations.

The rate of

absorption may vary both from horse to horse and with the amount and
type of food consumed in relation to the time of phenylbutazone
administration (Gerring et al., 1981; Lees et al., 1986a).
Rose et al. (1982) investigated the bioavailability of two
different oral preparations of phenylbutazone and the effect of the
state of stomach contents on the absorption of phenylbutazone.

They

administered 8.9 mg/kg phenylbutazone in a paste or a traditional
powder form either before or after a meal.

Ration consisted of a

full feed of lucerne chaff, wheaten chaff and bran or partial feed of
a small bran mash.

Both the paste and powder forms of phenylbutazone
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administered before a meal appeared to be almost completely absorbed.
Phenylbutazone paste administered after feeding or phenylbutazone
powder given in a full feed resulted in lower peak plasma phenylbuta
zone concentration compared to administration on an empty stomach or
relatively empty stomach (small bran mash).

They concluded

(1) the

oral route has a disadvantage of unpredictable absorption even though
it is the most convenient; (2) the paste has the advantage to ensure
the horse receives the entire dose; (3) the amount of food present in
the stomach at the time of phenylbutazone administration has an
important effect on absorption; (4) complete absorption of phenylbu
tazone can be anticipated when given as a powder in a small bran mash
or in paste before feeding.
In vitro studies have shown that phenylbutazone adsorption onto
hay does occur and, therefore, may affect absorption of the drug.
Large doses of phenylbutazone generally produce ulcers in the caecum
and colon, rather than the stomach.

Therefore, delayed absorption

might be due to adsorption of phenylbutazone onto roughage in the
feed, with subsequent release in the large intestine as a result of
fermative digestive processes (Maitho et al., 1986; Tobin et al.,
1986; Lees et al., 1988).
Maitho £t al. (1986) orally administered a powdered form of
phenylbutazone to ponies that had access to hay after dosing.

Double

peaks in the plasma concentration-time curve were frequently
observed.

A tentative hypothesis concerning the phenylbutazone

absorption was proposed.

The administered dose probably dissolved

first in the gastrointestinal fluids and a proportion was then
available for rapid absorption.

This dose portion comprised the
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first peak.

Then, a variable proportion of the administered dose

rapidly became adsorbed onto the hay components and subsequent
release did not occur until breakdown of the fibrous, cellulose
constituents of the diet that took place by fermentation in the
caecum and colon.

This phase comprised the second peak.

Three plasma concentration peaks were usually obtained when the
experiment was repeated using a phenylbutazone paste formulation.
The third peak was proposed to be a feature of the oil:water emulsion
of the product.

It was proposed that the administered dose became

divided into a number of boluses.

Dispersal and dissolution of the

phenylbutazone would presumably occur at different rates.

The

erratic absorption from an emulsion would be a consequential concern
when phenylbutazone is administered before a competitive equine sport
(Lees et al., 1986a).
Sullivan and Snow (1982) studied the absorption of orally
administered phenylbutazone (5 mg/kg) in 10 Thoroughbreds, 8 ponies
and 4 pony foals.

Large variations in area under curve (AUC) and

peak plasma concentrations were found both within an animal and
within groups of animals.

Administration of phenylbutazone (5 mg/kg)

following an overnight fast resulted in no difference in AUC (0 to 24
hours) among the 3 groups of animals:
68, 107 + 48 and 98 ± 6, respectively.

mean (± SD) values were 132 +
Feeding before phenylbuta

zone administration decreased AUC and peak plasma concentration and
extended the range of time taken to reach the latter.

Repeated,

twice daily administration of phenylbutazone (5 mg/kg) resulted in
more rapid absorption following the morning than afternoon dose.
Sullivan and Snow (1982) indicated factors that may contribute
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to slower absorption of phenylbutazone in horses fed prior to oral
administration of phenylbutazone.
major factor.
emptying time.

Slower gastric emptying time is a

Consistency of the roughage (grass versus hay) affects
Partially digested feed in the stomach interferes

with passage of the drug into the small intestine.

When horses were

fed after oral phenylbutazone administration, most of the drug may
have already passed into the small intestine.
When phenylbutazone is injected intravenously, it is rapidly
distributed taking approximately 30 minutes to disperse throughout
the horse (Tobin, 1979a).

Phenylbutazone is capable of transversing

the blood-brain barrier (Tobin, 1981a).
Sullivan and Snow (1982) also reported absorption was slower
with intramuscular injections of phenylbutazone (2.5 mg/kg) than
after oral administration in the fasted animal.

They postulated the

slower absorption may be caused by the precipitation of the drug into
an environment of neutral pH and the presence of only small amounts
of fluid restricting redissolution.

This slower absorption is in

contrast to most drugs which are absorbed more rapidly following
intramuscular than oral administration.
After intramuscular administration, peak plasma levels are
achieved in 6 to 10 hours.

This slower rate is explained by the fact

that after intramuscular administration, phenylbutazone is fixed to
muscle protein and consequently its absorption is delayed (Barragry,
1973).
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Distribution
Tissue concentrations of phenylbutazone had not been investigat
ed until studies conducted by Lees et al. (1987a).

Tissue residue

and body fluid concentrations of phenylbutazone and oxyphenbutazone
were determined 6 hours after intravenous and 6, 12 and 24 hours
after oral dosing with 4.4mg phenylbutazone/kg.

Tissue cage fluid,

peritoneal fluid and synovial fluid concentrations were generally
one-third to two-thirds of corresponding concentrations in plasma.
Tissue concentrations were even lower, indicating that no tissue
cumulation of phenylbutazone or oxyphenbutazone occurred.

Concentra

tions in the adipose tissue could not be determined accurately.

The

highest phenylbutazone and oxyphenbutazone concentrations were pre
sent in kidney tissue and the lowest were detected in muscle and
tendon.

Intermediate levels were in heart, liver and lung tissue.

These tissue concentration may merely reflect organ blood flow
differences rather than tissue differences in binding affinity.
There was no tendency for phenylbutazone and oxyphenbutazone to
accumulate in high concentrations in any particular tissue.

Most

tissues were shown to contain undetectable residue levels (< O.lpg/g)
24 hours after oral dosing with phenylbutazone.

Only lung, liver and

kidney contained higher concentrations at that time.

The relatively

good penetration into tissue fluids presumably reflects the ready
reversibility of the high
al., 1987a).

degree of plasma protein binding (Lees et
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Plasma Concentration with Intravenous Administration
Maylin (1974) administered 4.4 mg/kg phenylbutazone intravenous
ly to horses daily for 4 days.
by gas liquid chromatography.

Plasma concentrations were determined
Plasma concentrations increased from

18.2 to 31.1 ug/ml 1 hour after the first and fourth doses, respec
tively.

Twenty-four hours after the first and fourth doses, plasma

concentrations increased from 0.8 to 2.4 pg/ml, respectively.
Piperno et al. (1968) administered a single dose of 2 g/450 kg
phenylbutazone intravenously to 6 horses.

Mean plasma concentrations

declined from approximately 20 pg/ml a half-hour after administration
to about 4 ug/ml 9 hours after administration.

They also gave 1

horse 2, 4 and 8 g/450 kg phenylbutazone intravenously in a series.
With the 1 hour post-administration value as a reference point, a 2fold increase in dose (2 to 4 g level) produced a 33% increase in
plasma level.

A 4-fold increase (2 to 8 g) in dose caused a 300%

rise in plasma concentration.

Repeated daily doses of 4 g/450 kg

phenylbutazone intravenously were given to 5 horses for 3 days.

In

all horses, slight to moderate elevations in plasma levels occurred.
In all experiments by Piperno et al. (1968) peak phenylbutazone
plasma concentrations after intravenous administration occurred =1
hour post-administration.

Metabolism
The liver is the principle site of phenylbutazone metabolism.
Biotransformation of phenylbutazone occurs via hepatic mixed-function
oxidase activity.
horse.

No glucuronide metabolites have been found in the

The 4-glucuronide of phenylbutazone has been reported in man

34
and, therefore, is a potential metabolite in the horse (Tobin et al.,
1986).
The 2 major metabolites are hydroxylated derivatives, oxyphenbutazone and y-hydroxyphenylbutazone.

The latter is referred to as the

"alcohol metabolite".

The 1 minor hydroxylated metabolite is y-hy-

droxyoxyphenbutazone.

Ring hydroxylation occurs on oxyphenbutazone

and side chain hydroxylation occurs on y-hydroxyphenylbutazone.

Side

chain and ring hydroxylations occur on y-hydroxyoxyphenbutazone
(Traub, 1983; Tobin et al., 1986; Lees et al., 1987a)(Figure 3).
Oxyphenbutazone is an active metabolite which shares many of the
pharmacologic actions of phenylbutazone; however, rather high doses
(6 to 12 mg/kg; Gerring et al., 1981) are required for effect.
Gamma-hydroxyphenylbutazone and y-hydroxyoxyphenbutazone are presumed
to be inactive metabolites.

These 3 metabolites are secreted into

urine (Traub, 1983; Tobin e_t al., 1986; Lees et al., 1987).
Because y-hydroxyphenylbutazone is less tightly bound than
either phenylbutazone or oxyphenbutazone it is readily excreted in
urine and is the principle metabolite found in urine (14%) after a
single intravenous dose of 4.4 mg/kg phenylbutazone.

However, if

dosing was continued, the proportion of y-hydroxyphenlybutazone
excreted dropped to 6% of the dose.

This change in proportion of

different metabolites in the urine as dosing proceeds is likely
related to the dose-dependent kinetics of phenylbutazone due to
inhibition of drug metabolism by one of its metabolites (Maylin,
1977).
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Oxyphenbutazone has been shown to inhibit the metabolism of
phenylbutazone in the rat and horse (Maylin, 1977).

It was proposed

that a metabolite of phenylbutazone (probably oxyphenbutazone)
becomes bound to and inhibits liver microsomal drug metabolism
enzymes and alters both the metabolite pattern of phenylbutazone and
its plasma half-life (Maylin, 1977).

It is also possible that

phenylbutazone itself saturates mixed function oxidase to inhibit its
own metabolism (Tobin ejt al., 1986).
Piperno et al. (1968) determined that horses were remarkably
uniform in their rate of metabolism of phenylbutazone as indicated by
small standard errors (0.2 to 0.6 mg/liter) in plasma concentrations.
The greatest variability existed in the first hour after dosing, when
decay rate was accelerated.

After this time, the decay rate was

uniform and logarithmic.
Several studies confirmed that plasma disposition follows a
bi-exponential decline (Lees et al., 1983; Lees and Taylor, 1985;
Lees et al., 1986; Maitho et al., 1986).

By using a sensitive

chromatographic method and a frequent blood sampling schudule up to
72 hours, Lees et al. (1987a) investigated but did not observe a
third, slower phase of decreasing plasma concentration.

Therefore,

it seems improbable that phenylbutazone will achieve very high
concentrations in tissues since this would be likely to provide a
further phase of slower plasma elimination (Lees et al., 1987).
Sex differences did not appear to affect metabolism rate
(Piperno et al., 1968), but breed differences appear to affect phen
ylbutazone metabolism rate.

Chay et al. (1984) determined population

distributions of phenylbutazone and oxyphenbutazone after oral and
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intravenous dosing in Thoroughbred, Standardbred and half-bred horses
at pasture.

The plasma concentrations of phenylbutazone in half-bred

horses were only one-third of those observed in the Thoroughbred and
Standardbred horses.

Chay ejt al. (1984) proposed 1 possible inter

pretation is that phenylbutazone is metabolized more rapidly in halfbred horses; because phenylbutazone is more toxic in ponies than in
Thoroughbred horses (Lees and Mitchell, 1979; Snow et al., 1979,
1980, 1981, 1983; Gerring, et al., 1981; Rose et al., 1982;
MacAllister, 1983; Snow and Douglas, 1983), this data may suggest
that it is a metabolite of phenylbutazone rather than phenylbutazone
itself which is the toxic species.
Feeding times relative to dosing time appear to affect phenylbu
tazone metabolism.

Recovery of phenylbutazone and its metabolites

from urine was significantly reduced in the first 24 hours after dos
ing when horses had free access to hay.

This was probably a result

of markedly delayed absorption because this did not

occur in animals

deprived of food for a few hours before and after dosing (Lees et^
al., 1987a).
Finocchio et al. (1970) suggested various individual factors may
affect metabolism of phenylbutazone in the horse.

For example, liver

microsomal enzyme systems have been shown to be subject to nutrition
al inadequacy, hepatic glycogen content, stage of pregnancy, stage of
enzyme development, circulating hormone concentrations, liver dis
ease, presence of exogenous chemicals and simultaneously administered
drugs.

Any one or combination of factors may be present in a parti

cular horse such as variations in training, diet and prior or simul
taneous drug treatment.
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Excretion
Although the pharmacological action of phenylbutazone is over
within 24 hours, the time for the horse to eliminate phenylbutazone
is much longer (Tobin, 1981b).

Phenylbutazone is excreted in the

urine in an unchanged form and/or as its 2 major metabolites, oxy
phenbutazone and y-hydroxyphenylbutazone (Maylin, 1974).

Renal

clearance of phenylbutazone is influenced by the drug being 98X
plasma bound and its pKa of 4.5.

The acidic nature of phenylbutazone

will tend to reduce its reabsorption from the renal tubules, if the
tubular luminal fluid is alkaline (Tobin et al., 1986).

Only the

unbound drug is available for glomerular filtration (Moss, 1973) and
the pH of the urine affects excretion rate (Piperno, 1968).
Clearance is also affected by the age of the horse (Lees, 1985) and
route of administration (Moss, 1972).
Moss (1972) reported that route of administration is an
important factor in determining the phenylbutazone excretion pattern.
Generally after oral or intravenous administration, plasma levels
return to "zero” after about 24 hours, but phenylbutazone persists in
the urine for at least 36 hours and its metabolites for more than 48
hours.

After intramuscular administration, phenylbutazone appears to

persist in urine a much longer and variable period of several days.
Moss (1972) reported that Thoroughbreds during training and
certainly after a race produce an acidic urine, but produce a more
alkaline urine at rest and light exercise.

Moss and Haywood (1973)

investigated the significance of urinary pH on phenylbutazone drug
clearance time.

They administered an oral dose of 5 mg/kg phenyl

butazone daily to a pony for 3 days under both alkaline (normal) and

under a condition that induced acidic urine.

In alkaline urine,

phenylbutazone was detected by a routine screening procedure up to 11
hours after administration and oxyphenbutazone up to 48 hours after
dosing.

In the acidic urine experiment using the same pony and dose,

phenylbutazone was detected up to 48 hours and oxyphenbutazone up to
57 hours.

A more exhaustive solvent extraction of the urine detected

oxyphenbutazone for 54 and 88 hours in alkaline and acidic urine,
respectively.

They repeated the experiment dosing 3 ponies with 5

mg/kg phenylbutazone containing 10 microcuries of

14

C.

In 1 pony,

radioactive material was detected 6 days later in acidic urine.

Moss

and Haywood (1973) concluded aciduria in the horse prolongs clearance
time of phenylbutazone and/or its metabolites.
Houston et al. (1983) determined the effect of urine pH on
detection of oxyphenbutazone in racing horses.
horses may range from pH 4.5 to 10.

Urine pH in racing

Distribution tends to be

bimodal, with peaks at approximately pH 5 and pH 8.

They measured

blood and urinary levels of oxyphenbutazone in post-race samples from
Thoroughbred horses racing in Kentucky.

Data showed that oxyphenbu

tazone levels in equine blood are not significantly influenced by
urine pH, but urine concentrations of oxyphenbutazone are highly
dependent on urine pH and may vary up to 500-fold, depending largely
on whether the urine is acidic or basic.

If the pH of urine was < pH

6, blood and urinary concentrations of oxyphenbutazone were compara
ble: if the sample pH was > 8, the urinary concentrations of
oxyphenbutazone approached 100 pg/ml, while the plasma levels of
oxyphenbutazone remained low.

Houston et al. (1983) suggested their

results represented a classic example of "ion-trapping" phenomenon;
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as an acidic drug, the concentrations of oxyphenbutazone are high in
basic urines and low in acidic urines.
Houston et al. (1985) conducted a similar experiment to
determine the effect of urine pH on detection of phenylbutazone and
its metabolites in plasma and urine of Thoroughbred race horses.
Analysis of the pH of these post-race urine samples again showed a
bimodal frequency distribution.

The pH values ranged from 4.9 to

8.7, with peaks at about pH 5.25 and 7.25.

This bimodal pattern of

urinary pH values was consistent with observations of parallel
studies of race horses in England and Japan.
Urinary pH influenced the concentrations of phenylbutazone and
its metabolites oxyphenbutazone and y-hydroxyphenylbutazone found in
the urine samples.

The concentration of these metabolites found in

alkaline urines were 32 to 225 times greater than those found in
acidic urines.

Again, research by Houston et al. (1985) demonstrated

that as acidic drugs, these agents will be largely in their ionized
forms at alkaline urinary pH values, and will, therefore, tend to
trap in alkaline urine.

Plasma concentrations of phenylbutazone and

its metabolites, however, were not affected by urinary pH (Houston et
al., 1985).
Lees et al. (1985) determined that age affects elimination rate
of phenylbutazone in horses.

A clinical dose of 4.4 mg/kg phenylbu

tazone was administered intravenously or orally to 6 ponies.

In 3

ponies, 3-years-of age, drug clearance after intravenous administra
tion was almost twice as rapid as in 3 ponies 8 to 10 years-of-age.
After oral administration, plasma concentrations were greater in the
older ponies, the area under the plasma concentration time curve
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being almost twice as high as that of the younger ponies.

These

researchers stated that this did not result from more efficient
absorption but from slower plasma clearance (as demonstrated in the
intravenous study).

They added that in very young animals (< 8 weeks

of age) the plasma clearance of most drugs is slow (as in the older
ponies) but is due to immature mechanisms of metabolism in the liver
and excretion in the kidney.
Lees et al. (1985) results indicated that only 25% of the
administered dose was accounted for by excretion in the urine over 24
hours, the greatest fraction being excreted as oxyphenbutazone and a
slightly smaller fraction as y-hydroxyphenylbutazone.
dose was present in urine as unchanged drug.
remained unaccounted.
butazone may be

Only 2% of the

The remaining 75%

They speculated that other fates of phenyl

(1) formation of other unidentified metabolites; (2)

excretion via non-renal pathways such as bile; (3) storage of phenyl
butazone in tissues with a subsequent slow release which suggests a
further elimination phase will occur.

Unpublished data of J.B.

Taylor and P. Lees (see Tobin et al., 1986) indicated a third phenyl
butazone metabolite in horse urine; however, the quantities present
were not large and would add only a few percentage points to the 24
hour urinary excretion level (Lees ej^ al., 1985).

This third metabo

lite has been named y-hydroxyoxyphenylbutazone (Tobin et al., 1986).
Lees e^t al. (1987a) determined a lack of acumulation of phenylbu
tazone and oxyphenbutazone in tissues and body fluids and a limited
recovery in urine.

The fate of at least 50% of the administered

intravenous dose of phenylbutazone remained undetermined.

Lees ejt

al. (1987a) porposed that up to half of the administered oral and
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intravenous doses were probably passed into the gastrintestinal tract
as phenylbutazone or metabolites with eventual excretion in feces.
This could arise by active secretion in fluids such as bile or by
simple passive diffusion across the blood-gastrointestinal tract
barrier (Lees et al., 1987a).
Lees et al. (1985) considered that possibly the slower
phenylbutazone clearance in 8 to 10-year-old ponies could be related
to the 35% greater body weight of the older ponies as compared to the
3-year-old ponies.

However, these researchers suggested that this

was improbable since data from their laboratory showed that mean AUC
values were higher in ponies than in Thoroughbreds weighing
approximately twice as much.
Gerring et al. (1981) determined via high performance liquid
chromatography the urinary excretion pattern of phenylbutazone and
its metabolites after orally dosing horses:
13.2 mg/kg.

doses ranged from 1.1 to

Analysis of urine specimens demonstrated concentrations

of phenylbutazone were similar to or more than those in plasma.
However, the concentrations of both metabolites were very much higher
in urine than plasma.

Gerring et al. (1981) suggested the slow

excretion of phenylbutazone may result from tubular reabsorption of
the drug, but it is also attributed largely, possibly entirely, to
the high degree of plasma protein binding, that limits the amount of
phenylbutazone filtered at the glomerulus to a small fraction of the
total plasma concentration.

Gerring et al. (1981) stated their

results made it clear that tubular secretion of phenylbutazone does
not occur in the horse (although it has been reported in laboratory
animals); however, the hydroxylated phenylbutazone metabolites must
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be secreted as suggested by their urineiplasma concentration ratios.
Maylin (1974) administered 4.4 mg/kg phenylbutazone intravenous
ly daily for 4 days.

He determined the excretion of phenylbutazone

remained relatively constant following 4 consecutive doses.

Total

percent recovery of phenylbutazone for 24 hours post-administration
was 0.9%, 1.7%, 2.1% and 1.6% of the first, second, third and fourth
doses, respectively.

Concentration of oxyphenbutazone decreased

after each successive dose from 14.2%, 10.1%, 8.2% and to 6.4% of the
first, second, third and fourth doses, respectively.
Concentration of oxyphenbutazone increased after the second and
third doses but decreased after the fourth dose.

It accounted for

9.6%, 14.0%, 14.0% and 10.5% of the first, second, third and fourth
doses, respectively.

The concentration of y-hydroxyphenylbutazone

was greater than oxyphenbutazone for approximately 12 hours after
each dose whereas the oxyphenbutazone concentration exceeded that of
y-hydroxyphenbutazone beyond 18 hours.

Total urinary excretion of

phenylbutazone, oxyphenbutazone and y-hydroxyphenbutazone accounted
for 24.7%, 25.8%, 24.3% and 18.6% of the dose after the first,
second, third and fourth doses, respectively.

An additional 6.3% of

the dose was recovered 24 to 48 hours post-administration.

Toxicity
When phenylbutazone is used in the horse in recommended doses
for the recommended period of time, it is a very safe drug.

The

number of doses administered to horses over approximately 30 years
must be infinite but the incidence of reported toxicity is small
(Tobin, 1981b).

Horses have been kept on the usual maintenance dose
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of 2 g/450 kg/day for up to 2 and 3 years with no detectable toxic
effects (Gabel, 1977).
Toxicity has been reported most frequently in pony breeds (Lees
and Mitchell, 1979; Snow et al., 1979, 1980, 1981, 1983; Gerring et
al., 1981; Rose et al., 1982; MacAllister, 1983; Snow and Douglas,
1983).

The reason why phenylbutazone produces toxicity at relatively

low dose rates in ponies is unknown (Snow and Douglas, 1983).
Because ponies were reported to be a phenylbutazone toxicity risk,
horse mares were used in all 5 experiments in this study.
The paste preparation is considerably more toxic than the powder
preparation.

The reason for this is unknown (Snow, 1982).

It has

been suggested that the bioavailability was greater for the paste
and, therefore, would more readily produce toxicity (Snow and
Douglas, 1983; Tobin et al., 1986).

A lower dose schedule is

recommended if the paste preparation is used.

Higher dose rates

should not be instituted if there is a lack of clinical response
(Snow, 1982; Lees and Higgins, 1987).
The principle dangers with phenylbutazone are associated with
improper injection.

If phenylbutazone is accidentally injected

perivascularly it may cause severe inflammation, abscessation and
eventual sloughing of the jugular vein (Tobin, 1981b).

Rapid

intravenous injection of undiluted phenylbutazone (5£ solution) will
cause phlebitis with fibrosis and sometimes occlusion of the jugular
vein.

Phenylbutazone should be injected slowly and diluted with

saline solution.

Since blood levels reached following oral adminis

tration are similar to those after intravenous injection, intravenous
use of the drug can be justified only in cases when it is important
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to attain a more rapid onset of action than via oral administration
such as severe trauma, severe pain and selected colic cases (Gabel,
1977) or when standardization and predictability are necessary for
drug studies.

If phenylbutazone is accidentally injected directly

into the carotid artery, the horse immediately becomes excited,
prostrated and may die (Tobin, 1981b).
An extensive review of the literature shows there have been few
reports of phenylbutazone toxicity in horses.

The published reports

of phenylbutazone toxicity occurred when researchers elected to give
higher than usual doses of phenylbutazone to study its effects
(Tobin, 1981b).

These reports all conclude that toxic doses of

phenylbutazone cause lesions in the entire gastrointestinal tract,
liver and kidney.
toxicity:

All case reports list the same clinical signs of

central nervous system depression, anorexia, diarrhea,

listlessness and oral ulcerations.

The 2 following studies (one

involving ponies and one involving horses) are examples of all toxic
cases reviewed.
Snow et al. (1980) studied the toxic effects of phenylbutazone
by oral administration of 12 mg/kg/day for 8 days to ponies.

Blood

samples were taken at frequent intervals and necropsies were per
formed on all ponies.

The only consistent clinical biochemical find

ing was an approximate 25% decrease in total plasma protein.

Plasma

protein concentration seems to be the best biochemical indicator of
phenylbutazone toxicity in the horse (Lees and Higgins, 1986).
Hypoproteinemia was investigated by injecting "^CrCl^-labeled
plasma proteins and calculating the loss.

Labeled chromic oxide was

given orally and was concentrated in the feces.

The results clearly
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showed that the phenylbutazone-treated ponies had very high fecal
radioactivity compared with the untreated controls indicating a mas
sive loss of plasma protein into the gastrointestinal tract.

Necrop

sies revealed ulceration of the large colon and caecum in varying
degrees from few to massive ulcerations.
ulcerations.

All ponies had tongue

Radioactive determinations of gut contents indicated

that the site of plasma protein loss was variable throughout the
gastrointestinal tract.

The plasma protein loss was associated with

the gastrointestinal ulceration (Snow et al., 1980).
Gabriel and Martin (1962) chronically administered phenylbuta
zone to Thoroughbred and Standardbred horses.

Necropsies showed

ulcerative lesions in the intestines of horses given 8 and 16 g
phenylbutazone/day.
and stomach.

Ulcerations were also found in the oral mucosa

Extensive necrotic phlebitis was found in the portal

veins and liver degeneration was evident.

Autolysis of all tissues

submitted at necropsy in a horse given 16 g phenylbutazone/day was so
extensive that no definite conclusion could be reached as to the
extent of the involvement.
In summary, necropsy reports were extensive, but there was no
indication that the phenylbutazone caused any degeneration of the
reproductive tract of males or females.

It may be assumed that

phenylbutazone does not normally accumulate in the reproductive
tract.
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Phenylbutazone and Inflammation
The acidity of phenylbutazone enables it to accumulate in acidic
inflamed tissues (Tobin, 1979a).

The primary role of phenylbutazone

in treating inflammation in horses is to inhibit a massive prosta
glandin synthesis thus reducing the erythema, edema, hyperalgesia and
fever of inflammation.
tissue is slow.

Accumulation of phenylbutazone in inflamed

The anti-inflammatory action of phenylbutazone

develops slowly because first the preformed tissue prostaglandin
concentration must be significantly reduced before phenylbutazone can
start blocking synthesis of new prostaglandins (Brune, 1976).

After

the 30 minutes distribution of an intravenous injection of phenylbu
tazone in the horse, it then takes =3 to 4 hours for the preformed
prostaglandin concentration to decline by its own biodegradation
followed by the phenylbutazone blockage of newly synthesized prosta
glandins.
or more.

Loss of

the signs of inflammation may take up to

12 hours

When the

plasma level of phenylbutazone declines,

the

concentration of prostaglandins
again and signs of

in inflamed tissues builds back up

inflammation reappear.

Then, it is time

for

another daily therapeutic dose of phenylbutazone (Tobin, 1979a).
Accumulation of phenylbutazone into cells of inflamed tissues is
highly influenced by the variation of pH in both the extracellular
and intracellular spaces.

Table 5 shows that the normally alkaline

pH of the extracellular space (7.4) becomes acidic (6.8) in inflamed
tissues and the normally neutral intracellular pH (7.0) becomes
slightly alkaline pH (7.2) in cells of inflamed tissue.

Therefore,

there is a considerable shift of acidic phenylbutazone into a more
favorable alkaline pH in cell membranes and intracellular spaces
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(Brune, 1976).
Two experimental equine models of acute non-immune inflammation
have been developed to enable studies of the biochemical composition
and cellular content of exudates.

Both are based on the creation of

a mild, reproducible and reversible inflammatory reaction that is
free from uncontrolled incidental factors and that causes minimal
distress to the ponies.

The polyester sponge model involves the

insertion of small polyester sponge strips soaked in sterile
carrageenan solution into subcutaneous neck pouches and their serial
removal.

The tissue-cage model is based on the initial insertion of

a sperical tissue-cage subcutaneously in the neck and the subsequent
stimulation with carrageenan of the granulation tissue that lines and
permeates the cage.

Relationships between prostaglandin formation at

the site of inflammation and leucocyte accumulation, enzyme release,
total protein content of exudates and the temperature of the lesions
have been investigated (Higgins et al., 1987a).
Development of the equine model of acute inflammation facilitat
ed studies of the action of NSAID in horses (Higgins and Lees, 1983;
Lees e_t al., 1986b; Higgins et al., 1987b; Lees et al., 1987b).
Higgins and Lees (1983) determined a highly significant (P < 0.001)
reduction in prostaglandin

levels in inflammatory exudates from

phenylbutazone-treated ponies compared to untreated ponies.

Lees and

Higgins (1986) determined that phenylbutazone paste significantly
reduced skin temperature over the site of the inflammatory lesion for
24 hours and inhibited prostaglandin synthesis for at least 12 hours.
There were no significant differences in exudate protein concentra
tion and leukocyte numbers between phenylbutazone-treated and control
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ponies.

Phenylbutazone was cleared more slowly from exudate than

from plasma.

Lees et al. (1986b) utilized this model to determine

that phenylbutazone and oxyphenbutazone readily passed into the
inflammatory exudate and then were slowly cleared from the exudate.

Table 5.

Situation

Normal

Inflamed

Influence of variation of pH on the relative concen
trations of phenylbutazone (PBZ) in neighboring cell
ular compartments

Extracellular
space

Cell membrane

Intracellular
space

pH

PBZ

PBZ

pH

PBZ

7.4

1.0

5.8

7.0

0.5

15.8

7.2

2.0

6.8

1.0

The values were defined by equilibrium distribution of phenylbutazone
between citrate buffers (ionic strength 0.15 M) of different pH
values and octanol. The phases were always saturated against each
other.

(Adapted from Brune, 1976)
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INFLAMMATION AND PROSTAGLANDINS

Inflammation Defined
Inflammation has been defined as "the reaction of living tissue
to injury, which comprises a series of changes of the terminal
vascular bed, of the blood and of the connective tissue that tends to
eliminate the injurious agent and to repair the damaged tissue."

The

reaction which follows interaction between antigen and antibody in an
animal which has been in contact with that particular antigen is
referred to as "allergic inflammation" (Chand and Eyre, 1977).
Inflammation is a fundamental defense mechanism of the body against
physical, chemical or infectious injury.

Despite its protective

nature, the resulting tissue changes may be excessive and damaging
(Jones, 1977).
The chemical mediators of inflammation include

(1) biogenic

amines (histamine, serotonin and catecholamines); (2) vasoactive
polypeptides (kinins, cationic proteins, anaphylatoxins, connective
tissue activating peptide); (3) lysosomal enzymes; (4) vasoactive
lipids (prostaglandins, endoperoxides, thromboxanes, rabbit aortacontracting substance, slow-reacting substance of anaphylaxis);

(5)

phospholipid (platelet activating factor); (6) chemotactic substances
(eosinophil and neutrophil chemotactic factors of anaphylaxis).

The

type of principle chemical mediator(s) involved in a particular in
flammatory condition depends upon the underlying cause of inflamma
tion and the species (Chand and Eyre, 1977).
Many of these chemical mediators produce, directly or indirect
ly, inflammation characterized by redness, heat, swelling, pain and
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loss of function.

Pharmacological agents which inhibit the excessive

defense reactions (e.g. fever, pain and inflammation) have been
called "anti-defense" drugs.

The NSAID inhibit inflammation and

fever and are therefore known as "anti-defensive" agents (Chand and
Eyre, 1977).

Inflammation Process
The process of inflammation can be initiated in any vascular
ized part of the body by an injury or insult to living tissue.

Then,

the synthesis of eicosanoids is stimulated (Higgins, 1985).
Eicosanoids are derived from naturally occurring eicosapolyenoic acids, of which arachidonic acid is the most common in domestic
animals.

Arachidonic acid is either obtained from the diet or is

synthesized from linoleic acid.

It is widely distributed in the body

and is usually stored, covalently bound in its esterified form, in
the phospholipid fraction of cell membranes of most body cells
(Higgins, 1985).
Following an inflammatory stimulus, an acyl hydrolase and
phospholipase A ^ (and possibly others) act to release the arachidonic
acid from its phospholipid pool.

This free arachidonate is either

immediately re-esterified or metabolized by 1 of 2 enzyme pathways
(Figures 4 and 5).

The cyclooxygenase enzyme system (Figure 4) will

convert the arachidonate to a cyclic endoperoxide PGG , which is
2

acted upon by another enzyme to yield P G ^ (a cyclic hydroxyendoperoxide) which subsequently gives rise to the primary prostaglandins
(PGD , PGE
2

2

and PGF «x) as well as P G ^
2

prostanoate thromboxanes A

2

(prostacyclin) and the non-

(TXA ) and TXI^.
2

Members of this group
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acyl hydrolM (activated by injury!

/=V=\^s^COOH
\_ A s = A > ^ s /
Arachidonic Acid
I eyclooxygeneM

COOH

OOH

-COOH

OH
pgh5

Malondialdchyde

C17 Hydroxyacid. HHT

OH

OH
COOH

COOH

COOH

OH
PGD.

OH

HOOC
COOH

TXA.

OH

COOH

COOH
HO
OH

OH

Figure 4.
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Higgins (1985)
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PHOSPHOLIPIDS
acyl hydrolase (activated by injury)
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Higgins (1985)
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of eicosanoids have been implicated in every phase of inflammation
(Higgins, 1985).
Prostaglandins induce the signs of inflammation and sensitize
tissue including hypothalamus to pain provoking and fever inducing
effects of other substances.
enhanced.

Sensitivity to the kinins is especially

They cause exudation of fluid into the inflamed area and

intense leukocyte migration due to chemotactic factors (Jones, 1978).

Prostaglandins in Basal Conditions
Prostaglandins are crucial to many body functions and influence
the production and release of each other.
and cardiovascular control.

They modify blood pressure

In the lung, prostaglandins influence

both circulation and ventilation and may well match the delivery of
air and gas to provide gaseous exchange.

In the newborn, prostaglan

dins are instrumental in termination of umbilical blood flow and in
diversion of venous blood to the lung.

They are involved in many

facets of reproduction and regulation of growth hormone.

They in

crease intestinal fluids and gut mobility, often resulting in diar
rhea and cramps (Jones, 1978).
Prostaglandins are usually present in the central nervous
system and have been implicated in the function of both the central
and autonomic systems, especially in mediation or modulation of
chemical and other stimuli.

Prostaglandins depress behavior and

enhance barbiturate action, mediate response to pyrogens, modify food
intake, influence cerebral blood flow and modify neurotransmission
(Jones, 1977).
None of the synthesized prostaglandins persist long at their
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site of formation.

They rapidly diffuse to other sites or are con

verted to various derivatives.

Most prostaglandins do not survive

one passage through the lungs.

Therefore, they do not usually reach

the systemic circulation for redistribution (Jones, 1978).
Prostanoids (prostaglandins, prostacyclin and thromboxanes) are
not stored in tissues and are very unstable (Higgins, 1985).

In

aqueous solution at pH 7.5 and 37°C, half-life of the cyclic endoperoxides PGG

2

and P G ^ was found to be 4 and 3.5 minutes respectively,

before they are converted to primary prostaglandins.
of PGI

2

was 4 minutes and that of TXA

half-life values require that PGI

2

degradation products 6-keto-PGF^a

2

was 32 seconds.

and TXA

2

The half-life
These short

are measured as their

and TXl^, respectively. These

products have been found to be biologically less active but
relatively stable.

In vivo, prostaglandins have been shown to be

rapidly metabolized to urinary metabolites.
PGE

2

More than 95% of infused

was inactivated after one circulation through the lungs

(Higgins, 1985).

Only 3% of tritiated PGE

2

remained unchanged in the

plasma 90 seconds after intravenous administration (Higgins, 1985).
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Prostaglandins and Erythema
Prostaglandins E^, E£ and

(at higher concentrations) have a

direct vasodilating ability that may be responsible for characteris
tic erythema in inflamed tissue (Short and Beadle, 1978).

Erythema

results from a local blood pooling due to relaxation of smooth
muscles in walls of arterioles and venules (Ferreira and Vane, 1974).
This is a long-lasting effect in cutaneous vessels and superficial
veins, but lasts only a few minutes in other vascular beds.

Prosta

glandins may also cause vasodilation by inhibiting the release of
adrenergic mediator (Short and Beadle, 1978).

They have the ability

to counteract the vasoconstriction caused by substances such as
norepinephrine and angiotensin (Ferreira and Vane, 1974).

Prostaglandins and Edema
Prostaglandins E j ,

and A

2

can directly cause some degree of

localized edema, that is likely caused by increased vascular permea
bility resulting from contraction of venular endothelial cells.

This

effect is additive in the presence of other mediators such as hista
mine and bradykinin.

Therefore, prostaglandins have an indirect

sensitizing action on the wheal-forming potential of other agents
(Short and Beadle, 1978).

Experiments have clearly demonstrated that

prostaglandin E can sensitize blood vessels (at postcapillary and
collecting venules) to the permeability-increasing effects of other
edema mediators locally released (Ferreira and Vane, 1974).
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Prostaglandins and Pain
Prostaglandins directly induce headache and long-lasting pain
when injected in man.

They can induce hyperalgesia.

Low concentra

tions of prostaglandins as released in inflammation, alone usually do
not invoke pain.

However, the addition of histamine or bradykinin

causes intense pain.

Furthermore, neither histamine nor bradykinin

injected alone has been shown to induce pain (Short and Beadle,
1978).

It appears prostaglandins must act synergically with

histamine and/or bradykinin to cause sensitivity to pain receptors.
Prostaglandins
potent than PGE .
2

causes long-lasting pain and is 10 times more

Injections of PGF

2 0 1

cause an initial brief pain

effect followed by a delayed gradual increase over 4 hours.

Subder-

mal PGE^ infusions mimicking continuous release of mediators at an
injury site showed that hyperalgesic effects of prostaglandins were
cumulative, since they depended on concentration plus duration of
infusions (Ferreira and Vane, 1974).
Prostaglandin E^ must act with histamine to cause pruritus.
When infused with bradykinin, there was pain induction rather than
itching (Ferreira and Vane, 1974).
Fatty acid hydroperoxides can also induce pain in man.
Intensity of pain produced by injections of hydroperoxides of
arachidonic, linoleic and linolenic acids was greater than that
induced by either the parent fatty acids or PGE^, acetylcholine,
bradykinin or histamine.

Thus, lipoperoxides formed during

prostaglandin biosynthesis may also be important pain-producing
substances (Ferreira and Vane, 1974).
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PROSTAGLANDINS
I. S E N S I T I Z E

PAIN RE CE P TO R S TO PA IN A G O N IS T S

NORMAL
PAIN
RECEPTOR

PAIN /
AGONIST

IN F L A M E D

,<
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PROSTAGLANDIN

2. IN C RE A SED PROST AG LA ND IN

RECEPTOR - AGONIST
PROSTAGLANDIN C O M PL EX

L E V E L S (INJ ECT ION OR WITH

I N F L A M M A T I O N ) CAUSES H Y P E R A L G E S IA .

3. BLOCK P R O S T A G L A N D IN

S Y N T H E S IS : TISSUE R E T U R N S TO

NORMAL (SLOWLY - PROSTAGLANDINS FORMED MUST BREAK DOWN )

Figure 6.
S c h e m a t i c r e p r e s e nta tio n of the p a i n - s e n s i t i z 
ing a c t i o n of p r o s t a g l a n d i n s . P ain is m e d i a t e d b y cer
tain c h e m i c a l s w h i c h int eract w i t h p ai n receptors.
The
p r o s t a g l a n d i n s a pp ear to act b y i n c r eas in g the s e n s i t i v 
ity of p a i n r e c ept ors to p a i n agonists, h ere repres ent ed
as a l o c k i n g of the p ai n a gon i s t s onto the p a i n r e c e p t o r s .
In an i n f l a m e d tissue the i ncr eas ed le vels of p r o s t a g l a n d i n
cause the h y p e r s e n s i t i v i t y c h a r a c t e r i s t i c of in fl ame d t is
sues.
O n c e p r o s t a g l a n d i n f o rma tio n is blocked, the h igh
tissue l ev els of p r o s t a g l a n d i n have to d e c a y over a number
of h our s b e f o r e the tissue returns to normal.
Th i s is
the reas on m a n y n o n - s t e r o i d a l a n t i - i n f l a m m a t o r y drug s of ten
take se ve ral h our s to act.

Tobin

(1981b)
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Prostaglandins and Fever
Prostaglandin E^, PGF^a and PGA^ are potent pyretic agents.
Prostaglandin

is the most potent pyrogen known when injected into

the cerebral ventricle or the anterior hypothalamus (Short and
Beadle, 1978).

The hyperthermic effect is dose-dependent, almost

immediate and lasts for about 3 hours.

Prostaglandin E^ or E

2

causes

fever acting on the same region on which monoamines and pyrogens act
to affect temperature.

Fever occurs during induction of human abor

tion with PGF <x, but it is rather ineffective in cats and rabbits.
2

The pyrogenic action of PGE
mals.

is greater than that of PGF <x in ani

2

2

Generation of a PGE ~like substance in the central nervous
2

system has been measured during fever.

Concentrations in the cere

bral spinal fluid rise after intravenous pyrogen by 2.5 to 4-fold,
sometimes to as much as 35 ng/ml (Ferreira and Vane, 1974).

Fever

and pain are the first signs of inflammation to be relieved by
antiprostaglandin therapy.

Edema and erythema are alleviated more

slowly (Jones, 1977).

Prostaglandins and Leukotaxis
Prostaglandin E^ has been observed to cause an initial
migration of polymorphonuclear (PMN) leukocytes followed by an
invasion of mononuclear cells into an area of inflammation.
Inhibitors of prostaglandin synthesis have been found to greatly
reduce the emigration of monocytes from blood vessels in the
inflammatory site in an acute inflammatory reaction (Short and
Beadle, 1978).

Significant inhibition of polymorphonuclear and

mononuclear leukocyte locomotion was produced by indomethacin,
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flunixin, phenylbutazone and oxyphenbutazone (Dawson et al., 1987;
Sedgwick et al., 1987).

Leukotaxis is also demonstrated by other

arachidonic acid derivatives, the thromboxanes and hydroxyeicosatetraenoic acid (Short and Beadle, 1978).
Leucocytes enhance eicosanoid-mediated aspects of the inflamma
tory reaction and its maintenance.
acid metabolites are released.

During phagocytosis, arachidonic

These products mediate inflammatory

responses and may be chemotactic for more leucocytes. This cycle of
phagocytosis and leucotaxis may continue for as long as debris or the
inflammatory stimulus is present (Higgins, 1985).

Prostaglandins and Anti-inflammatory Actions
Prostaglandin F CX is a potent vasoconstrictor in many vascular
2

beds.

It is possible that in some tissues the PGE:PGF ratio deter

mines the degree of inflammation.

Some antiprostaglandin drugs alter

this ratio in favor of the F series.

Prostaglandin

and PGE

2

have

proven to be effective at low concentrations as inhibitors of hista
mine release in basophils.

Lysosomal enzyme release by neutrophils

has also been shown to be inhibited at higher levels of PGE^.
taglandin E^ and E
cytes.

2

Pros

will also inhibit lymphokine secretion by lympho

The development and regression of inflammation probably de

pend partly upon relative concentrations of pro- and anti-inflamma
tory prostaglandin activity and possibly on feedback inhibitory
mechanisms (Short and Beadle, 1978).
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PROSTAGLANDINS AND FEMALE REPRODUCTION FROM
CYCLICITY TO EARLY EMBRYONIC DEVELOPMENT

Introduction
Prostaglandin F OC, PGE
2

2

and PGI

2

have been documented having an

important role in directing estrous cycles, ovulation, fertilization
and uterine environment of females.

Embryos depend on prostaglandins

for hatching, expansion, development and implantation.

Researchers

have demonstrated these aspects of prostaglandins in female reproduc
tion by administering prostaglandin antagonists and recording various
antifertility effects (see Table 6).

Ovulation
Espey (1980) described ovulation as an inflammatory reaction.
It was hypothesized that an ovulatory surge of gonadotropin induced
an inflammatory condition in mature follicles that brought about the
rupture of the ovarian surface.

This theory gives prostaglandins the

central role as mediators of the inflammatory process.

The principle

modifications in the ovarian vascular system include an increase in
local blood flow (vasodialation) and edema, both effects documented
to be caused by PGE.

Within minutes of an ovulatory surge of lutein

izing hormone there is a significant increase in ovarian circulation
associated with the hyperemic condition developed in follicles.
These vascular changes cause the follicle to become edematous
to the time of rupture.

At the time of ovulation, thecal fibroblasts

migrate into the stratum granulosum laying down collagenous support
for the mass of developing lutein tissue.
fibroblast proliferation.

Prostaglandins promote

In addition, fibroblasts themselves are a
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common source of prostsglandins.
It is well known the ovulatory surge of luteinizing hormone
activates the adenylate cyclase system and stimulates cyclic adeno
sine monophosphate (cAMP) synthsis in follicle cells.

Subsequently,

cAMP stimulates prostaglandin synthesis by stimulating an acyl hydro
lase, which liberates arachidonic acid.

Mature follicles begin a

cAMP mediated increased secretion of steroids, specifically estrogens
that may contribute to the ovulatory process by increasing
prostaglandin synthsis (particularly PGF

2 0

O (Espey, 1980).

Prostaglandin F reaches a maximum level in the follicle by
ovulation time and then rapidly declines, but PGE continues to be
produced for several hours after ovulation (Espey, 1980).

Granulosa

cells produce significant amounts of prostaglandins, but so do thecal
cells that generate PGF.

It has been suggested that

causes

rupture of the follicle by increasing ovarian contractility and then
vasoconstriction, thus diminishing blood flow to the ovary during the
luteal phase of the cycle (Espey, 1980).
There is evidence that mature ovarian follicles contain proteo
lytic enzymes that have been implicated in inflammatory processes.
Fibrinolytic activity increases in the follicle during the hours
preceding ovulation.

This is associated with production of plasmino

gen activator in the follicle during ovulation.
and E

2

Cyclic AMP and PGE^

are also capable of stimulating follicular cells to produce

plasminogen activator, which leads to plasmin formation.

Plasmin

stimulates production of collagenase that is necessary for collagen
degradation resulting in the follicle wall becoming flaccid and
distensible.

The decomposition of follicular connective tissue
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accelerates rapidly during the final hour preceding ovulation (Espey,
1980).

Prostaglandin F and E appear in the follicular fluid the last

few hours before ovulation (Stabenfeldt and Eqvist, 1984).

Prosta

glandins may contribute to the formation of the collagen decomposi
tion cascade since they are known to stimulate collagenase activity
in fibroblasts and related cells (Espey, 1980).
This hypothesis encourages the evaluation of anti-inflammatory
agents as potential antifertility agents (Espey, 1980).

The Espey

hypothesis describing roles of prostaglandins in the mechanism of
mammalian ovulation appears to be unchallenged at this time (Lipner,
1988).

Luteolysis
Prostaglandin

is considered to be the substance that

initiates regression of the corpus luteum.

Numerous studies have

demonstrated that increased PGF <x levels in blood due to either
2

exogenous administration or physiological synthesis and release was
concomitant with corpus luteum regression.

Prostaglandin F «x is
2

released episodically beginning approximately 14 days after ovulation
in large domestic species.

Individual surges average 5 to 6 hours in

duration with approximately the same interval intervening between
surges.

Functional luteolysis, involving a decline in progesterone

secretion, usually begins 3 to 6 hours after the initiation of PGF OC
2

release.

Regression of the corpus luteum is usually complete within

24 to 48 hours in farm animals except in the sow, which has increased
amounts of PGF C* several days before the initiation of functional
2

luteolysis (Stabenfeldt and Edqvist, 1984).
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Prostaglandin F <* is synthesized in the uterus and released in
2

a series of pulses, each lasting about an hour with a frequency of
about 6 hours (McCracken, 1984).

It may pass via general systemic

circulation to reach the ovary or be transferred from the utero-ovarian vein to the ovarian artery via local countercurrent type exchange
(Stabenfeldt and Edqvist, 1984).

The local transfer permits only

small amounts of PGF « (=1%) to reach the ovary directly (McCracken,
2

1984).

A local route has been found in the ewe and cow and appears

to be general circulation in swine and mares.

The general route

indicates that each uterine horn can influence the life span of the
corpus luteum on the contralateral ovary (Stabenfeld and Edqvist,
1984).
Chronic inflammatory processes in the mare uterus (often
resulting in pyometra) often results in destruction of the endometri
um and loss of ability to synthesize PGF <x.
2

Depending upon the

amount of uterine damage present, luteal function may be prolonged
for variable periods of time (days to months) or may be extended
indefinitely in cases of severe obliterative endometritis.

Most cows

and many mares with pyometra have a persistant corpus luteum.

The

condition does not necessarily lead to a poor fertility prognosis in
the cow (Archbald, 1976), but it does in the mare because tissue
damage is usually more extensive in the mare compared with the cow.
The accumulation of fluid in the uterus in the ewe and cow can also
result from a prolonged luteal phase.

In general, in large domestic

species, abnormalities in estrous cycle lengths are usually related
to uterine dysfunction (Stabenfeldt and Edqvist, 1984).
Naturally occurring prolongation of luteal activity in the
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nonpregnant mare is one of the most primary causes of infertility.
The cause is a failure to release adequate amounts of PGF « at =14
2

days post-ovulation.

Some

release often occurs with dampening

of luteal activity, but not complete luteolysis.

Luteal function can

persist for months with return to cyclic ovarian activity when the
uterus regains the capacity

to synthesize and to release PGF «.
2

In a

mare with a pyometra, continual luteal activity has been noted for
over a period of 613 days.

The usual treatment for such cases is

administration of exogenous PGFjix (Stabenfeldt et al., 1980).
Zavy et al. (1978) measured PGF « concentrations in uterine
2

flushings in cycling mares and demonstrated an abrupt peak on day 14
of the estrous cycle coinciding with the onset of luteal regression.
Results showed a 45-fold increase in the amount of PGF « in uterine
2

flushings from day 4 to day 14 of the estrous cycle.

A 3-fold

increase was noted from day 12 to day 14 of the cycle.
Prostaglandin is luteolytic in the mare when administered after
day 5 of diestrus via either uterine infusion or subcutaneous injec
tion (Douglas and Ginther, 1972; Noden et al., 1974).

Luteotropic Effects of Prostaglandins
Evidence of the luteotropic role of P G ^ during the early
development of the bovine corpus luteum was determined by

(1)

injection of P G ^ directly into the corpus luteum at mid-cycle, which
produced a prolonged increase in peripheral plasma progesterone
concentrations; (2) P G ^ stimulated progesterone synthesis by luteal
cells in vitro; (3) PGI

2

synthesis by luteal cells was greatest

during the period of early luteal tissue development (days 5 to 10 of
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the estrous cycle) and reached a low level by day 15 and remained low
during the remainder of the cycle (Hansel and Convey, 1983).
Hansel and Convey (1983) infused either PGE^ or PGE
to PGI

2

2

(both bind

receptors) into either the ipsilateral or contralateral

uterine horn of unilaterally ovariectomized ewes and concluded both
compounds had antiluteolytic effects.

Both PGE^ and PGE

shown to inhibit the luteolytic effects of estradiol.
PGE

2

2

have been

Infusions of

directly into ovaries transplanted to the neck inhibited the

luteolytic effects of concurrently infused PGF « (Henderson et al.,
2

1977; Hansel and Convey, 1983).
PGE

2

Multiple intra-uterine infusions of

also resulted in an increase in peripheral progesterone concen

trations and a delay of 2 days in the time at which plasma progester
one declined in the sow although estrous cycle lengths were unaffect
ed (Schneider et al.,1982; Hansel and Convey, 1983).

Antifertility Effects of Non-steroidal Anti-inflammatory Drugs
Many studies that implicate prostaglandins in reproductive
processes are based on the determination of a response to the admin
istration of prostaglandin synthetase inhibitors and the reversal of
that effect by prostaglandin administration.

Prostaglandin synthe

tase inhibitors prolong gestation, inhibit ovulation, reduce gonado
tropin releasing hormone release from the hypothalamus and reduce
pregnancy and live birth rates (Seeley, 1983).

Antifertility effects

have been reported when NSAID are administered to various mammalian
species (Table 6).

Results of these experiments suggest involvement

of prostaglandins in these reproductive functions.
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Table 6.

Antifertility effects of non-steroidal anti-inflammatory
drugs (NSAID) administered to various female mammalian
species

Function of
fertility inhibited

NSAID

Animal

Reference

1.

Ovum transport,
implantation

IND

Rabbit

Hodgson, 1976

2.

Blastocyst expansion

IND

Rabbit

Hoffman et al., 1978

3.

Fetal development

IND

Rabbit

Hoffman, 1978

4.

Live birth rate

IND

Deermice

Seeley, 1983

5.

Blastocyst hatching

MF, PA

Mouse

Baskar et al., 1981

6.

Implantation

MF,PA

Mouse

Biggers et al., 1981

7.

Corpus luteum develop

IND

Cow

Hansel & Convey, 1983

8.

Pregnancy

IND

Pig

Kraeling et al., 1985

9.

Endometrial PG
synthesis & release

IND,
ASA

Sheep

Lacroix & Kann, 1982

10. Luteolysis

IND

Sheep

Lacroix & Kann, 1986

11. Luteolysis

FM

Pony

Berglund & Sharp,1983

IND
MF
PA
ASA
FM
PG

=
=
=
=
=
=

Indomethacin
Meclofenamic acid
Prostynoic acid
Acetylsalicylic acid
Flunixen meglumine
Prostaglandin
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EMBRYO PROSTAGLANDIN SYNTHESIS IN FARM ANIMALS

Introduction
The viable conceptus (embryo and extraembryonic membranes)
exerts a biochemical dialogue with the maternal unit to prolong life
of the corpus luteum.

This dialogue continues the secretion of

progesterone essential for a uterine histotroph production.

Concep

tus secretory proteins direct the synthesis of major prostaglandins
that relate to conceptus viability (Thatcher et al., 1989).

There

are publications on the production of prostaglandins by the harvested
embryo in farm animals (Table 7).

No reports are presently available

in the mare.

Ovine Embryo Prostaglandin Synthesis
Marcus

(1981) collected intact embryos from pregnant ewes on

day 12 or day 15 of gestation.

Embryos were incubated in 1 ml tissue

culture medium-199 (TCM-199) containing 10% fetal calf serum and
14

C-arachidonic acid for 3 to 10 hours in a shaking water bath at

37°C.

The medium was analyzed by thin layer chromatography.

Day 12

embryos synthesized approximately equal quantities of PGE , P G ^ and
2

PGF OC, with PGI
2

2

being the principle product.

It was concluded that

maternal recognition of pregnancy in the ewe occurs at least by day
12 post-coitus and involves synthesis of PGI
Hyland
ewes

2

and PGE .
2

et al. (1982) collected intact embryos from pregnant

on days 13, 14 and 15 of gestation.

Embryos were homogenized in

ice-cold saline or were incubated in Dulbecco's phosphate-buffered
saline with 10% normal sheep serum in Dubnoff shaking incubators at
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Table 7.

Summary of farm animal embryo prostaglandin (PG)
synthesis
PG
assayed for

Major
PG

Animal

Day

Marcus et al.
(1981)

Ewe

12
15

Hyland et al.
(1982)

Ewe

13,14,15

Lacroix & Kahn
(1982)

Ewe

14
23

E9 »^2

PGF„a

E2 ’F2

pge2

Lewis & Waterman
(1983a)

Sow

16

E2 ,E2

PGE„
z

Shemesh et al.
(1979)

Cow

13,15,16

Lewis et al.
(1982)

Cow
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37°C for 0.5, 4.5 or 8.5 hours.

Strips of endometrium were also

cultured and prostaglandin E£ and PGF <x synthesis was determined by
2

RIA.

Prostaglandin F <x release rates were consistently higher than
2

those of PGE

2

at all incubation stages.

Prostaglandin E and PGF <x
2

output by embryos on a weight basis was up to 200 and 1000 times
higher than that from cultured endometrium, respectively.

Prosta

glandin release declined as the incubation proceeded.
Hyland et al. (1982) stated

(1) that the production of higher

amounts of PGF than PGE by embryos at a time when luteal maintenance
was crucial to pregnancy is difficult to rationalize though similar
findings have been recorded; (2) if PGE

2

is a potential anti-luteo-

lysin as suggested in the ewe, its production by embryos may be
accompanied by a non-specific
PGE

2

increase in PGF secretion; (3) if so,

could perhaps counteract the luteolytic effects of PGF <x at this
2

time.
Lacroix and Kann (1982)

incubated ovine day 14 and day 23

intact embryos for 2 hours at

25°C in 1 ml of incubationmedium

5% CO

(Krebs-HEPES) under an atmosphere of 95%
incubation medium.
mined by RIA.

Prostaglandin F OC and E
2

2

bubbling in the

synthesis was deter

Day 14 embryos produced a high prostaglandin

concentration of PGF
PGE *

2

2

2 0 1

and PGE , with PGF <x being much greater than
2

2

Day 23 embryos produced much lower concentrations of prosta

glandins with PGE

2

being dominant.
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Porcine Embryo Prostaglandin Synthesis
Lewis and Waterman (1983a) recovered day 16 blastocysts from
pregnant gilts and incubated them in a petri dish containing 15 ml
minimum essential medium (MEM) incorporated with radiolabeled
arachidonic acid.

Incubates were placed into a culture chamber on a

rocking platform for 24 hours at 37°C in an atmosphere of 50% N j :45%
02^5% C02*

Aliquots of medium were transferred to storage vials and

the tissue was homogenized.

Prostaglandin synthesis was determined

by high performance liquid chromatography (HPLC).
was the predominant arachidonic acid product.

Prostaglandin E

2

Blastocysts metabo

lized 79.8 ± 1.8% of the arachidonic acid added to the MEM.

Of the

arachidonic acid that was not metabolized by blastocysts during the
24 hour incubation period, 80.2 ± 2.5% was found in the blastocyst
homogenates.

Bovine Embryo Prostaglandin Synthesis
Shemesh et al. (1979) collected bovine blastocysts on days 13,
15 and 16 post-mating.
placed

Blastocysts from each superovulated cow were

(1) in 1 ml uterine flushing medium (O.lM-sodium phosphate

buffer with 0.1% glucose and bovine serum albumin, 5 mg/ml) and
stored at -20°C or

(2) in 1 ml TCM-199 supplemented with 5% fetal

calf serum and incubated in an incubator at 37°C and continuously
flushed with 95% air and 5%
F and PGE were determined by RIA.

saturated with water.

Prostaglandin

There was a steady rise in PGF and

PGE concentrations with increase of embryo age.

The prostaglandin

concentrations of cultured blastocysts were 4 to 17 times greater
than those of uncultured blastocysts.

At all 3 gestation ages, PGF
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concentration was considerably greater than that of PGE.
Lewis et al. (1982) recovered bovine blastocysts on days 16 and
19 post-mating.

Blastocysts were placed in 15 ml MEM and incubated

in a culture chamber on a rocking platform for 24 hours at 37°C in an
atmosphere of 50% ^ :45%

COj.

Culture medium was assayed for

blastocyst prostaglandin synthesis by RIA.

Results concurred with

those of Shemesh et al. (1979) in that blastocyst production of PGF «
2

and PGE

2

increased with day of pregnancy and the quantity of PGF «
2

was much greater than PGE *
2

Lewis and Waterman (1983b) recovered day 19 bovine blastocysts
and incubated them in 15 ml MEM containing arachidonic acid for 24
hours at 37°C in an atmosphere of 50% ^ ^ 5 % 02^5% C02*
of arachidonic acid was determined by HPLC.
increase in PGF «
2

Metabolism

Results show a 3-fold

synthesis as compared with PGE .
2

Lewis (1984)

repeated this procedure except blastocysts were incubated in 10 ml
MEM and prostaglandins was quantified via RIA.

Again there was

approximately a 3-fold increase in PGF <x synthesis as compared with
2

PGE2 .
Thatcher et al. (1984) reported that day 16 bovine conceptuses
produced approximately 4 times the amount of PGF a as compared with
2

PGE .
2

This concurs with other studies indicating bovine conceptuses

produce PGF
pregnancy.

2 0 1

and PGE

2

and that production increased with day of

It was proposed that these prostaglandins may be sequest

ered and compartmentalized within the uterine lumen.
Hwang et al. (1988) determined the profile of arachidonic acid
metabolites synthesized by bovine embryos recovered on days 6 through
3

17.

Embryos were incubated in MEM with

H-arachidonic acid for 15
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hours at 37°C in a humidified atmosphere of 5% CO

2

in air.

To

evaluate the time course of prostaglandin synthesis, day 15 embryos
were incubated for 24 hours in 5 ml MEM, but without arachidonic
acid.

An aliquot of medium was taken at 0, 2, 4, 6, 8, 12, 15 and 24

hours and assayed for PGE
RIA.

Formation of PGE

hour incubation.

2

2

and 6-keto-PGF^a (metabolite of P G ^ ) by

and PGI

2

increased linearly during the 24

Analysis of embryo samples incubated with

3

H-arachidonic acid was determined by HPLC.

Embryos collected on

days 6 through 10 metabolized arachidonic acid primarily to PGEg.
Day 13 embryos metabolized arachidonic about equally to PGE
PGF «.
2

and

2

The appearance of PGF <x peaks in other embryo samples
2

occurred between days 12 and 15.

The enhanced ability of embryos to

synthesize PGF « tended to coincide with rapid development of
2

trophoblastic tissue surrounding the embryonic disc.

Embryos

harvested after day 15 metabolized arachidonic acid to PGI
addition to PGE

2

and PGF «.

transitional changes in

2

2

in

Results indicate there are distinct

arachidonic acid metabolism during early

stages of development by bovine embryos.
A summary of embryo prostaglandin synthesis studies in ewes,
gilts and cows is presented in Table 7.

Embryos ranging in age from

day 6 to day 23 of gestation were incubated in these studies.
Incubation medium was TCM-199, Dulbecco's phosphate-buffered saline
or MEM and incubation times ranged from 2 to 24 hours.

Prostaglan

din synthesis was determined via RIA, thin layer chromatography or
HPLC.

All embryos were incubated intact, except Hyland et al. (1982)

who homogenized one group of embryos.

In most studies, research

ers also homogenized and cultured endometrial tissue to compare
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prostaglandin synthesis.

Endometrial prostaglandin synthesis was

negligible as compared with that of similar stage embryos.
These findings suggest that endometrial cells harvested with
the embryos did not affect prostaglandin concentrations.

Hwang et

a l . (1988) was the only researcher to report washing embryos before
incubation.

Only Marcus et al. (1981) and Hwang et al. (1988) also

assayed for P G ^ synthesis.

There was no absolute pattern of prosta

glandin synthesis for various ages of embryos across the species.
Embryo prostaglandin synthesis appeared to have transitional changes.
The dominant prostaglandin changed as the embryos progressed through
the early stages of development.

MARE ESTROUS CYCLE
Introduction
The reproductive cycle of the mare and its related phenomena
are unique.

Because the mare is susceptible to environmental

changes, many so called "normals" that are reported for the mare may
actually fluctuate month by month.

Such variations deem it necesary

to consider every mare as an individual (Belling, 1983).

Breeding Season
Most mares are seasonally polyestrous.

Summer is the physio

logical breeding season when the mare has normal-length

cycles,

follicular development with ovulations and full uterine growth.
Approximately 85 to 95% of all mares exhibit estrus and ovulate
regularly in the summer (Ginther, 1979a; Neely, 1983a).
Most mares become anestrus during the cold season because
decreased daylight (photoperiod) decreases ovarian activity due to
the melatonin effect (Ginther, 1979a).

High levels of melatonin

secreted by the pineal gland are promoted by darkness and decrease
gonadal activity.

Only 15 to 25% of all mares are in estrus and

ovulate during the months of December, January and February (Ginther,
1979a).
Spring is a transitional period when there is a slow increasing
ovarian response to increasing day length.

Mares are emerging from

winter anestrus.

Follicles may or may not ovulate and cycles are

often irregular.

Uterine epithelium changes from a thin lining of

simple cuboidal epithelial cells to a thicker lining due to an
increase in height, diameter and number of cells (Ginther, 1979a;
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Neely, 1983a; Banks, 1986).
In the Fall there is a slow decrease in ovarian activity due to
decreasing day length (Ginther, 1979a).

Cycles become irregular,

ovarian activity usually terminates in October or November and
uterine epithelium regresses and becomes thin again due to a decrease
in height, diameter and number of cells (Ginther, 1979a; Banks,
1986).
Some mares cycle all year long, especially those living closer
to the equator.

A more pronounced period of anestrus is exhibited in

mares living at higher latitudes (Ginther, 1979a).

Estrous Cycle
An estrous cycle is defined as the time between the first day
of estrus of one cycle and the beginning of estrus of the subsequent
cycle whether or not accompanied by ovulation (Ginther, 1979a).

The

average estrous cycle is 21 days with the normal range reported as 18
to 24 days (Day, 1940).

Ranges in estrous cycle have been reported

from 12 to approximately 40 days (Belling, 1983).
Estrus is defined as the period when the mare accepts teasing
and mounting by the stallion and is normally associated with
follicular development and ovulation (Ginther, 1979a; Neely,1983a).
The normal range is 4 to 8 days with ranges from 1 to 40 days
reported.

The average length of estrus is 5 days (Belling, 1983).

Diestrus is defined as the time between 2 estrous periods when
the mare will not accept teasing and mounting by the stallion.

It is

highly variable due to the life-span of the mare corpus luteum
(Ginther, 1979a).

The normal range for diestrus is 11 to 17 days
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with a range of 2 to 59 days reported (Belling, 1983).
The normal mare estrous cycle is

diagramed inFigure 7.

Relative endocrine and PGF <* levels are representedin Figure 8.
2

Ovulation
Ovulation may occur on any day of the cycle, any time of day,
may be single or multiple and may vary within a mare from cycle to
cycle.

Mares may ovulate throughout the year.

Ovulation normally

occurs 1 to 2 days prior to the end ofestrus; however, it
on the first or last day of estrus, or

may occur

the first or second day after

the end of estrus (post-estrous ovulation).

Ovulation may occur

during diestrus in about 5% of cycles without signs of estrus.
mares ovulate during the night or early morning.

Most

Multiple ovulations

occur about 20% of the time, may be from the same or both ovaries and
may be simultaneous or at intervals (Belling, 1983; Neely, 1983a).
Ovulation occurs only at the ovulation fossa.

The ensuing

corpus luteum has approximately a 12 day lifetime, with abrupt
termination after an increase in PGF OC from the uterus (Ginther,
2

1979a; Neely, 1983a).

78

Corpus
Lutsum
Forms
Corpus
Luteum
Exists

V\

/«

iw ? i
± _ ____
Ovum not fertilized
or embryo dies

F i gur e 7.
Sch e m a t i c r e p r e s e n t a t i o n of the m a r e
e s t r o u s cycle

79

(Hormone)

ov

LH

FSH

FSH
A
FSH

8

-6

-4

-2 OV
ESTRUS

FSH
LH
PGFjCt
OV

*
*
=
=

2

4

6

8

10 12 14 16

DAYS

Follicle s t i m u lat in g hormone
L u t e i n i z i n g hormone
Prostaglandin F2 «
Ovulation

Figure 8.
E n d o c r i n e and P G F 2 <x
e s t r o u s cycle

P4
E2

« P r o g est er one
« Est r o g e n

p r o f i l e of the mare

A d a p t e d from S t a b e n f e l d t and
Hu ghes (1977) and G i n t her (1979b)

80
ENDOMETRIAL BIOPSY IN THE MARE

Induced Luteolysis in the Mare
Arthur (1970, 1975) and Neely et al. (1975, 1979) reported
intrauterine saline infusion in the early diestrous cyclic mare
shortened the interestrous interval by inducing premature luteolysis.
Plasma progesterone levels decrease within 1 day after infusion and
declined to <

1 ng/ml within 4 days.

Arthur (1975)

infused mares in prolonged diestrus that showed

tory estrus within 3 to 9 days.
during estrus

Then, mares returned to estrus.
ovula

In these experiments, infusion

or late diestrus had no significant effect.

It was

postulated that the luteolytic effect of early diestrus intrauterine
saline was induced by a premature release of uterine PGF OC.
2

Hurtgen (1975) reported that uterine and/or cervical manipula
tions caused alterations of the estrous cycle.

Several experiments

were conducted to evaluate these observations in cycling mares.
Hurtgen (1975), Hurtgen and Whitmore (1978) and Hurtgen and Ganjam
(1979) tested the effect of specific procedures versus day of estrous
cycle it was performed.

He grouped estrous cycles as follows

(1)

control cycles included no cervical or uterine manipulations; (2)
cycles included endometrial biopsy and uterine culture (passing a
cotton swab through the cervix and rolling it against uterine endome
trium) on day 4 post-ovulation; (3) cycles included biopsy and cul
ture on the first and third days after ovulation; (4) cycles included
manual dialation of the cervix with the gloved index finger 4 days
after ovulation.

Serum progesterone concentrations were measured by

RIA in all experiments.
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In summary, in the first group endometrial biopsy and culture 4
days after estrus resulted in early regression of the corpus luteum
that was evidenced by a sharp decline in serum progesterone concen
tration and a significantly shortened interestrous interval.

Estrous

cycle length was decreased although the duration of the subsequent
estrus was increased.

The second and third groups also demonstrated

sufficient stimulus to shorten diestrus and lengthen estrus, though
the effect was less stimulating than endometrial biopsy when compar
ing experimental parameters.

Double ovulation that required 2 cor

pora lutea to regress responded in the same manner.

Uterine culture

on day 4 post-ovulation did not significantly alter estrous cycles.
Hurtgen and Whitmore (1979) did induce estrus and ovulation by
endometrial biopsy in mares with prolonged diestrus suggesting that
regression of persistant luteal tissue was caused by stimulating the
release of endogenous PGF <x.
2

Baker (1981) verified earlier results and also determined that
endometrial biopsy

(1) during estrus had no effect on the cycle; (2)

on day 4 post-ovulation induced premature luteolysis; (3) signifi
cantly reduced length of diestrus.

Baker (1981) questioned whether

luteolysis was induced by the biopsy procedure or by an induced
uterine infection because premature luteolysis had been previously
induced by bacterial infections (Hughes, 1969), saline infusions
(Arthur, 1975; Neely, 1975), cervical manipulation (Hurtgen, 1979a)
and exogenous PGF « (Noden, 1974).
2

Therefore, Baker (1981) cultured

endometrial swabs taken before and after the biopsy procedure.

No

bacterial contamination was apparent or detected by culturing the
uterine swabs.

These results suggested luteolysis was induced by the
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biopsy procedure and was not due to uterine infection.

Luteolysis in Mares Induced by Endometrial Biopsy
Hurtgen (1975), Hurtgen and Whitmore (1978), Hurtgen and Ganjam
(1979), Hurtgen and Whitmore (1979) and Baker et al. (1981) postulat
ed that endometrial biopsy could potentiate an acute inflammatory
response caused by the biopsy and, thus, increase endogenous release
of uterine luteolysin PGF « and cause subsequent premature luteal
2

regression.

The equine corpus luteum was shown not to be sufficient

ly mature to respond to the luteolysin until day 4 post-ovulation.

Technique for Performing Endometrial Biopsy in the Mare
The mare is restrained in an equine stock as for rectal examina
tion.

The gauze-wrapped tail is tied aside and feces are removed

manually from the rectum.

The perineum and vulvar lips are thorough

ly washed 3 times with Betadine

surgical scrub, each wash being

followed by a thorough rinse with clean, warm water, taking care to
wash and rinse the vulvar orifice (Ricketts, 1975; Kenney, 1978).
The tissue specimen is taken with a biopsy punch having alliga
tor-type jaws with a basket 20 x 4 x 3 mm and an overall length of 70
cm (Kenney, 1978).

2

This instrument provides a specimen 2 cm , which
2

is on average 0.2% of the entire (850 to 1350 cm ) endometrium
(Kenney, 1975).

A hand is covered first with a plastic sleeve and

covered with a sterile disposible glove lubricated with a sterile,
surgical jelly (Kenney, 1978).

The tip of the sterile biopsy instru

ment is placed in the palm of the gloved hand.
The vulva lips are spread and the gloved hand cupping the biopsy
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punch (jaws closed) is passed through the vagina.

The index finger

is inserted through the cervix and the instrument passed along the
index finger into the uterus.

While maintaining the forceps in

position, the gloved arm is then withdrawn from the vagina and passed
into the rectum where the instrument is palpated and positioned to
the desired sites (Ricketts, 1975).
To avoid penetrating the entire uterine wall if a straight bite
is taken, the biopsy punch is laid on its side, and the endometrium
is pushed into the side of the open jaws and pinched off by closing
the jaws.

There is usually hemorrhage (1 to 2 ml) at the biopsy site

(Kenney, 1978).

Endometrial biopsy may be performed any time of the

year (Shideler, 1982) and at any stage of the estrous cycle (Kenney,
1978).
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
AS A METHOD TO ASSAY PHENYLBUTAZONE IN BODY FLUIDS

Introduction
Phenylbutazone was first synthesized in 1946 by H. Stengyl in
Switzerland and was later marketed by J. R. Geigy, A.G. (Jeffcott and
Coles 1977).

This compound was not detected in biological material

until 1953 (Burns, 1953).

Indiscriminate use of phenylbutazone at

race tracks and high performance equestrian events has stimulated
interest in devloping a fast, reliable, specific method for phenylbu
tazone detection in various equine biological materials such as
plasma, urine and sweat.

Since phenylbutazone is almost completely

metabolized in the horse, recovery rates are low (Maylin, 1977) and
detection can be difficult, inaccurate or even missed.

In separate

studies, only 3.7£ of a 2 g/450 kg intravenous dose was recovered in
the first 24 hours (Piperno, 1968).
In another study, only 1 to 2% of the parent drug was recovered
in the urine of the horse when dosing 2 g/450 kg intravenously at
consecutive 24-hour intervals (Maylin, 1974).

The principle

metabolites in the horse, oxyphenbutazone and y-hydroxyphenylbutazone, together accounted for only about 25% of the phenylbutazone
administered.

The remaining 75% of the parent drug was undetected by

gas liquid chromatography (Maylin 1974; Maylin, 1977).
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Chromatography History

et al. (1953) pioneered the method for estimating the

Burns

concentration of phenylbutazone in body fluids.

They isolated

phenylbutazone from acidified human plasma and urine by extraction
into heptane.

The drug was then extracted from the heptane solution

with aqueous alkali and the phenylbutazone concentration was measured
at 265 nm in an ultraviolet spectrophotometer.
Burns et al. (1953) also designed a tissue procedure by
homogenizing up to 2 g of tissue in 10 ml of 1^0 that followed the
same method used for plasma and urine except that it used heptane
containing 3% isoamyl alcohol.

This is the technique that many

equine phenylbutazone researchers have used primarily for 2 to 3
decades (Gabriel, 1962; Piperno, 1968; Gandal, 1969; Finocchio, 1970;
Quijano, 1979).
Stevens (1970) developed a faster extraction of phenylbutazone
from blood, plasma and liver.

He used formic acid to deproteinize

the material, hexane instead of heptane for extraction and 263 nm
instead of 265 nm to perform the spectrophotometric assay.

A 95%

recovery yield was reported from plasma and =45% from whole blood or
liver.

This new method extracted phenylbutazone from water with a

99% yield.

It was concluded that the poorer recoveries from biologi

cal fluids resulted from plasma protein binding.
Stevens (1970) also collected a blood sample from a human
receiving phenylbutazone treatment and divided it into 2 equal
portions and estimated the phenylbutazone concentration by both the
Burns et al. (1953) method and his own.

The same result was obtained

by each method, but the Burns et al. (1953) procedure lasted 45 to 50
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minutes and the Stevens method could be completed in only 10 to 15
minutes.

Equine researchers then started using the Stevens method to

estimate phenylbutazone concentration in biological tissues and
fluids (Sullivan and Snow, 1982; Rose et al., 1982).

Gas Liquid Chromatography Analysis of Phenylbutazone
Modern advances in chromatography broadened the field to
include detection of therapeutic and doping agents.

Gas liquid

chromatography and high performance liquid chromatography (HPLC) have
become popular with equine researchers for phenylbutazone analysis as
easier and more specific methods than ultraviolet spectrophotometry.
Bruce et al. (1974) used gas liquid chromatography to measure
phenylbutazone concentration in plasma and urine after giving a
single, oral dose (8.9 mg/kg) of phenylbutazone to horses either as
tablets or granules.
administration.

Samples were obtained at 0.5 to 72 hours post

The plasma half-life was =4 hours.

Measurable

concentrations of phenylbutazone were present in some horses for 48
hours in plasma and urine.

They concluded that gas liquid chromato

graphy analysis of blood and urine for phenylbutazone and oxyphenbutazone is simple, specific and adaptable to analysis of race horses
suspected of doping.
Maylin (1974) also used gas liquid chromatography to study the
metabolism and pharmacokinetics of phenylbutazone in the horse.
Horses were given 4.4 mg/kg phenylbutazone intravenously daily for 4
days.

It was reported that

(1) phenylbutazone and its metabolites

are chemically unstable and decompose readily; (2) urine and blood
samples improperly refrigerated or analyzed usually contain several
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impurities or decomposition products that must be distinguished from
phenylbutazone and metabolites; (3) plasma metabolites could not be
assayed accurately at all intervals although they could be detected
in most samples; (4) total percent recovery of phenylbutazone in
urine for 24 hours post-administration was 0.9%, 1.1% 2.1% and 1.6%
of the first, second, third and fourth doses, respectively; (5)
plasma concentrations increased from 18.2 ug/ml 1 hour after the
first dose to 31.1 Ug/ml 1 hour after the fourth dose and increased
from 0.8 to 2.4 ug/ml 24 hours after the first and fourth doses,
respectively.

High Performance Liquid Chromatography Analysis of Phenylbutazone
Pound et al. (1974) pioneered the analysis of phenylbutazone
and its major metabolites in plasma by HPLC.

Results of his study

demonstrated that HPLC is a sensitive procedure for determination of
phenylbutazone concentration in plasma that also offers high speci
ficity, since it differentiates the parent drug from oxyphenbutazone
and y-hydroxyphenylbutazone.

Analysis time was less than 7 minutes.

No extraneous interfering compounds were extracted from plasma by
using n-hexane.

Neither of the 2 known metabolites, oxyphenbutazone

and y-hydroxyphenylbutazone, were detected.

The output of the ultra

violet detector was linear thus allowing quantitation of phenylbuta
zone by electronic integration and peak-height measurements.

The

limit of detection was approximately 0.2 ug/ml of phenylbutazone.
Data determined by integration and peak-height measurements showed
straight lines over the concentration range of 1.8 to 41.7 ug/ml.
Mean recovery values of 99.9 + 1.1% and 99.3 ± 3.1% were obtained by
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integration and peak-height measurement, respectively.

It was noted

that refrigerated plasma samples containing phenylbutazone were
stable for several weeks.
Pound et al. (1974) tested their procedure by doing a compara
tive analysis of phenylbutazone in plasma using 3 established methods
(1) ultraviolet spectrophotometry; (2) gas liquid chromatography; (3)
their own HPLC procedure.

The overall difference between HPLC and

ultraviolet methods was 8.2 X and that between gas liquid chromatogra
phy and HPLC 8.9%.

The ultraviolet method would not distinguish

between any side-chain hydroxy- metabolite present and the parent
drug.

They concluded that their HPLC procedure was a more specific

and sensitive method for measurement of phenylbutazone and its major
metabolites than classical methods and could form the basis for a
method for metabolic studies.
Alvienerie (1980) developed a specific and precise reversedphase HPLC assay that detected minute quantities of phenylbutazone in
horse plasma, urine, saliva and sweat.

Recovery from the extraction

procedure for both plasma and sweat was 65 ± 2% with a concentration
of 100 ng to 10 yg.

Concentrations as low as 50 to 100 ng/ml of

phenylbutazone in 0.5 to 1.0 ml of body fluids were determined.

This

reverse-phase HPLC method detected the lowest concentrations of
phenylbutazone in horses to date.
Although Pound et al. (1974) did not report detecting oxyphen
butazone or y-hydroxyphenylbutazone, they developed the method that
was the basis for analysis of phenylbutazone and its metabolites
utilizing HPLC.

Taylor et al. (1981) made modifications and improve

ments on the Pound method.

Their limits of detection were 0.01, 0.05
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and 0.10 yg/ml and mean recovery rates in spiked equine plasma were
100.08 + 1.4%, 90.4 ± 0.9% and 59.74 + 1.4% for phenylbutazone,
oxyphenbutazone and y-hydroxyphenylbutazone, respectively.

Taylor et

a l . (1981) also reported that phenylbutazone is relatively stable in
frozen plasma and urine, but less stable (plasma) and very unstable
(urine) when stored at 4°C.
Gerring et al. (1981) tested the Taylor method to determine
levels of phenylbutazone and its metabolites in plasma and urine with
regard to time and clinical doses administered orally to horses.
Gerring et al. (1981) concluded that HPLC is a simple and sensitive
method and achieved good recoveries for phenylbutazone and oxyphenbu
tazone.
During the 1980's, HPLC methods were developed proving to be
superior to previously reported methods.
ted for forensic purposes by HPLC.

Phenylbutazone is quantita

The variability of this method

within a laboratory is reported to be < 5%, however, between differ
ent laboratories it is + 25% (Tobin et al., 1986).
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PREVIOUS EXPERIMENTS LEADING TO FIRST HYPOTHESIS

The basic hypothesis and experiments for studying the effects
of chronic administration of phenylbutazone on reproduction in the
mare were proposed and undertaken by Dr. Louis F. Archbald and his
graduate student Lawrence M. Olsen, Department of Veterinary Clinical
Sciences, School of Veterinary Medicine, Louisiana State University,
Baton Rouge, Louisiana.

They conducted 2 preliminary experiments

during the 1979 and 1980 breeding seasons.
Prostaglandins, specifically PGF «, have been shown to be
2

luteolytic in the mare.
release of PGF

2 0 1

It has been suggested that the synthesis and

from the uterus is the primary cause of cyclic

luteolysis and consequently controls the estrous cycle of the mare
(Stabenfeldt et al., 1980).

Archbald (1980) postulated that since

phenylbutazone inhibits the cellular synthesis of PGF O , it could
2

1

prolong the life span of the corpus luteum and subsequent length of
the estrous cycle.

Furthermore, it was proposed that prolonged

luteal function might alter the uterine environment due to an
extended production and circulation of progesterone.
The immunologic competence of the mammalian uterus appears to
be steroid hormone-dependent.

The progesterone-dominated bovine

uterus is more susceptible to bacterial infections than the estrogendominated uterus (Black et al,1953; Rowson et al., 1953).

It may be

assumed that prolonged luteal function would cause the uterus to be
more susceptible to infections.

Clinical records indicate that

following retirement from the racetrack many mares experience varying
degrees of infertility.

The possibility exists that previous phenyl
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butazone medication may have been involved in luteal tissue dysfunc
tion, resulting in increased susceptibility of the uterus to infec
tious organisms.

The primary objectives of the first 2 experiments

at this station were to evaluate expression of estrual behavior,
peripheral plasma progesterone concentration and uterine luminal
PGF « concentrations in mares parenterally treated with phenylbuta
2

zone (Archbald, 1980).
Tobin (1979a) reported that in average horses (500 kg body
weight) an intravenous dose of 2 to 3 g phenylbutazone daily produces
an optimal anti-inflammatory effect.

Therefore, in both preliminary

experiments and all subsequent experiments, each mare was given
intravenously 2 g phenylbutazone which was proposed to be sufficient
phenylbutazone to inhibit prostaglandin synthesis (Archbald, 1983).
In the first experiment, 5 mares of mixed breeding between 3
and 4 years of age and 450 to 500 kg body weight were maintained as
an experimental group.

All mares were teased daily with a stallion

to determine onset of estrus (day 0) and rectally palpated daily
during estrus to evaluate ovarian follicle development and day of
ovulation.

Hares were monitored for 2 untreated estrous cycles.

Then, each mare served as treatment and control using a switchback
experimental design.

Between days 13 to 14 of the third estrous

cycle each mare was given a daily intravenous dose of either 2 g
phenylbutazone as treatment or 10 ml of physiological saline as
control until estrus.

Blood samples were obtained daily via jugular

venipuncture from each mare prior to the daily injection of phenylbu
tazone or physiological saline.
determined by RIA.

Progesterone concentrations were
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In the second experiment, 8 mares averaging 3 to 4 years-of-age
and 450 kg body weight were maintained as an experimental group.

All

procedures were the same as the first experiment except that treat
ment began on the first day of estrus and was continued daily until
mares exhibited estrus.

Also, uterine secretions were collected via

cervical approach from each mare on days 0, 4, 8, 12, 14, 16, 18 and
20 of the treatment estrous cycles.

Samples were stored at -19°C

until assayed for PGF <x concentration by RIA.
2

Results of the first experiment determined that there was no
significant difference in estrous cycle lengths within individual
mares or across all cycles of all physiological saline-treated mares.
Saline-treated estrous cycles were similar in length to pretreatment
cycles of each mare.

When mean estrous cycle lengths of saline-

treated mares were compared with mean estrous cycle lengths of phen
ylbutazone-treated mares having normal length cycles, no significant
differences were noted between the mean cycle lengths of each treat
ment group.

However, signs of estrus were not observed in 2 mares

for 34 days during phenylbutazone treatment.

Treatment with 5 mg

PGF OC induced overt estrus in these 2 mares on days 2 and 4 post
2

injection.

Estrous cycle lengths of these same 2 mares while being

first treated with physiological saline on the switchback design were
24 and 22 days (Archbald, 1980).
Results of the second experiment showed no significant differ
ences in estrous cycle lengths in 15% of the mares treated with
physiological saline.

The estrous cycle lengths were shorter (cycle

was 14 days for each mare) in the 2 remaining mares while treated
with physiological saline.

However, estrous cycle lengths of normal
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duration (cycle was 20 days for each mare) were noted when these 2
mares were treated daily with phenylbutazone in their subsequent
cycles (Archbald, 1980).
Prolongation of estrous cycle lengths was recorded for 3 mares
following phenylbutazone treatment.

However, signs of estrous

behavior were observed at the end of the extended cycles in these
mares unlike the pattern observed in the 2 mares in the first
experiment where estrus was induced with PGF « following phenylbu
2

tazone treatment.
Plasma progesterone profiles determined that 37.5% of the
phenylbutazone-treated mares failed to exhibit overt estrus at their
predicted time, although progesterone levels had decreased to < 1
ng/ml.

The expected time of estrus was based on previous estrous

cycle lengths during physiological saline treatment.
In both treatment groups, mean (± SEM) PGF <x concentrations of
2

uterine flushings were between 3.10 + 0.33 and 3.34 + 0.40 ng/ml on
the first day of estrus, decreased on day 4 and then increased to
between 2.71 + 0.33 and 3.49 ± 0.55 ng/ml on day 14.

Values for

mares treated with saline then increased on days 16 (3.27 ± 0.22
ng/ml) and 18 (3.47 ± 0.19 ng/ml).

These mares exhibited estrus on

days 20 to 22 of the saline-treated cycle.

In phenylbutazone-treated

mares, PGF «x concentrations were significantly lower on days 16 and
2

18 (< 1 ng/ml) when compared with corresponding days of saline-treat
ed mares.

The phenylbutazone-treated cycles from these same 3 mares

were 5, 6, and 8 days longer than expected, respectively.

Progester

one values of these mares decreased on days 16 and 18 of phenylbuta
zone-treated cycles, but then increased again before the decline
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preceding overt estrus (Archbald, 1980)
Results of the second experiment indicated that there were no
significant differences in interestrous intervals between

(1)

control mares; (2) treatment versus pretreatment cycles of control
mares; (3) mares treated with phenylbutazone (mean = 23.1 ± 0.24
days) versus those given saline (20.7 ± 0.28 days).

Plasma proges

terone profiles of treated mares showed no significant difference
compared with controls.

Results suggest there was no effect on

ovarian cyclicity and plasma progesterone concentration in mares
treated with 2 g phenylbutazone intravenously for 21 days.

There was

no apparent carryover effect of phenylbutazone on subsequent estrous
cycle lengths when mares were totally removed from treatment
(Archbald, 1983).
Results of these earlier experiments suggested validity in
pursuing the effects of parenteral phenylbutazone treatment in mares
because some phenylbutazone-treated mares

(1) exhibited prolonged

cycles; (2) exhibited shortened cycles; (3) did not express estrual
behavior even though progesterone concentration was < 1 ng/ml.
Because phenylbutazone treatment did significantly decrease uterine
PGF OC concentrations on days 16 and 18 of the estrous cycle, it was
2

presumed that phenylbutazone may be able to concentrate in the uterus
and alter the estrous cycle of the mare.
Perhaps the phenylbutazone

(1) was not potent enough to cause

significant luteal tissue dysfunction; (2) did not accumulate in the
ovaries or uterus; (3) caused incomplete luteolysis with subsequent
recovery of the corpus luteum; (4) did not effectively cause luteal
dysfunction when administered for 8 to 21 days.
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Therefore, because results of phenylbutazone-treated mares were
varied and questions were not answered regarding why the phenylbuta
zone may not have acted according to the hypothesis, 5 additional
experiments were conducted by this research station.

EXPERIMENT I

Estrual Behavior, Ovulation and Fertility of Mares
After Chronic Administration of Phenylbutazone

INTRODUCTION
Results of previous experiments conducted in this laboratory
suggested that some of the mares receiving short-term phenylbutazone
treatment apparently responded to the treatment by exhibiting pro
longed cycles and/or failed to exhibit overt estrus.

However, other

mares receiving the same treatment did not appear to be affected by
the treatment because they exhibited normal cycles and estrual
behavior (Archbald, 1980; Archbald, 1983).

It was then proposed that

possibly long-term phenylbutazone treatment may alter the mare
estrous cycle.

OBJECTIVES
The objectives were

(1) to test the hypothesis that chronic

use of phenylbutazone can cause infertility in mares by inhibiting
prostaglandin synthesis; (2) to substantiate previous data collected
by this laboratory suggesting that short-term (8 to 21 days) phenyl
butazone treatment affected mare fertility; (3) to determine the
effects of chronic (182 days) administration of phenylbutazone on
estrual behavior, ovulation, luteal function and fertilization in
mares; (4) to confirm cyclicity in the mares by using results of
progesterone assays used to validate a new commercial, solid-phase,
no-extraction
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I progesterone radioimmunoassay kit (Appendix III).
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MATERIALS AND METHODS
Nine mares of mixed breeding, ranging from 3 to 4 years of age
and weighing 450 to 500 kg were purchased and maintained under exper
imental conditions at the Louisiana State University School of Veter
inary Medicine.

Each mare was given a thorough physical examination

before purchasing.
were unknown.
a.

Complete reproductive histories of these mares

All mares tested negative for equine infectious anemi-

They were fed 8 liters of mixed grain concentrate/mare/day and

free-choice hay and water from December 1, 1980 until August 15,
1981.
On December 1, 1980, each mare was given intravenously 2 g
phenylbutazone (Butazolidin , D-M Pharmaceuticals, Inc., Rockville,
MD).

This treatment was continued daily until May 31, 1981.

Beginning on February 12, 1981, all mares were teased daily by an
androgenized gelding, estrous mares were palpated per rectum to
evaluate ovarian activity and a heparinized blood sample was collect
ed daily via jugular venipuncture to be used for determination of
progesterone concentration via RIA (Appendix III).
Cyclicity (estrus versus diestrus) was confirmed by the
progesterone assays outlined in Appendix III.

Estrus as detected by

teasing was confirmed by correlation with progesterone concentrations
< 1 ng/ml.
By June 1, 1981, 8 mares had exhibited at least 2 estrous
cycles of normal duration (18 to 24 days).
one of 2 groups as follows.

Mares were assigned to

The first mare to display estrus was a

phenylbutazone treatment and the second mare physiological saline.
The experimental design for Experiment I is presented in Figure 9.

Mares were alternated via this pattern of grouping until all 9 mares
were placed into either the treatment or the control group.

The

treated group continued to receive 2 g of phenylbutazone daily until
the day of embryo collection.
physiological saline treatment.

The control group received
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Phenylbutazone-Treated
(n = 5)

73 days

109 days
PS controls

a December 1, 1980, to February 11, 1981, 9 mares were
daily administered 2 g phenylbutazone intravenously.
k On February 12, 1981, phenylbutazone treatment continued daily
for the same 9 mares plus daily teasing, blood collection and
ovarian palpation of estrous mares.
c June 1, 1981, the same 9 mares were randomly assigned to
either continuation of daily phenylbutazone-treatment or
physiological saline (PS) control treatment. Teasing and
palpation continued and estrous mares mated. Non-surgical
embryo collection was performed day 7 or 8 post-ovulation.

Figure 9.

Schematic representation of the experimental design
for Experiment I
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All mares were teased daily for signs of estrual behavior.

Any

mare of either group that exhibited estrus was artificially insemi
nated with semen from a fertile stallion.

With standard artificial

insemination techniques each mare was inseminated on the second day
of estrus and on alternate days until no signs of estrus were evig

dent.

A standard dose of 500 x 10

stallion was used for all the mares.

motile spermatozoa from the same
Within 5 to 10 minutes after

insemination, each mare received an intrauterine infusion of 20 ml
semen extender prepared as previously described (Pickett and Back,
1973).
The day of ovulation (day 0) was determined by ovarian palpa
tion.

Starting 7 to 8 days after ovulation, fertilized ova were

collected using an established non-surgical embryo collection
technique (Imel et al., 1981).

A 30 French Foley catheter with a

30-ml inflatable cuff was manually inserted through the cervix.

To

ensure a snug fit against the internal os of the cervix, the cuff was
inflated with =30 ml sterile water and pulled caudally.

Both uterine

horns were filled by gravity flow with 1,000 to 1,500 ml Dulbecco's
phosphate-buffered saline solution (Appendix I).

The uterus was

manipulated per rectum and the medium was collected by gravity flow
into an embryo concentrating filter device positioned on top of a
sterile 2 liter graduated cylinder.

This flushing procedure was

performed twice and/or until a fertilized ovum was recovered.

If the

procedure was successful, the embryo could be detected macroscopically in the filter device.

If an embryo was not located macro-

scopically, the collection medium was searched under low magnifica
tion through a dissecting microscope (lOx).
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Embryos were transferred to a sterile petri dish containing
fresh PB-1 holding medium (Appendix II).

Subsequently, embryos were

stained with fluorescein diacetate using the procedure previously
described by Looney et al., 1981.
Percentages were calculated for normal, extended and shortened
cycles, embryo recovery rate and embryo flushing medium recovered.
Mean (± SEM) cycle length was determined for each treatment mare.

RESULTS
One mare (No. 5) did not exhibit signs of estrus or ovarian
activity until June (180 days).

The remaining 8 mares exhibited

initial signs of estrus between February 12 and February 24, 1981.
From February 12 to June 15, 1981, (124 days) 36 cycles were observed
(Table 8).

Of these, 21 cycles (58.3%) were within the normal range

of 18 to 24 days as reported by Belling (1983).
was 23.6 ± 0.98 days.

Mean cycle length

Ten cycles (27.8%) were slightly extended (25

to 28 days) and 3 cycles (8.3%) were very extended (> 30 days).
cycles (5.6%) were shortened (< 18 days).

Two

Thirty-eight ovulations

were recorded from 9 mares and of these, 4 mares had double ovula
tions.
Percentage of Dulbecco's phosphate-buffered saline solution
recovered from the uterus during attempts to recover the embryos was
91.7 ± 1.6.

An embryo was collected from only 1 of the 5 mares

treated with phenylbutazone during the breeding cycle (Table 9).

Of

the 4 treated mares that an embryo was not collected, 2 had a muco
purulent vaginal discharge when collection was attempted.

One con

trol mare also had a mucopurulent vaginal discharge at the time of

attempted collection.

An embryo was not recovered from this mare.

However, one embryo was recovered from each of the other 3 mares in
the control group.
mares (44.4%).

In summary, embryos were recovered from 4 of 9

Control mares contributed 75% and treated mares 25%

of the total embryos recovered.
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Table 8.

Mare
no.

Cyclicity and ovulatory results determined by teasing
mares with an androgenized gelding and by palpation of
ovaries per rectum of phenylbutazone-treated mares
between February 12 and June 15, 1981

No. of days/
estrous cycle

No. of
ovulations

Cycle comment

1

18b , 25, 24, 20

3

3

N, 1 SE

2

26, 17, 19, 18

5a

2

N, 1 SE, 1 S

3

25, 22, 24, 21, 20

6a

4

N, 1 SE

4

40*, 21, 23, 18

4

3

N, 1 VE

5

---- 21b
**active ovaries

0

1

N,

6

21, 28, 25, 23, 22

6a

3

N, 2 SE

7

20, 28, 23, 26

4

2

N, 2 SE

8

44***, 19, 33, 27

5a

1

N, 1 SE, 2 VE

9

28, 19, 15, 26, 19

5

2

N, 2 SE, 1 S

Total=
N
S
SE
VE

36 cycles

38

21 N, 2 S, 10 SE, 3 VE

= normal cycles (18 to 24 days)
= short (< 18 days)
= slightly extended
(25 to 28days)
= very extended (> 30 days)

* 25 days of estrus and 15 days diestrus
** 65 total days of estrus and 29 total days diestrus
*** 6 days estrus, 38 days diestrus

(no cyclicity)

fdouble ovulation
follicle regressed
Note:

The first cycle recorded is on the left of
sequentially across the row to the right.

each row and then
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Table 9.

Mare No.
1
2
3
4
5
6
7
8
9
PBZ
PS
PM
%

=
=
=
=

Embryo collection data for individual mares, intravenous
treatment, embryo recovery results and the percent of
embryo flushing medium recovered

Treatment
PBZ
PS
PBZ
PS
PS
PS
PBZ
PBZ
PBZ

Embryo
recovered
No
No
No
Yes
Yes
Yes
Yes
No
No

daily treatment with 2 g of phenylbutazone
daily treatment with 10 ml physiological saline
pyometra noted at embryo collection
percent return of embryo collection medium

Clinical
evaluation
PM,94%
PM,95%
88%
87%
93%
90%
94%
84%
PM,100%
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DISCUSSION
The decision to administer phenylbutazone to all mares was the
result of a limited number of mares and a limited budget.

Because

results with short-term treatments from previous studies had not been
very consistant, it was decided that it might require all of the
available mares to find some that might respond to phenylbutazone
by demonstrating altered cycles.

Results were to be evaluated on the

basis of cycles outside of an accepted norm (21 ± 3 days).

In

retrospect, it is questionable that having control mares would have
added much to that information gained.
Mare No. 5 did not exhibit estrual behavior or ovarian activity
for several months during the experimental period.

It probably was

not an effect of treatment with phenylbutazone because when this mare
was placed in the experimental herd, it was very thin.

However,

after being fed grain on a regular basis and since pasture grass was
abundant in the spring, it gained weight.

This mare exhibited a

normal-length cycle at the end of the experimental period and
produced a viable control embryo from a typical uterus (Table 9).
During the first part of the experimental period, the intervals
between estrus were irregular and erratic.

This effect was assumed

to reflect the transition period between winter anestrus (when cycles
are often longer than later in the year) and the breeding season.
Subsequently, the interval between estrus for these 9 mares during
the entire period of study was 23.6 + 0.98 days, which is slightly
longer than the reported average of 21 days (Ginther, 1979a; Belling,
1983).

However, this cycle mean was within the normal range of 18 to

24 days as reported by Day (1940).

Therefore, it was assumed that
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administration of phenylbutazone for 180 days (December 1, 1980 to
May 31, 1981) did not have a significant effect on the initiation or
regularity of estrous cycles.
The mean recovery rate for embryo flushing medium was 92% and
was similar to recovery rates reported previously with 93% and 96% by
Imel et al. (1981), 97% by Oguri and Tustsumi (1972) and 92% by
Douglas (1979).

Therefore, the low embryo recovery rate was probably

not due to inadequate flushing technique.

Medium recovery rates

tended to be higher for mares exhibiting pyometra.

This was asssumed

due to other fluid accumulated in the uterus due to inflammation.
Active vasodialation with increased permeability of blood vessels
resulting in accumulation of a protein-rich fluid and leukocytes
making up the inflammatory exudate is a major feature of inflammation
(Higgins and Lees, 1984; May et al., 1987).
Embryo recovery rate (44%) was considerably less than those
reported in previous reports with 72% and 83% by Imel et al. (1981),
90% by Oguri and Tsutsumi (1974) and 65% and 56% by Douglas (1979).
The recovery rate was comparable with the 47% recovery rate reported
by Oguri and Tsutsumi (1972), but greater than the 39% recovery rate
reported by Allen and Rowson (1975).
The cause of the mucopurulent vaginal discharge was not
ascertained.

A review of utero-ovarian palpation records did not

give any indication that there was an obvious pyometra during the
cycle prior to the cycle that they were mated.

Because no abnormal

ities were observed in the vagina or cervix on vaginoscopic examina
tion, the source of the discharge was likely the uterus.

The fact

that no embryos were recovered from these mares may have been due to
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uterine infection and/or lack of fertilization.

However, uterine

infection does not necessarily interfere with fertilization in cattle
(Archbald, 1976).
discharge.

Forty percent of the treated mares had vaginal

It may or may not have been caused by phenylbutazone

because all mares had received phenylbutazone for an extended period
of time.

Also, semen collection and insemination equipment may have

been inadequately sterilized by the methods used (placed in Nolvasan
solution and air dried).
The low percentage of embryos recovered could also be stallion
related.

At the beginning of the experimental breeding season, the

stallion was given a complete fertility examination and was consi
dered acceptable.

This procedure was not conducted again.

There

after, each semen collection was simply visualized to evaluate dens
ity and measured in a graduated cylinder to estimate semen dose per
mare.

If only 1 mare was mated per day, artificial insemination was

still used to maintain the same protocol for every mare.

Possibly,

stallion fertility was lowered to less than acceptable for some un
known reason.

Others have reported a difference in fertility between

stallions (Douglas, 1979).
The low embryo recovery rate (20%) from phenylbutazone-treated
mares may also be related to ovum transport.

Inhibition of ovum

transport in rabbits treated with indomethacin was reported by
Hodgson (1976).

Possibly the ovum in treated mares did not reach the

uterus.
Figure 13 shows an example of an embryo (blastocyst) recovered
from one of the mares in this study.

The same blastocyst is

presented after staining with fluorescein diacetate (Figure 14).
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This stain has been used to assess the viability of cell lines
cultured in vitro because living mammalian cells take in fluorescein
when exposed to fluorescein diacetate (fluorochromasia).

Fluorochro-

masia occurs because fluorescein diacetate, being nonpolar, can
readily pass into the cell.

There, it is hydrolyzed by esterases to

yield fluorescein, which cannot readily cross the cell membrane and,
therefore, accumulates intracellularly.

The test is a measure of

esterase enzyme activity, cell membrane integrity and, indirectly,
cell viability (Rotman and Papermaster, 1966).
The fluorescein diacetate stain has been reported not to be
detrimental to embryos recovered from other species.

Exposure of

2-cell mouse embryos to fluorescein diacetate and ultraviolet light
did not alter the rate of implantation or post-implantation develop
ment in vivo (Mohr and Trounson, 1980).

Also, the fluorescein diace

tate viability assay did not inhibit development of hamster and
bovine preimplantation embryos (Looney et al., 1981; Hoppe and
Bavister, 1983;1984).

In this study, all 4 blastocysts recovered

were positive by the fluorescein diacetate test.
The results of this study suggest that chronic treatment with
phenylbutazone had little if any effect on estrual behavior, estrous
cycle length or ovulation.

In addition, it appears that blastocysts

from phenylbutazone-treated mares may be viable when recovered from
the uterus between 7 and 8 days after ovulation.

Figure 10.
Bla st ocy st recovered from a mare on
d a y 8 po st - o v u l a t i o n ( x 4 0 ) . The red stai n is
d e r i v e d from the phenol red in PB-1 embry o
hol din g medium.

Figure 11.
Bl a s t o c y s t (Figure 10) stai ned w i t h
fl uo res cei n di a c e t a t e ( x 4 0 ) . The gree n stain
sugg es ts em bryo viability.

EXPERIMENT II

Analysis of Phenylbutazone in Plasma and Uterine Secretions
of Mares by High Performance Liquid Chromatography

INTRODUCTION
Since phenylbutazone distributes throughout the horse (Tobin,
1979a) and is capable of traversing the blood-brain barrier (Tobin,
1981a) it was assumed in Experiment I that phenylbutazone was poten
tially capable of entering uterine tissue following parenteral admin
istration.

However, results of Experiment I did not support the

hypothesis that long-term phenylbutazone therapy would interfere with
prostaglandin synthesis in the uterus and consequently disrupt
estrous cycle length in the chronically-treated mare.

It was then

proposed that possibly phenylbutazone did not have any receptor sites
in the mare uterus and did not accumulate there.

Consequently, it

was decided to evaluate if phenylbutazone was being concentrated in
the uterine fluids.
The appearance of a mucopurulent vaginal discharge when embryo
collection was attempted in Experiment I prompted the investigation
to determine if circulating progesterone concentrations affected the
incidence of uterine inflammation.

The progesterone-dominated bovine

uterus is more susceptible to bacterial infections than the
estrogen-dominated uterus (Black et al., 1953; Rowson et al., 1953;
Archbald, 1980).

Therefore, it was decided to determine if circulat

ing progesterone concentrations affected the incidence of uterine
inflammation in the mare.
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OBJECTIVES
The objectives were

(1) to test the hypothesis that phenylbu

tazone accumulates in the normal and/or pathological equine uterus by
determining concentrations of phenylbutazone in uterine secretions;
(2) to determine if progesterone levels affected incidence of uterine
inflammation; (3) to determine phenylbutazone concentrations in
circulating blood at the time the uterine samples were collected.

MATERIALS AND METHODS
Seven mares of mixed breeding (4 to 6 years-of-age) averaging
450 kg bodyweight were housed in large pens at the Louisiana State
University School of Veterinary Medicine and fed good quality grass
hay, trace mineral salt and water ad libitum.

Four mares were each

given 2 g phenylbutazone (Butazolidin , 200 mg/ml; D-M Pharmaceuti
cals, Kansas City, MO.) intravenously (treated group) and 3 mares
were given 10 ml sterile physiological saline intravenously daily
(control group).
Uterine secretions were obtained 1 day prior to treatment
(December 21, 1981) and daily until January 20, 1982.

They were

obtained by a modified non-surgical collection technique described by
Zavy et al., 1978.

After perineal washing (Pickett, 1973) a sterile

long-sleeved glove was used to insert a 30 French Foley catheter with
a 30-ml inflatable cuff through the cervix.

To ensure a snug fit

against the internal os of the cervix, the cuff was inflated via a
sterile syringe with =30 ml air and pulled caudally.

Sixty ml of

sterile physiological saline were infused through the catheter via a
sterile syringe into the uterine lumen.

The uterus and uterine horns
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were manipulated per rectum for 5 minutes after which the flush
containing the uterine secretions was slowly massaged out of the
uterus, through the catheter and collected by gravity flow into a
sterile 60 ml syringe case.

Samples were immediately refrigerated

standing upright in the syringe case.

All of the mares were collect

ed following the same sequence at the same time each day.

Collection

time was recorded and then each mare was immediately administered
intravenously 2 g phenylbutazone or 10 ml physiological saline.
Visual examination of the recovered uterine flushing was then
conducted and catagorized as follows

(1) clear, appeared to have no

uterine particles and looked like the physiological saline infused
into the uterus; (2) cloudy, had diffuse white or slightly yellow
particles and some sediment; (3) purulent, had a thick white or
yellow sediment.
The uterine flushes were allowed to stand overnight in the
refrigerator.

Every morning the entire volume of each uterine

flushing was measured, the supernatant was poured into another
sterile 60 ml syringe case for storage at -20°C until analysis and
the sediment was discarded.

Percent of flushing medium recovered was

calculated and recorded.
For the current experiment, sodium heparin and ethylenediaminotetraacetate (EDTA) anticoagulant vacutainers were utilized to
harvest jugular blood samples from mares.

Ethylenediaminotetraace-

tate samples were designated to confirm circulating phenylbutazone
levels.

Sodium heparinized samples were designated to determine

circulating progesterone concentrations, but they were also utilized
to run duplicate plasma samples because there was a shortage of EDTA
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plasma for the experiment.

During the process of assaying plasma

samples for phenylbutazone concentrations, it was noted there was a
distinct chromatographic peak height difference between EDTA and
sodium heparin blood samples even though they were collected one
right after the other from the same mare.

Therefore, a concurrent

experiment evolved to determine if plasma from the 2 anticoagulants
gave different phenylbutazone concentration values (Appendix IV).
Heparinized and EDTA blood samples were collected daily from
each mare via jugular venipuncture.

Progesterone concentrations were

analyzed by the solid-phase, no extraction Coat-A-Count assay kit
described in Appendix III.
Two preliminary studies were conducted in our laboratory.

The

first one determined that removing the organic extraction solvent in
a stream of air instead of nitrogen did not adversely affect the
determination of phenylbutazone concentrations in uterine secretions
or plasma (Appendix V).

The second one determined that phenylbuta

zone concentrated in the supernatent rather than the sediment
(Appendix VI).
Concentrations of phenylbutazone in uterine samples were
determined by HPLC as described for plasma samples by Taylor et a l .
(1981).

The following modifications were made

(1) the organic

solvent was removed in a stream of air instead of nitrogen; (2) 25 ml
aliquots of uterine flushing were used instead of 2 ml; (3) 2 ml 10%
(w/w) hydrochloric acid was used instead of 1 ml; (4) residue was
dissolved in 50 yl of tetrahydrofuran instead of 150 yl.
A Waters Associates 254 Model-440 liquid chromatograph was used
with a prepacked Whatman Partisil PXS 10/25 Column No. IB separation
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column and an HC Pellosil CKS1 guard column.
Statistical analysis was performed using an unpaired Student's
t-test (Snedecor and Cochran, 1980) to determine if there was a sig
nificant difference in percent of uterine flushing medium recovered
from inflamed versus normal uteri in both treated and control groups.
A Chi-Square analysis (SAS, 1988) was used to determine if there was
a significant difference in incidence of uterine inflammation between
phenylbutazone-treated and physiological saline control mares.

RESULTS
A total of 109 samples of uterine secretions were collected
from treated mares (n = 4) and were monitored for phenylbutazone.

Of

these, 53, 28 and 28 secretions were catagorized as clear (48.6%),
cloudy (25.7%) and purulent (25.7%), respectively.
positive for phenylbutazone.

Nine samples were

Of these, 6 and 3 samples were from

purulent and cloudy secretions, respectively.

Percentage of secre

tions positive for phenylbutazone content from phenylbutazone-treated
mares was 8.33% (Table 10).

Two phenylbutazone positive samples

demonstrated a trace estimated at =40 and 120 parts per billion,
respectively.

Concentrations of phenylbutazone in the other 7

uterine secretion samples that tested positive were 3.0, 3.5, 6.0,
12.0, 13.0, 25.0 and 31.5 pg/ml, respectively.
A total of 122 uterine secretion samples from physiologicalsaline control mares were analyzed for phenylbutazone content and
none of these were positive for phenylbutazone.

Of the total, 99

(81.1%), 14 (11.5%) and 9 (7.4%) were catagorized as clear, cloudy
and purulent, respectively (Table 10).
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More uterine secretion samples from control mares were analyzed
than from treated mares because pretreatment samples were collected
from each mare to be used to run standard curves and preliminary HPLC
studies (Appendix VIII).
Mares with cloudy and purulent secretions were thought to have
uterine inflammation.

Inflammation was also evaluated by measuring

the volume of secretion recovered.

Secretions were grouped as normal

uterus (clear) and inflamed (cloudy + purulent).

More fluid was

recovered from inflamed uteri than the 60 ml physiological saline
infused, suggesting fluid accumulation.

Means (± SEM) uterine fluid

volume recovered from control mares were 45.6 ± 0.2 ml and 129.7 ±
9.8 ml for normal and inflamed uteri, respectively.

Mean uterine

fluid volume recovered from phenylbutazone-treated mares was 47.5 +
14.5 ml and 125.4 + 2.5 ml for normal and inflamed uteri, respective
ly (Table 11).
Volume of uterine secretions recovered from inflamed uteri was
larger (P < 0.01) than from normal uteri in both treatment and con
trol groups (Table 11).

Chi-Square analysis determined there was a

greater (P < 0.001) incidence of uterine inflammation in mares being
treated with phenylbutazone compared with saline-treated control
mares.
Results of the progesterone assay determined that 2 of 4
control and 2 of 4 treated mares had active corpora lutea (progester
one values > 1 ng/ml).

Two control and 2 treated mares did not have

active corpus lutea as determined by progesterone values < 1 ng/ml.
Of the 9 uterine secretion samples that were phenylbutazone positive,
7 had a concurrent progesterone value of < 1 ng/ml and 2 had
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progesterone values of 17.94 and 18.50 ng/ml, respectively.

Table 10. Results of visual examination of uterine secretions
recovered from phenylbutazone-treated and physiological
saline (PS) control mares and of high performance liquid
chromatography (HPLC) analysis for phenylbutazone (PBZ)
content

Treatment
Visual
appraisal

Sali ne
no.
%

PBZ
no.

Clear
Cloudy
Purulent

99
14
9

53
28
28

Total

122

81. 1
11. 5
7. 4

109

%

48.6*
25-7b
25.7b

HPLC
analysis
PBZ positive
(treated mares)

0
3
6
9 (8.3%)

cL b
’ Percents with different superscripts within column are signifi
cantly different (P < 0.001)
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Table 11.

Mean percent and volume of uterine flushing medium
recovered from phenylbutazone-treated and physiological
saline (PS) control mares

Recovered flushing medium/mare
Uterine
treatment

condition

(n)

Percent (%)

Volume(ml)^

Saline
Normal

99

Inflamed

23

Normal

53

Inflamed

56

75.6a
176.8

45.6
129.7

Phenylbutazone
78.3a
180.3

47.5
125.4

^ Flushing significantly different (P < 0.01) between conditions
60 ml of physiological saline was infused into the uterus

DISCUSSION
Phenylbutazone was detected only in cloudy and purulent uterine
secretions from phenylbutazone-treated mares.

Results suggested that

phenylbutazone accumulated in detectable amounts (HPLC) only in mares
with an inflamed uterus.

Inflammation was appraised in phenylbuta

zone positive secretions by presence of a mucopurulent sediment and/
or a volume of recovered medium greater (P < 0.01) than that which
was infused into the uterus, which suggested accumulation of other
fluids in the uterus as described by Archbald (1976), Higgins and
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Lees (1984) and May et al. (1987).
Results show there was a 2 and 3-fold increase in the number of
uterine samples catagorized as cloudy and purulent, respectively, for
phenylbutazone-treated mares when compared with cloudy and purulent
samples from control mares.

Results suggest that phenylbutazone

treatment enhances (P < 0.001) the chances of uterine infections in
mares.

This possiblity was also suggested in Experiment I because

40% of the phenylbutazone-treated mares exhibited pyometra at the
time of embryo collection when compared to 25% of the control mares.
Results showed a doubling (6 versus 3) of the number uterine
fluids samples in which phenylbutazone accumulated in detectible
amounts in purulent flushes (indicating heavy inflammation) compared
with cloudy flushes (suggesting slight inflammation).

An explanation

of this finding may be that phenylbutazone adhered to the leucocytes
found in the sediment because phenylbutazone is 98% protein bound
(Tobin, 1981b).
Phenylbutazone accumulated in detectible amounts in only 9 of
the 56 (16.1%) uterine flushings appraised as those from inflamed
uteri.

This suggests that phenylbutazone does not necessarily

accumulate at all times in all mares exhibiting a uterine infection
even though it appears that phenylbutazone potentiates a uterine
inflammatory condition.
During the course of the experiment, 50% of the treated and 50%
of the control mares had active corpora lutea (progesterone > 1
ng/ml).

Therefore, it appeared that phenylbutazone had no affect on

luteal function.
Progesterone concentrations determined that phenylbutazone
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accumulated in inflamed uteri under both high and low progesterone
concentrations.

Seven of 9 (77.7%) phenylbutazone positive uterine

flushings had concurrent progesterone values of < 1 ng/ml while 2 of
9 (22.2%) had high progesterone concentrations.

Phenylbutazone

accumulation in the inflamed uterus appeared to be associated with
low peripheral progesterone concentrations.
plained at this time.
physiological basis.

This finding is unex

This phenomenon may or may not have had a
It is contrary to that reported in the cow

where the progesterone-dominated bovine uterus is more susceptible to
uterine infections than the estrogen-dominated uterus (Black e_t al.,
1953; Rowson et al., 1953).
The source of the uterine inflammation was not ascertained.

It

appeared that it was the result of daily manipulation and intubation
of the uterus.

All pretreatment samples were clear and the amount of

flushing medium recovered was less than that which was infused, which
concurred with uterine secretions from normal uteri.

This finding

confirmed that all uteri were normal before that daily saline infu
sions started.

Therefore, uteri became inflamed due to the daily

intubation procedure and was potentiated (P < 0.001) by chronic phen
ylbutazone treatment.

EXPERIMENT III

Effect of Phenylbutazone on Luteolysis
Induced by Uterine Biopsy in the Mare

INTRODUCTION
Results of Experiment I demonstrated that chronic administra
tion of phenylbutazone to mares exhibiting a nonpathological uterus
did not affect estrual behavior, ovulation or length of estrous
cycle.

Results of Experiment II suggested that phenylbutazone accum

ulated primarily in the inflamed uterus of the mare.

It was then

proposed that parenterally administered phenylbutazone will accumu
late in an inflamed uterus, interrupt prostaglandin synthesis and,
therefore, extend the estrous cycle of the mare.
The method chosen to specifically inflame the uterus was endo
metrial biopsy.

Uterine biopsy performed on day 4 post-ovulation

shortened the estrous cycle of mares by inducing an inflammation that
stimulated an increased synthesis and release of uterine prostaglan
dins resulting in premature luteolysis (Hurtgen, 1975; Hurtgen and
Whitmore, 1978; Hurtgen and Ganjam, 1979; Baker et al., 1981).

OBJECTIVES
The objective of this experiment was to test the hypothesis
that parenterally administered phenylbutazone in the mare will
accumulate in the uterus that has been inflamed by biopsy and inhibit
uterine PGF OC synthesis.
2

Consequently, to evaluate if the phenyl

butazone treatment will block the luteolysis induced by the uterine
biopsy performed on day 4 post-ovulation and will extend the estrous
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cycle.

MATERIALS AND METHODS
Seven mares of mixed breeding, between 4 and 6 years of age and
averaging 450 kg body weight, were purchased and maintained as an
experimental group at the Louisiana State University School of Veter
inary Medicine.

Each mare was given a thorough general physical and

breeding soundness examination prior to purchase.

Prior to and dur

ing the period of study (March through mid-August) mares were fed 8
liters of mixed grain concentrate/mare/day, grass hay and water free
choice.

All mares were in good body condition at the beginning of

treatment and were subsequently maintained in large pasture lots with
native grass cover during the study.
Mares were teased every morning with an androgenized gelding to
determine the onset of estrus and each estrous mare was rectally pal
pated to evaluate ovarian structures on a daily basis.

Mares were

monitored for estrual activity during untreated estrous cycles start
ing in mid-February.

After mares had exhibited 2 normal length

estrous cycles (18 to 24 days), they were allotted to treatment on
the first day of the third cycle.

On the first day of the treatment

estrous cycle each mare was administered intravenously 2 g phenylbu
tazone (Butazolidin , 200 mg/ml; D-M Pharmaceuticals, Kansas City,
MO.) in Treatment A.

On the first day of the control estrous cycle

each mare was administered intravenously 10 ml of sterile physiologi
cal saline in Treatment B.
Treatments were continued daily until each mare exhibited an
estrous response.

Mares were treated with phenylbutazone or physio-
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logical saline using a switchback experimental design alternating
between Treatment A and Treatment B on successive estrous cycles.
The first mare exhibiting a third estrus received phenylbutazone, the
second received physiological saline.
ed into treatments in this manner.

Remaining mares were alternat

Assignments were made until the

end of the cyclic season in mid-August.

The switchback treatment

design was used to aid in reducing individual animal variability
within the experiment by allowing each treated mare to also serve as
her own control.
The day of ovulation (day 0) was determined by rectal palpation
and later verified by peripheral plasma progesterone levels.

On day

4 post-ovulation all mares were subjected to uterine biopsy using the
instrument and methods previously described (Hurtgen and Whitmore,
1978; Baker et al., 1981).

Following uterine biopsy, mares were

teased each morning (0800 hours) and then either Treatment A or
Treatment B was continued on a daily basis.

Estrual behavior was

evaluated from the response of each mare to the androgenized gelding
and later verified by plasma progesterone concentrations.
Blood samples were collected prior to administration of Treat
ment A or Treatment B on a daily basis via jugular venipuncture.
Circulating progesterone levels on the first day of estrus, on the
day of presumed ovulation, on the day of biopsy and on the day of
induced estrus verified follicular development, a functional corpus
luteum and ensuing luteal regression.

Plasma progesterone concentra

tions were determined by a no-extraction solid-phase RIA (Appendix
III).

Coefficient of variation for both intra-assay and inter-assay

analysis was 5.8Z and 7.2%, respectively, for all plasma samples
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evaluated in this study.
Mean plasma progesterone levels for specific days and mean
number of days from uterine biopsy to the next estrous period for
both treated and control cycles were compared for significance using
a Student's paired t-test (Snedecor and Cochran, 1980).

RESULTS
A total of 19 estrous cycles (10 treated and
were evaluated

(Table 12).

9 control cycles)

Mean number of days (+ SEM) from uterine

biopsy to the next estrous period was 9.20 ± 0.34 days for treatment
cycles and 5.00 + 0.16 days for control cycles.
to estrus were

These mean intervals

significantly different (P < 0.025) withphenylbuta

zone treatment cycles longer than control cycles.
Plasma progesterone concentrations verified low concentrations
(< 1 ng/ml) at ovulation and at the estrus after uterine biopsy
(Figure 12).

Ovulation and the presence of functional luteal tissue

at the time of uterine biopsy (day 4) were also verified by
progesterone levels (> 5 ng/ml).
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Table 12.

Mean intervals from biopsy to estrus and plasma proges
terone (P^) concentrations in mares treated daily with
either phenylbutazone (PBZ) or physiological saline (PS)

Treatment3

Item

No. of cycles evaluated*5

Mean interval from biopsy
to estrus (days)

Mean plasma P^ concentra
tions at day 0 (ng/ml)

Mean plasma P, concentra
tions at day 4 (ng/ml)

Mean plasma P^ concentra
tions at induced estrus (ng/ml)

A
2 g PBZ daily

B
Saline daily

9

10

9.20c
±0.34

5.00°
±0.16

0.98
±0.34

0.88
±0.34

15.56
±1.72

14.21
±1.77

0.75
±0.37

0.44
±0.25

aMean (± SEM)
^A total of 7 cyclic mares allotted to a switchback design
c ci
’ Means with different superscripts in rows were
significantly different (P < 0.025)
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Mare No. 7 (Cycles 2 and 3)
“ PBZ Treatment
™ Saline Treatment

26

22

-
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e
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o
a
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Estrus
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I

4

6
8
10 12
Treatm ent Cycle | Days

i
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Saline Daily
Experimental
Design 1.

|

Estrus

OV
Estrus

Start
PBZ Dally

BIO[",y

f

Diestrus

12

Start
' PBZ Dailv
I.Eatrus fig | | Diestrus
Start
Saline Dally

♦

OV
Estrus

20

Diestrus

Estrus

Fi g u r e 12.
P l a s m a p r o g e s t e r o n e p r o f i l e s for a typical
e x p e r i m e n t a l m a r e (No. 7) for t r e a t m e n t cycles 2 a n d 3
u s i n g the s w i t c h b a c k design.
D u r i n g trea t m e n t cycle
nu m b e r 2 this m a r e w a s a d m i n i s t e r e d 2 g of p h e n y l b u t a z o n e
(PBZ) d a i l y u n t i l it e x h i b i t e d an e s t r o u s response.
O n the
first d a y of t r e a t m e n t cycle n u m b e r 3 this m are w a s a d m i n i s 
te r e d p h y s i o l o g i c a l saline u n t i l the s u b s e q u e n t estrus.
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DISCUSSION
Results support the hypothesis presented in the objectives of
this experiment indicating that treatment with phenylbutazone can
delay luteolysis induced by uterine biopsy on day 4 post-ovulation.
It seems reasonable to assume that acutely inflamed uterine tissue,
resulting from the biopsy, sequestered phenylbutazone in adequate
concentrations to inhibit synthesis of uterine prostaglandins.

In

this regard, it has been previously shown that phenylbutazone does
accumulate in inflamed tissues (Brune et al., 1976; Tobin, 1979a).
This finding agrees with the results of Experiment II, which showed
measurable levels of phenylbutazone in uterine flushings collected
from phenylbutazone-treated mares that exhibited an inflamed uterus.
Results of Experiment II showed that uterine flushings from phenyl
butazone-treated mares containing purulent material also contained
measurable levels of phenylbutazone.

Uterine flushings from treated

and control mares in which there was no evidence of uterine inflamma
tion did not have a detectable level of phenylbutazone.
The occurrence of estrus at 5.0 days following uterine biopsy
during the early luteal phase of the equine estrous cycle in the
control group (Treatment B) agrees with the findings of others
(Hurtgen, 1975; Hurtgen and Whitmore, 1978; Hurtgen and Ganjam,
1979; Baker et al., 1981).

Presumably, uterine biopsy caused release

of uterine prostaglandin resulting in luteolysis and return to estrus
in these mares.
From the results of the present experiment and those previously
reported from this laboratory, it is proposed that phenylbutazone
will cause inhibition of prostaglandin synthesis with a consequental
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blockage of luteolysis only in those mares with an existing acute
uterine inflammatory reaction.

These previous experiments also

demonstrate that the synthesis and cyclic release of uterine prosta
glandin from a nonpathological equine uterus appears to be unaffected
by parenteral treatment of the mare with phenylbutazone.

EXPERIMENT IV

Effect of Chronic Administration of Phenylbutazone
on Fertilization, Embryo Size and Embryo
Prostaglandin Synthesis in Mares

INTRODUCTION
Results of Experiment II showed that parenterally administered
phenylbutazone accumulated in detectable amounts in mares exhibiting
an inflamed uterus.

Results from Experiment III suggested that phen

ylbutazone accumulated in the equine uterus that had been stimulated
by biopsy on day 4 post-ovulation and effectively inhibited uterine
prostaglandin synthesis that is necessary for luteolysis.
It is proposed that biopsy illicites an inflammatory response.
Vasodialation is a major feature of inflammation (Higgins and Lees,
1984; May et al., 1987).
of pregnancy.

Vasodialation is also a prominant response

Ford (1985) reported a 2 to 3-fold increase in uterine

blood flow to the gravid uterus of the cow, sow and ewe during the
late luteal phase of early pregnancy coinciding with maternal
recognition of pregnancy.

It was proposed that pregnancy will

sequester parenterally administered phenylbutazone to the uterus in
adequate concentrations to inhibit uterine and embryo prostaglandin
synthesis and consequently inhibit equine embryo development.
In Experiment I, 1 viable embryo was recovered from a phenylbu
tazone-treated mare.

This result demonstrated that fertilization and

embryo viability were possible in phenylbutazone-treated mares.
Further investigation was deemed necessary to determine if fertility
and embryo viability were inhibited in phenylbutazone-treated mares.
An extensive literature search showed no method previously
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established for preparing the equine blastocyst for quantification of
embryo prostaglandin synthesis.

OBJECTIVES
The objectives of this experiment were to

(1) test the

hypothesis that increased blood flow to the gravid equine uterus will
increase the accumulation of phenylbutazone that will interrupt
uterine prostaglandin synthsis and therefore affect early embryonic
development; (2) test if phenylbutazone daily administered to preg
nant mares will interrupt conceptus prostaglandin synthesis; (3) to
substantiate previous data from our laboratory regarding fertility
and embryo viability in mares treated with phenylbutazone; (4) to
develop an acceptible method to collect and process the equine
blastocyst for extraction of embryo synthesized prostaglandins.

MATERIALS AND METHODS
Fourteen mares of mixed breeding (averaging 450 kg body weight)
between 4 and 6 years-of-age were used in this experiment.

Mares

were maintained from May to September on a grass pasture at the
Louisiana State University School of Veterinary Medicine with miner
alized salt free-choice and supplemented with 8 liters mixed grain/
mare/day.

Mares were teased daily by a stallion and ovulation was

determined using daily rectal palpation once a day at mid-morning.
Mares were mated by natural service once or twice a day after detect
ing a follicle > 30 mm in diameter.

Treated mares were administered

2 g phenylbutazone (Butazolidin ; D-M Pharmaceuticals, Kansas City,
MO.) intravenously (Treatment A).

Control mares were similarly
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treated with 10 ml physiological saline (Treatment B).

Treatment A

or B started on the first day of estrus and continued daily there
after until the day of embryo collection.

Non-surgical embryo col

lection was performed as described (Imel e_t al., 1981) starting on
days 8, 9 or 10 post-ovulation (day 0 = palpation day of follicle
rupture).

Dulbecco's phosphate-buffered saline (PBS) with 1% fungi

zone and antibiotic was used the as flushing medium (Appendix Table
I.)
Recovered embryos were immediately placed into a sterile petri
dish containing =6 ml flushing medium (Appendix Table II).

The

embryo was then examined for morphological development under the
stereomicroscope.

Embryos were then photographed at 6x, 12x, 25x and

50x using a 35 mm Nikon camera attached to a Wild M5D light micro
scope.

Each embryo was then transferred to a capped tube containing

6 ml sterile PB-1 holding medium at room temperature for transport to
the laboratory.

Embryos were then prepared by one of 3 different

methods for prostaglandin synthesis determination by RIA.
The first method was labeled homogenization, incubation and
extraction (HIE).

The embryo was transferred into a glass homogen

izing vial filled with 10 ml PB-1 holding medium and placed on ice.
Embryos were homogenized in each method by 10 strokes of a glass
teflon homogenizing apparatus attached to a hand drill.

One ml

aliquots of homogenate were put into plastic tubes and incubated for
0, 5, 10, 20, 30, 40, 50 and 60 minutes in a 37°C shaking water bath.
The incubation was stopped by the addition of 20 pi of 5% formic
acid.

Then, 5 ml of ethyl acetate was added to each tube to extract

prostaglandins.

The solution was allowed to stand at room tempera-
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ture for 30 minutes and the extraction phase was then repeated.

The

tubes were then evaporated in a stream of

reconstituted in 2 ml

phosphate buffered saline-gel and sonicated,

Aliquots of 600 pi from

each incubation time (set of 3 tubes) were covered and stored at
-20°C until assayed by RIA (Hwang, 1985) for PGE , PGF «x and 6-keto2

PGF^a (the PGI

2

2

metabolite).

The second method was labeled intact embryo incubation and
extraction (HE).

One day 8 embryo was put in 10 ml flushing medium

in a sterile covered embryo collection dish and incubated in a 37°C
incubator for 5, 24, 48 and 72 hours.

Another day 8 embryo was incu

bated in a sterile capped glass vial containing 4 ml PB-1 holding
medium in a 37°C water bath for 0, 6, 12 and 18 hours.

One ml ali

quots of medium were drawn off at the prescribed times, extracted and
frozen as previously mentioned.
The third treatment was homogenization (H).
was homogenized in 4 ml PB-1 holding medium.

The day 10 embryo

The homogenate was not

extracted but rather frozen in 600 pi aliquots.
Uterine flushing medium recovered along with each embryo was
also assayed for prostaglandin concentrations.

One ml aliquots from

every embryo collection medium were extracted and frozen.
Embryos from control mares were assayed for prostaglandins by
RIA as described by Hwang (1985).
PGI

2

Results showed a distinct PGE

peak at 5 minutes of incubation for the day 9 HIE embryo.

10 HIE embryo peaked at 60 minutes for PGE .
2

2

and

A day

Consequently, serial

incubation time for future HIE embryos was stopped at 30 minutes.
The day 8 IIE embryos had a PGE

2

and PGI

2

peak at 24 hours, but the

concentration was one-third less than the 5 minute HIE peak.

The
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homogenized (H) embryo showed a very high PGE
HIE and IIE embryos.

2

content compared with

Results suggested that in order to stay safely

within the RIA assay standard curve, day 9 embryos should be collect
ed and processed as HIE for the remainder of Experiment IV.
Three more control and 4 treated embryos were collected on day
9 post-ovulation, processed as HIE, frozen and assayed.

Another day

10 control embryo was collected and homogenized (H) but this time in
10 ml PB-1 instead of 4 ml in order to study an appropriate tissue
dilution factor.

One uterine flushing sample was assayed from all 5

control and 4 treated HIE embryos.

All these embryos and uterine

flushings were assayed by RIA.
Data was tested for significance using

SAS (SAS Institute,

1988) analysis of variance with a split plot design.

Data was tested

for significance using SAS (SAS Institute, 1988) Student's unpaired
t-test.

RESULTS
The 4 embryos from the phenylbutazone-treated mares demonstrat
ed a standard zona pellucida and capsule reaction under microscopic
examination (12x).
normal.

All cellular aspects of the blastocysts appeared

However, embryos from the phenylbutazone-treated mares were

noticeably smaller and more fragile than embryos

from control mares.

Embryos from control mares had a thick whitecapsule,

but the embryos

from the phenylbutazone-treated mares had a thin translucent capsule.
One embryo from a phenylbutazone-treated mare broke apart simply
being drawn into the transfer pipette.
Results of the RIA assays for prostaglandins are presented in
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Tables 13, 14 and 15.

The prostaglandin peak in Table 13 for a day 9

HIE embryo at 5 minutes incubation in the preliminary prostaglandin
assay was not demonstrated by any other embryos.
Incubation time was not significant, but there was a highly
significant difference of prostaglandin synthesis between embryos
from phenylbutazone-treated mares and embryos from saline-treated
control mares for PGE
0.0004).

2

(P < 0.0001), PGF «x (P < 0.0001) and P G ^
2

(P <

Three of 4 (75%) embryos from phenylbutazone-treated mares

synthesized no detectible amounts of PGF <x or P G ^ *

Prostaglandin E

2

appeared to be the dominant prostaglandin synthesized by the day 9
blastocyst from phenylbutazone-treated mares.

Data of embryos from

control mares shows PGE2 and PGF2a were produced in approximately
equal concentrations and PGI

2

approximately two-thirds less.

A

summary of means for the prostaglandin assay is present in Table 17.
Data of embryos from control mares shows another prostaglandin
synthesis pattern (Table 14).
higher concentrations of PGI
synthesis of PGI

2

2

The day 9 HIE embryo synthesized
than PGE .

Day 8 H E embryos had

2

dominanting between 0 to 18 hours, but PGE

dominant at 24 to 72 hours.

2

was

The control day 10 H embryo showed

another pattern with PGF <x being dominant at near double the concen
2

tration of approximately equal concentrations of PGE

2

and P G ^ -

The 3 prostaglandins assayed were also detected in uterine
flushings.

There was no significant difference in prostaglandin

concentration between uterine flushings recovered from phenylbuta
zone-treated and saline control mares for all 3 prostaglandins
evaluated in this experiment (Table 16).
Results in Table 13 show a peak PGE

2

and PGI

2

at 24 hours for

2

day 8 H E

and a much higher prostaglandin synthesis for day 10 HIE

than day 9 HIE.

A review of the methods and summary of results is

presented in Table 14.
concentration.

Homogenization produced a high prostaglandin

It remained undetermined if it was the procedure or

the embryo itself that produced the high prostaglandin concentration.
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Table 13.

Results of preliminary radioimmunoassay for prosta
glandins E„ and ^ synthesized by equine embryos recover
ed from saline-treated control mares on days 8, 9
or 10 post-ovulation
u

Daya

Treatment

Time0

9

HIE

0 minutes
5
10
20
30
40
50
60

10

HIE

0
5
10
20
30
40
50
60

8

8

10

IIE

IIE

H

pge9
ng/ml

PGH
ng/ml

0.62
8.95
0.16
0.13
0.11
0.12
0.13
0.17

0.00.
18.50
0.13
0.12
0.10
0.11
0.18
0.44

3.41
4.14
4.34
4.83
6.47
7.63
7.49.
10.54

_d
-

—

0 hours
6
12
18

0.13
0.29
0.00
0.30

0.37

5
24
48
72

°-03*
3.06
2.95
2.78

0.11
0.82
0.56
0.51

-

13.13

^Number of days ovulation to embryo collection
Treatment to prepare embryo for assay
HIE = Homogenized, Incubated, Extracted
H E = Intact embryo, Incubated, Extracted
H = Homogenized
^Incubation time
Assay not run
*Peak prostaglandin concentration

0.62.
0.71
0.43

-
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Table 14.

Equine embryo treatment groups and peak prostaglandin
E concentrations from Table 13
2

Day of
cycle

Treatment
of embryo

8

IIEa

9

HIEb

Incubation time
of peak PG

24 hours

PGE„
(ng/ml)

3.06

5 minutes

8.95

10

HIE

60 minutes

10.54

10

HC

0 minutes

13.13

aIIE = intact embryo incubated and medium extracted
bHIE = homogenized embryo, medium incubated and then extracted
H = homogenized embryo (no incubation or extraction)

Table 15. Prostaglandin synthesized by day 9 post-ovulation
embryos recovered from physiological saline (PS) and phenylbutazone
treated mares. Embryos were homogenized, incubated and extracted.
Prostaglandin (ng/ml)

Mare
number
Saline
28

Incubation
time
(minutes)

pge2

0
5
10
20
30

0.10
0.12
0.12
0.13
0.15

0
5
10
20
30

0.17
0.15
0.17
0.15
0.16

0
5
10
20
30

0.18
0.21
0.21
0.19
0.18

Phenylbutazone
0
28
5
10
20
30

0.14
0.15
0.14
0.19
0.16

0
5
10
20
30

0.05
0.14
0.15
0.13
0.14

0
5
10
20
30

0.13
0.08
0.11
0.14
0.09

0
5
10
20
30

0
0
0.13
0.10
0.07

23

24

32

29

27

X

PGF2a

0.12

0.13
0.15
0.14
0.13
0.18

0.16

0.16
0.15
0
0.12
0.10

0.19

0.21
0.20
0.22
0.18
0.18

0.16

0
0
0
0
0

0.12

0
0
0
0
0

0.11

0.04
0.06
0.05
0.06
0.03

0.06

0
0
0
0
0

X

pgi2

X

0.15

0.02
0
0.04
0
0.009

0.01

0.11

0.09
0
0.04
0.04
0

0.03

0.20

0.007
0.07
0.22
0.11
0.13

0.11

0

0
0
0
0
0

0

0

0
0
0
0
0

0

■

0.05

0

0.001
0.05
0.002
0
0
0
0
0
0
0

0.01

0
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Table 16.

Prostaglandin concentrations for uterine flushings
recovered with day 9 equine embryos

Prostaglandin (ng/ml)
Mare
treatment group

Physiological
saline

Phenylbutazone

P*^

0.11
0.09
0.07
0.06
0
0
0.10

0
0.07

_
X

0.07

0.04

p^F2a

0.20
0.07
0.69
0.06
0.06
2.32
0.02

_
X

0.22

0.60

_
X

0.02
0
0
0
0
0.45
0

0.02

0

0.02

0

0

0.11
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Table 17.

Sample

Uterine
flushing3

Embryos**

Mean prostaglandin concentrations for equine uterine
flushings and day 9 equine embryos from phenylbutazone
(PBZ) treated and physiological saline (PS) control mares

n

PGE?
ng/ml

p g f 9«
ng/ml

pgi7
ng/ml

PS
PBZ

5
4

0.066 ± 0.010
0.043 ± 0.025

0.216 + 0.121
0.595 ± 0.575

0.004 + 0.004
0.113 ± 0.113

PS
PBZ

3
4

0.159 + 0.007° 0.150 ± 0.007° 0.052 + 0.008c
0.112 ± 0.006 0.012 ± 0.006 0.002 ± 0.007

Treatment

?Mean (± SEM)
Least-Squares Mean (± SEM)
cTreatment significantly different (P < 0.001)
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DISCUSSION
Results suggest that fertilization was not impaired by
parenteral treatment of mares with phenylbutazone.

Analysis of

embryo photographs suggests that treatment did not affect the zona
pellucida reaction and other standard morphological developments.
Embryos recovered from phenylbutazone-treated mares appeared viable,
but less likely to survive compared with embryos from control mares.
Most of the embryos from phenylbutazone-treated mares were
difficult to locate in the flushing medium without a microscope while
embryos from control mares were easily visible.

Inhibition of embryo

expansion appeared to occur in phenylbutazone-treated mares similar
to the results reported for the embryos of indomethacin-treated
rabbits (Hoffman et al., 1978).

Because embryos were not systemati

cally photographed in this experiment to determine diameter, this
observation was not statistically evaluated.

It was then decided to

photograph every embryo in the subsequent experiment to determine its
diameter.

This apparent size difference also generated interest in

determining whether embryo protein content was affected by phenylbu
tazone treatment of the mare.

Thus, future embryos were also to be

prepared for the Lowry protein assay.
Results from this experiment suggest that phenylbutazone
administered to pregnant mares significantly inhibited embryo synthe
sis of prostaglandins F^a,

and

This finding may have been the

cause of inhibition of ovum transport, blastocyst hatching, blasto
cyst expansion, embryo implantation, fetal development and live birth
rate reported by other researchers (see Table 6).
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The dominant prostaglandin synthesized by equine embryos
changed with age of the embryos.

This finding concurs with Hwang

et . a l . (1988) who reported transitional changes in prostaglandin
synthesis by bovine embryos at different developmental stages.
PGF <x was the dominant prostaglandin detected in uterine
2

flushings, PGE

was intermediate and PGI

2

tion (Table 16).

2

was the lowest concentra

The dominance of PGF « is in agreement with
2

Bergland et al. (1982) and Sharp et al. (1984), who reported a
significant increase of uterine luminal PGF <x synthesis and/or
2

secretion in pregnant mares due to transcervical lavage stimulation
in the presence of a prostaglandin antagonist.
Results showed no significant difference in uterine prostaglan
din synthesis between phenylbutazone-treated and saline control
mares.

However, phenylbutazone treatment did significantly affect

embryo prostaglandin synthesis.

Therefore, the effect of phenylbuta

zone on diminished size appears to associate with the embryo itself
rather than the uterine environment.
The PGE

2

and PGI

2

peaks at 5 minutes incubation for the HIE

embryo was not demonstrated by any other embryos.
embryo produced PGE

2

However, this

concentrations for the other incubation times

falling within close range to those assayed at the end of the
experiment (Table 15).

Therefore, it was concluded that the peak was

caused by a laboratory error.
Comparison of the day 10 H embryos in Table 13 and Table 15
homogenized in 4 ml and 10 ml PB-1 holding medium, respectively,
suggests that 4 ml is too concentrated and 10 ml is too dilute in
order for the embryo prostaglandin concentrations to fall within the
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standard curve of the assay.

It was concluded that future embryos

should be placed in 6 ml PB-1 holding medium for incubation.
Due to overall laboratory time, the HIE method was discarded.
Day 10 embryos appear to synthesize the 3 prostaglandins investigat
ed. A decision was made to collect day 10 embryos and incubate them
for 24 hours in 6 ml PB-1 holding medium in the subsequent experi
ment.
Natural service breeding at =6:00 P.M. daily appeared to be
more effective than A.M. artificial insemination every other day.
When stallion power was available, natural service was conducted
twice a day (A.M. and P.M.) for any mare with a > 45 mm follicle.
Damaged embryos were found in the filter apparatus attached on
top of the 2 liter collection cylinder after flushing 3 mares on 3
separate attempts.

When a mare strongly contracted her abdomen, the

flushing medium was expelled so forcefully through the tubing that
the embryos broke apart when they hit the filter screen.
the filter was removed.

Therefore,

Outflow tubing was placed directly into the

2 liter cylinder and then embryos gently sank to the bottom of the
collection cylinder.

The top portion of the medium was then poured

off and the lower portion slowly poured through the filter to trap
the embryo.

Both modifications thereafter enhanced embryo recovery

rates and were utilized in the subsequent experiment.

EXPERIMENT V

Effect of Chronic Administration of Phenylbutazone
on Fertilization, Embryo Diameter, Embryo Prostaglandin
Synthesis and Total Embryo Protein in Mares

INTRODUCTION
Results from Experiment IV substantiated results from
Experiment I demonstrating that fertilization and embryo viability
were observed in mares being chronically treated with phenylbutazone.
Results of Experiment IV also showed that mare phenylbutazone
treatment appeared to inhibit embryo expansion and embryo prostaglan
din synthesis.

It was proposed to conduct a subsequent experiment

utilizing the same protocol as Experiment IV except to also determine
embryo diameter and embryo total protein.

Methods investigated in

Experiment IV that appeared to be the most appropriate were utilized
in Experiment V.

OBJECTIVES
The objectives of this experiment were to

(1) substantiate

data from Experiment IV; (2) determine embryo diameter; (3) quanti
tate embryo prostaglandin synthesis; (4) quantitate total embryo
protein; (5) use the experimental protocol designed from results
of Experiment IV.

MATERIALS AND METHODS
Test mares and all experimental procedures were the same as
Experiment IV except that all embryo collections were performed on
day 10 post-ovulation, a Bivona equine uterine flushing catheter
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(Bivona Inc., Gary, IN.) was used to accommodate the larger embryo
and modifications were made in embryo processing.

Within 15 minutes

after embryo collection, the embryo was placed in a sterile petri
dish and photographed at 6x, 12x, 25x and 50x magnifications.

Embry

os were transferred via sterile pipette to a capped sterile glass
tube containing 6 ml PB-1 holding medium and incubated in a 37°C
water bath for 24 hours.

Then, 3 aliquots (1 ml) of medium were

transferred to 3 parafilm covered glass vials and stored at -20°C
until assayed for prostaglandin content by RIA.

The embryo was homo

genized in the remaining 3 ml of medium with a glass teflon homogen
izing apparatus attached to a Dayton Workshop bench-top drill press
(Model 4Z660A) and frozen for Lowry protein determination.
First, 6 embryos from control mares were collected.

Then,

mares were treated with 2 g phenylbutazone intravenously and 6 embry
os were collected from these mares.

Because embryos from phenylbuta

zone-treated mares appeared smaller than those from control mares and
it was thought perhaps the diminished size was due to advanced breed
ing season rather than treatment, additional control embryos were
collected, 3 to 4 months after the first embryos were collected from
control mares.
Embryo diameters were measured with a Wild stereomicroscope
equipped with a 35 mm camera and micrometer to measure across the
embryo from zona pellucida border to zona pellucida border with a
transparent metric ruler.

First, a micrometer was placed under the

microscope where the embryos were photographed on top of a 35 mm
slide.

Slide length and width gradations were counted at 6x and 12x

magnifications.
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Homogenized embryo samples were thawed at room temperature and
assayed according to modified Lowry protein determination (Cooper,
1977).

A standard curve was determined using 0 to 250 yg bovine

serum albumin (Fraction-V; Sigma Chemical Co.) as standard protein.
Samples were diluted 1:40 with 0.1 N NaOH.

One-half ml phenol

reagent (IN) was added to each tube.

Absorbance was read at 540 nm

on a Baush and Lomb Spectronic 2000.

Data were tested for signifi

cance using SAS (SAS Institute, 1988) Student's unpaired t-test.

RESULTS
Evaluation of embryo photographs showed that parenteral
maternal phenylbutazone treatment did not affect fertilization or
blastocyst viability.

Morphological development appeared typical.

Results of embryo diameters determined at both 6x and 12x
magnifications are presented in Table 19.

The embryos from phenylbu

tazone-treated mares were SI mm smaller than embryos from control
mares.

Mean (± SEM) embryo diameters at 6x and 12x magnifications

were 2.54 ± 0.56 mm and 2.42 ± 0.20 mm for embryos from control mares
and 1.41 ± 0.18 mm and 1.80 ± 0.27 mm for embryos from phenylbuta
zone-treated mares, respectively.

Embryos from phenylbutazone-treat

ed mares were significantly (P < 0.05) smaller at both 6x and 12x
than embryos from controls mares.
Embryo total protein results are presented in Table 19.
There was no significant difference in total protein between embryos
from phenylbutazone-treated and saline control mares.

However,

embryos from phenylbutazone-treated mares tended to contain more
protein (mean + SEM) (28.01 ± 0.94 yg) than those from control mares

(25.17 + 1.25 yg).

Data suggested that as the breeding season

advanced, the trend was for protein content to increase whether in
embryos from phenylbutazone-treated or saline control mares.
Therefore, a linear regression analysis was used to determine if a
relationship existed between embryo collection dates throughout the
experimental season and protein content.

Days of embryo collection

were numbered 1 to 117 starting with the first to last embryo
collection.

There was a highly significant (P < 0.0007) (r = 0.66)

correlation between advancement of breeding season and increased
embryo total protein content.
Results of prostaglandin embryo synthesis are presented in
Table 20.

There was no significant difference between embryos from

phenylbutazone-treated and saline control mares for prostaglandin
synthesis, although PGF^a approached significance (P = 0.06).

A

comparison of mean prostaglandin concentration presented in Table 21
suggests reduced concentrations of all 3 prostaglandins synthesized
by embryos from phenylbutazone-treated mares as compared with those
from control mares.
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Table 18.

Diameter at 6x and 12x magnifications and total protein
(TP) of embryos recovered on day 10 post-ovulation from
physiological saline control and phenylbutazone-treated
mares

Embryo

Mare#

Treatment

6x(mm)

12x(mm)

A
B
C
D
E
F
M
N
G
H
I
J
K
L

135
139
135
88
2
39
88
88
88
46
2
139
39
3

C
C
C
C
C
C
C
C
P
P
P
P
P
P

2.19
1.17
2.04
2.19
2.34
1.46
2.63
6.28
1.02
1.46
1.61
1.17
1.02
2.19

2.74
1.71
2.23
2.57
2.57
1.89
3.26
_ *
1.20
1.89
1.97
1.37
1.37
3.00

TP yg/
embryo
22.83
23.10
24.23
23.45
24.87
25.37
32.37
_ *
23.71
30.01
28.87
28.96
27.12
29.39

C = saline-treated control mares
P = phenylbutazone-treated mares
TP = total protein (yg)
* Embryo too large a diameter to fit in field at 12x and was
broken when transferred to the incubating vial in the laboratory.
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Table 19.

Prostaglandin synthesis of intact incubated equine
embryos recovered on day 10 post-ovulation from
physiological saline control and phenylbutazone-treated
mares

Prostaglandin (ng/ml)

Embryo
A
B
C
D
E
F
M
G
H
I
J
K
L

Mare

Treatment

135
139
135
88
2
39
88
88
46
2
139
39
3

C
C
C
C
C
C
C
P
P
P
P
P
P

pge2

36.00
9.24
17.58
4.20
_*

8.18
1.85
0.70
12.39
1.83
3.56
_*

12.65

PGF2a

pgi2

4.31
0.70
1.84
1.02
4.39
0.70
0.61
0.13
0.46
0.23
0.50
0.27
1.14

1.58
0.26
0.74
0.16
2.34
0.26
0.10
0.08
0.19
0.11
0.16
0.11
0.59

C = saline-treated control mares
P = phenylbutazone-treated mares
* = high concentration and off standard curve

Table 20.

Mean concentrations (± SEM) of prostaglandin
synthesized by day 10 equine embryos recovered
from physiological saline (PS) control or phenylbut
azone-treated mares

Prostaglandin (ng/ml)

Treatment

PS

control

Phenylbutazone

n

PGE2

PGF2a

FGI2

6

12.84 ±

5.12

1.94 +

0.64

0.78 ± 0.32

6

6.23 +

2.60

0.46 +

0.15

0.21 + 0.08
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DISCUSSION
Results of Experiment V substantiated results from Experiment IV
regarding fertilization, embryo viability, embryo development and
embryo prostaglandin synthesis.

As in Experiment IV, most of the

embryos from phenylbutazone-treated mares were difficult to locate
with the naked eye in flushing medium while embryos from control
mares were clearly visible.
Embryo photographs showed that fertilization and blastocyst
viability were not impaired by mare phenylbutazone treatment.
Embryos from phenylbutazone-treated mares appeared to be viable, but
less likely to survive compared with embryos from control mares.
appeared that embryo expansion was inhibited.

It

Embryos from phenyl

butazone-treated mares were smaller (P < 0.05) at both 6x and 12x
magnifications than embryos from control mares.
The diminished diameter of the embryos from phenylbutazonetreated mares compared with the diameter of the embryos from control
mares coincide with the findings of other researchers (Hoffman, 1978;
Hoffman et al.,1978; Lacroix and Kann, 1982).

Blastocyst diameters

from female rabbits receiving 8 mg indomethacin/kg subcutaneously
twice daily on days 4 to 6 of pregnancy were significantly smaller
than the diameter of control embryos (Hoffman et al., 1978).

Also,

when 8 mg indomethacin/kg was administered subcutaneously twice daily
to rabbits on days 4 to 7 of gestation nearly complete inhibition of
fetal development resulted (Hoffman, 1978).

The number of fetuses

that survived to day 14 were smaller than controls and their associ
ated decidual and placental tissues weighed less.

A lower dose of 3

mg indomethacin/kg administered subcutaneously twice daily on days 4
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to 7 of gestation likewise reduced fetal, placental and decidual
weights.
Lacroix and Kann (1982) treated ewes on days 7 to 22 of
gestation with 300 mg indomethacin resulting in diminished embryo
weights on day 23 of treated (67 + 14 mg) compared with embryo
weights of the controls (90.5 ± 28 mg).

These results suggest that

parenteral maternal treatment with prostaglandin antagonists inhibit
embryo development.
Theoretically, embryo diameters at 6x and 12x should be the same
size.

However, diameters in Table 19 show 12x larger than 6x.

Possibly, magnification values differed due to distortion through
medium in the petri dish where the embryo was floating when photo
graphed and/or the lens system in the camera and microscope.
Four embryos did not follow the trend of embryos from control
mares being =1 mm larger than embryos from phenylbutazone-treated
mares.

Variances from the mean were possibly due to the true age of

the embryo.

It was possible that some embryos may have been as much

as 12 hours older than others due to ovulation palpating error, hour
of ovulation, time on day 10 of embryo collection and/or date of
embryo collection.

For example, if a mare ovulated at 2300 day -1

and was collected day 10 late in the afternoon, the embryo would be
at a more advanced growth stage compared with an embryo from a mare
that ovulated at 0700 hours on day 0 and was collected at noon day
10.
Witherspoon and Talbot (1970) reported most mares tend to
ovulate at night between 2300 and 0700.

Neely (1983) reported once

the equine embryo enters the uterus, it increases rapidly in size to
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SI mm diameter by day 8.
(Ginther, 1979).

By day 9, the vesicle diameter is =2 mm

Possibly, the mares producing the smaller control

embryos B and F ovulated early in the morning on day 0.
collected at 1145 and 1245, respectively.

They were

Embryos L, M and N were

collected in September at 1200, 1230 and 1700 hours, respectively.
Embryos M and N from control mares were the last and largest embryos
collected and embryo L was the last and largest embryo collected from
a phenylbutazone-treated mare.

The larger size of these 3 embryos

may have been due to an extra half-day growth when compared to those
embryos collected early in the day.
Day 10 embryos from phenylbutazone-treated mares were approxi
mately the same size as a normal day 8 embryo.

It appeared that as

the breeding season advanced, embryos were larger for both treated
and untreated mares.

However, there was no significant correlation

between season and embryo diameter.

Perhaps late summer hot ambient

temperatures advanced ovulation to early day -1.

It is proposed that

parenteral maternal phenylbutazone treatment rather than season was
the cause of diminished size of embryos from phenylbutazonetreated mares.
Results suggest that maternal phenylbutazone treatment may
inhibit embryo prostaglandin synthesis.
concentrations of PGF (x, PGE
2

2

and PGI

2

Results showed reduced
by embryos from phenylbuta

zone-treated mares compared with those from control mares.

The

diminished synthesis of prostaglandins in embryos from phenylbu
tazone-treated mares compared with those from control mares was not
significant in Experiment V.
significant in Experiment IV.

However, the difference was highly
The reasons for this discrepancy may
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have been due to age of the embryo (day 9 versus day 10) and/or the
difference in methods utilized to prepare the embryo for quantifica
tion of prostaglandin production.
From these data it appears the prostaglandin synthesized in
highest quantity by the day 10 equine embryo is
being intermediate and P G ^

the least synthesized.

with PGF OC
2

This finding

concurs with those from Hwang et al. (1988) who reported bovine
embryos < 12 days of age followed the same pattern of prostaglandin
synthesis.
In summary, results of this study suggested parenteral maternal
phenylbutazone treatment may inhibit embryo expansion and prostaglan
din synthesis, but does not affect fertilization, embryo viability
and total embryo protein.

There is a significant correlation between

chronological advancement (June to October) of breeding season and
increase in total embryo protein.

SUMMARY OF CONCLUSIONS
In Experiment I, 36 estrous cycles of mares chronically treated
with phenylbutazone were evaluated and compared with the reported
normal mare estrous cycle range of 18 to 24 days.

The majority of

cycles (58.3%) were within the average mare estrous cycle range.
Cycles that did not fall within the standard range were slightly
longer (27.8%) or were very prolonged (8.3%).
shorter than usual.

Three cycles were

The mean (± SEM) estrous cycle length for all 36

estrous cycles evaluated was 23.6 ± 0.98 days.

This mean cycle

lengths value concurred with previous experiments conducted by
Archbald et al. (1983).

These researchers used the same mares under

the same experimental conditions as Experiment I and reported mean
cycle length to be 23.1 ± 0.24 and 20.7 ± 0.28 for phenylbutazonetreated and saline-treated control mares, respectively.
Mean length of the estrous cycles was at the high end of the
established

mare estrous cycle range.

This is likely due to the

experimenal period including winter months and the early spring
transitional phase when cycles are usually longer than normal rather
than due to phenylbutazone treatment.

However, it should be consi

dered that phenylbutazone may have had an effect on extending some of
the estrous cycles.

Perhaps phenylbutazone would have inhibited

luteolysis in an experimental group housed in the northern latitudes
where seasonality has a pronounced effect on mare cyclicity.
Thirty-eight ovulations that included 4 double ovulations were
recorded for the same 36 estrous cycles evaluated.
development and ovulation appeared normal.

Follicular

These findings suggest

that chronic phenylbutazone treatment of mares did not inhibit
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follicular development and ovulation.
After these 36 cycles were evaluated, mares were mated by
artificial insemination.

A viable embryo was recovered in 75% of the

saline-treated control mares.

One viable embryo from 5 (20%) phenyl

butazone-treated mares was recovered.

The pyometra exhibited at

embryo collection may have been due to contaminated semen collection
and insemination equipment.

These same mares were used in Experiment

IV but were mated by natural service from a different stallion and
did not exhibit any pyometra.
Results from Experiment I could have been substantiated by
having control mares for the cyclicity part of the experiment and by
more breeding cycles in a switchback design.

This was not possible

due to lack of both available mares and time to breed and collect
embryos before these mares were to be used for another purpose.
Experiment II results determined that phenylbutazone
parenterally administered to mares accumulated in detectible levels
in uterine flushes recovered from inflamed uteri of mares exhibiting
either a high or low concurrent peripheral progesterone concentra
tion.

There was a trend for phenylbutazone positive uterine flushes

to be from mares with a corresponding low progesterone concentration,
as determined in 7 of 9 of the phenylbutazone positive secretions.
Treated mares exhibiting a nonpathological uterine environment had no
detectible phenylbutazone levels in uterine fluids.
Results suggest that phenylbutazone treatment enhanced (P <
0.001) the incidence of uterine infection.

Possibly the pyometra

exhibited in Experiment I was potentiated by the phenylbutazone
treatment.
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Experiment III results suggested that phenylbutazone treatment
will cause inhibition of prostaglandin systhesis and blockage of
luteolysis only in those mares with an existing uterine inflammatory
reaction.

The synthesis and cyclic release of uterine prostaglandin

from a nonpathological equine uterus appears to be unaffected by
parenteral treatment of the mare with phenylbutazone.
Results of Experiment III established a workable model to test
the effect of other NSAID or corticosteroids on luteolysis.
Experiment IV results suggested that fertilization was not
impaired by parenteral treatment of mares with phenylbutazone.
Cellular aspects of the blastocysts recovered from phenylbutazonetreated mares appeared typical; however, the embryos were noticeably
smaller and appeared more fragile than those from control mares.
Assay results suggested that phenylbutazone significantly inhibited
embryo synthesis of prostaglandins.
Results of Experiment IV suggested methods modifications to be
used to design Experiment V.

The embryo collection filter was

removed from the collection system because embryos broke when the
conceptus hit the filter screen.

Results of the prostaglandin assay

led to the decision to collect day 10 embryos and incubate them for
24 hours in 6 ml PB-1 holding medium.

It was decided to subsequently

photograph future embryos to determine diameter.

A homogenization

procedure was added to prepare embryos for the Lowry protein assay.
Results of Experiment V showed there was no significant
difference between embryos from phenylbutazone-treated and saline
control mares for prostaglandin synthesis; however, synthesis of
PGF <x by embryos collected from phenylbutazone-treated mares compared
2
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with embryos from saline control mares approached significance (P =
0.06).

There was a reduced concentration of all 3 prostaglandins

synthesized by embryos from phenylbutazone-treated mares as compared
with embryos from saline control mares.

Results suggested that

maternal phenylbutazone treatment may inhibit embryo prostaglandin
synthesis and embryo expansion, but it apparently does not affect
fertilization, embryo viability and total protein.

There was a

significant correlation between an increase in the length of the
breeding season as it progressed from June to October and an increase
in total amount of protein/embryo.

This phenomenon may have been due

to loss of embryo protein during the longer storage time of embryos
collected early in the season compared with those collected in the
fall.

However, this may also have had a physiological basis.
Results of all experiments suggest that it would be acceptable

to chronically treat a breeding mare exhibiting a nonpathological
uterus with phenylbutazone until conception.

After fertilization,

however, the phenylbutazone may affect embryo development.

Further

studies are needed to access the affect of chronic treatment of
pregnant mares with phenylbutazone on embryo development.

NOTES

Experiment I was published in Veterinary Medicine/Small Animal
Clinician, January, 1983, Volume 78, pp. 83-85.

Appendix III was published in Theriogenology, December, 1986,
Volume 26, pp. 779-793 as part of a validation of this assay for
general veterinary use.

Experiment II was presented at the 36th Annual Meeting of Animal
Disease Research Workers in the Southern States, March, 1983.

Appendix IV

was published in the Journal of Veterinary

Pharmacology and Therapeutics 9, 227-229, 1986.

Experiment III was published in Theriogenology, 23, 381-387,
1985.
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APPENDIX I

Ingredients of modified Dulbecco's
Phosphate-Buffered Saline Solution

Ingredient

Amount (g)

CaCl2 .2H20

1.325

MgCl2 .6H20

1.00

NaCl
KC1
Na2HP04
k h 2p °4

Glucose

80.00
2.00
11.50
2.00
10.00

Streptomycin sulfate

0.50

Na pyruvate

0.36

Penicillin G, sodium
Fetal calf serum
Distilled H20

(1,000,000 IU)
200 ml
q.s. to 10 liters

Adapted Imel et al. (1981)

APPENDIX II

Ingredients of one liter PB-1 embryo holding medium

Ingredient

Amount

Stock Solution
Dulbecco's Phosphate Buffered Saline (PBS)

1 liter

Bovine Serum Albumin (BSA)

4 g

Glucose

1 g

Sodium pyruvate
Phenol red

0.036 g
1 ml

The following ingredients were added to the stock solution
just prior to use.

Fetal Calf Serum (FCS)

10%

Penicillin (IU/ml)

100

Streptomycin (wg/ml)

100
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APPENDIX III
Val|g^tion of a new commercial, solid-phase, no-extraction
I progesterone radioimmunoassay kit for monitoring
luteal function in the mare

OBJECTIVE
To validate a new commercial, solid-phase, no-extraction
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I

progesterone radioimmumoassay kit for monitoring luteal function in
the mare.

MATERIALS AND METHODS
On December 1, 1980, and daily thereafter, a heparinized blood
sample was collected from each mare in Experiment I via jugular
venipuncture.

Samples were immediately placed on ice for storage

until transfer to the laboratory.

Samples were then centrifuged.

Plasma was poured into plastic vials and stored at -20°C until
assayed.
During the sampling interval, mares were monitored via rectal
palpation and teasing to detect ovulation and behavioral estrus.
All samples (n = 547) were assayed by 2 different assay
procedures.

First, plasma samples were assayed for progesterone

using a modified procedure of a previously validated RIA method as
described by Abraham et al., 1971.
used for plasma extraction.

Nano-grade petroleum ether was

Separation of free from bound steroid

was accomplished with dextran-coated charcoal.

The specific antiser

um used was CSU No. 337 (Colorado State University, Fort Collins,
CO).

The intra- and inter-assay coefficients of variation were 9 and

10%, respectively, for a plasma pool averaging 8 ng/ml of progester-
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one.
Secondly, a 100-pl volume of plasma was assayed using the
commercial kit assay (Coat-A-Count No-Extraction Progesterone Assay,
Diagnostic Products Corp., Los Angeles, CA), which had been
previously developed for human serum.

Seven progesterone standards

(0.0, 0.1, 0.5, 2, 10, 20 and 40 ng/ml in human serum) were furnished
with the kit assay for construction of the standard curve.

In

addition, a second set of standards was diluted with stripped equine
plasma to determine if plasma components would interfere with the
binding of the labeled hormone to the antibody.
A correlation analysis was utilized to evaluate relationships
between the 2 assay methods.

RESULTS
An example of plasma progesterone levels from 2 cyclic mares
(No. 1 and 3) from Experiment I using both the extraction assay and
direct no-extraction assay methods are presented in Figure I.
Results from the direct method are regressed against those from the
extraction method for the same 2 mares in Figure II.

For all 9 mares

and all cycles used in the study there was good agreement for proges
terone levels up to 2 ng/ml using both assay methods (Figure II).
Above that level, the direct method resulted in increasingly higher
progesterone values than the extraction method.

Correspondingly, the

slope of the regression line relating the 2 methods was not the same
for all mares (Figure II).

One mare in the group (No. 8) had higher

progesterone values over the full range of sampling when monitored by
the direct method (Figure II).

The reason for this could not be
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ascertained.
A total of 547 plasma samples from 9 cyclic mares was assayed
by both methods.

When all data were included, the formula best

describing the relationship between the 2 progesterone data sets was
exponential with a correlation coefficient of 0.938.

The resulting

equation was y = 1.27(x^*®^), where y was the result of the direct
method and x was the result of the extraction method.
When the human serum standards were diluted 1:1 with stripped
mare's plasma, the percent bound hormone was reduced to an average of
8.1% below the standards of equal progesterone concentration fur
nished with the kit (Figure III).

When this diluted standard curve

was used, the progesterone values for plasma samples were similar to
those resulting from the extraction assay.

These findings suggest

that the 2 assays would have been closer in agreement if the stan
dards were diluted in stripped equine plasma.
Plasma samples with progesterone values ranging between 20 and
28 ng/ml using the direct method were then diluted 1:1 with zero
standards furnished with the kit and sebsequently reassayed.

When

the results were corrected for the dilution, values were within 11.3%
of the undiluted values, indicating that the assay did provide
reproducible progesterone values in this range for mares.
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R e s u l t s fro m a d i r e c t a s s a y r e g r esssed
a g a i n s t results for the same s amples a s s a y e d b y an
e x t r a c t i o n assay.
Data fro m two m a r e s (No. 1 and 3,
see Figure I) w e r e pooled.
V a l u e s f r o m one mare
(No. 8) are p l o t t e d s e p a r a t e l y b e c a u s e the plas m a
s h o w e d e x a g g e r a t e d v a l u e s acro s s all c o n c e n t r a t i o n s
c o m p a r e d w i t h other mares.

181

2.4
2.0
Undiluted Standards

1.6

1.2

0.8
0.4
o> 0 .0

-0.4
-

0.8

-

1.2

-

1.6

-

2.0

Standards Diluted 1:1 with
Stripped Mare Plasma

Log P

C o n c e n tra tio n (ng/m l)

Figure III.
L o g i t - l o g p l o t d e m o n s t r a t i n g the effe c t
of a d d i n g s t r i p p e d m a r e plas m a at a ratio of 1:1 to
the s t a n d a r d s on b i n d i n g of the r a dioactive p r o g e s t 
ero n e to the antibody.

182
DISCUSSION
Results of the extraction, liquid-phase progesterone assay
validated the use of the new, commercial, no-extraction solid-phase
Coat-A-Count progesterone assay kit when exact concentrations are not
necessary above 2 ng/ml.

The extraction, liquid-phase method

presented lower progesterone concentrations when compared with the
Coat-A-Count kit.
The direct, solid-phase RIA kit offers a fast, convenient and
acceptable method for monitoring luteal function during the estrous
cycle of mares.

The direct-assay progesterone concentrations may not

be in complete agreement with those obtained by the extraction,
liquid phase method, especially during diestrus.

If absolute values

for progesterone are required, an extraction step may be desirable
with the direct RIA method.

The practice of diluting the kit stan

dards with stripped equine plasma may be an acceptable alternative.
The kit is of potential use to the equine industry for

(1)

detecting estrus in shy breeders who do not display estrual behavior;
(2) to plan ahead for appointment breedings; (3) to confirm diestrus
progesterone levels and then plan to feed a commercial progesterone
supplement in order to prevent competition mares from coming into
estrus during the meet.
The kit appeared to be acceptable for use in future experiments
when mare cyclicity was to be evaluated rather than absolute proges
terone concentrations.
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APPENDIX IV

Effect of sodium heparin and ethylenediaminotetraacetate
(EDTA) anticoagulants on phenylbutazone levels in equine
plasma detected by high performance liquid chromatography

OBJECTIVE
The objective was to determine whether the anticoagulant used
(sodium heparin or EDTA) alters the results from high performance
liquid chromatography (HPLC) analysis for phenylbutazone in equine
plasma.

MATERIAL AND METHODS
Plasma samples were obtained daily via jugular venipuncture at
approximately the same time each morning before feeding.

A 15 ml

vacutainer (Becton-Dickinson, Rutherford, NJ) containing 286 USP
units of sodium heparin was filled and detached and then an EDTA-K^
(Becton-Dickinson, Rutherford, NJ) tube was placed on the same 20
gauge needle and filled.
ice.

The vacutainers were immediately placed on

After the plasma samples were obtained, each treated mare was

given 2 g phenylbutazone intravenously.

Within 1 hour the vacutain

ers were centrifuged in a refrigerated centrifuge for 10 minutes at
2000 rpm.

The plasma was immediately poured into sterile vials and

stored at -20°C until analysis.

Visual inspection revealed that all

samples were free of hemolysis.
Concentrations of phenylbutazone in all plasma samples were
determined by HPLC as described by Taylor et al., (1981), with minor
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modifications. The organic extraction solvent was removed in a stream
of air in place of nitrogen (Appendix V).

The HPLC solvent (80:20

mixture of n-hexane:tetrahydrofuran containing 0.002% glacial acetic
acid) was delivered at a flow rate of 2 ml/minute rather than 100
ml/hour.

The same HPLC instrumentation was used as in Experiment II.

Peaks were measured with an ultraviolet absorbance detector at
240 nm and 0.1 absorbance units full scale using a strip chart re
corder.

The phenylbutazone and hexoestrol (internal standard) peaks

were measured to the nearest mm by hand from the strip chart record
er.
Forty-two paired heparin and EDTA plasma samples were selected
for analysis.

Each sample was processed in duplicate.

Pairs were

extracted on the same day, dried under an air stream, covered and
stored overnight at room temperature.

The extracted samples were

reconstituted and subjected to chromatography the next day.

Extracts

of the heparinized sample were always chromatographed first followed
by the corresponding EDTA sample.
The phenylbutazone concentration was determined both by using
the internal standard method, and by reference to an external
standard curve of phenylbutazone alone.

A paired Student's t-test

(Snedecor and Cochran, 1980) was performed to determine if any
difference existed between the mean EDTA and heparin plasma
phenylbutazone concentrations by either the internal or external
standard methods.

Linear regression analysis (Snedecor and Cochran,

1980) contrasting the paired values for the 2 anticoagulants was
performed.
was:

The regression equation for the internal standard method
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[phenylbutazone-EDTA] = 0.862[phenylbutazone-heparin] -0.142yg/ml.
For the external standard method the equation was:

[phenylbutazone-EDTAJ = 0.819 [phenylbutazone-heparin] -0.002yg/ml.

When the highly significant difference between plasma phenylbu
tazone levels in samples collected at the same time using different
anticoagulants was observed, a subsequent study was conducted.

Plas

ma samples, either EDTA or heparin, collected from untreated mares
were separately pooled.

Phenylbutazone was added to aliquots of both

the plasma pools at 15 known concentrations.

The plasma samples were

frozen, stored, processed and analyzed as in the first experiment.
Peak height ratios and phenylbutazone peak heights of the paired sam
ples at the 15 known concentrations were evaluated using the Stu
dent's paired t-test.

RESULTS
Using either the internal or external standard methods, the
heparinized samples gave in higher phenylbutazone values (P < 0.01).
Mean plasma phenylbutazone concentrations, calculated with the use of
the internal standard, were 5.49 and 4.59 ug/ml for heparin and EDTA,
respectively, and 4.98 and 4.07 ug/ml by use of the external standard
method.

For both the internal and external standard methods, a high

ly significant (r = 0.96, P < 0.01) linear relationship was noted
between the phenylbutazone concentrations of paired heparin and EDTA
plasma samples.
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Results of the subsequent study using pooled mare plasma spiked
with phenylbutazone showed no significant differences between the
phenylbutazone levels for the heparin or EDTA plasma pools for either
the internal or external standard methods (Table I).

Table

I.

Peak height ratios and peak heights of pooled equine
plasma spiked at 15 known phenylbutazone concentrations

Peak height ratios

t-test value

Internal standard method
Heparin
EDTA

0.313 + 0.06a
0.311 ± 0.06

0.452
(NS)

External standard method
Heparin
EDTA

2.522 + 0.40
2.340 + 0.40

1.007
(NS)

a Mean (± SEM)

DISCUSSION
The initial study demonstrated an apparent difference in plasma
phenylbutazone concentrations dependant on the anticoagulant used
during blood collection.

Heparinized plasma consistently yielded

higher values than EDTA plasma.

For several pairs of samples phenyl

butazone was detected in the heparin sample, but trace levels or no
phenylbutazone was detected in the EDTA sample.

However, when pooled

plasma was spiked with phenylbutazone to make standard curves, no
differences were detected.

For both EDTA and heparin plasma, the

limit of detection was 0.03 yg/ml of plasma.

Therefore, the differ

ence does not appear to be attributable to anticoagulant effects on
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the extraction or assay procedure.

It has been reported (Taylor et

al., 1983) that hemolysis reduces phenylbutazone concentration in
plasma.

No visible hemolysis was detected in any of the plasma

samples used for these studies and does not appear to have been a
factor.

An area which remains unexplored is the effect of the 2

anticoagulants on erythrocytes which could allow sequestration of
phenylbutazone by the erythrocyte.

Apparently the erythrocyte and

its separation from the phenylbutazone containing plasma is critical
to this phenomenon, but no explanation is offered at this time.
The research investigator or regulator of performance horses
and the veterinary practitioner should use heparinized plasma for
phenylbutazone analyses, or at least specify which anticoagulant was
used.

Differences observed in absolute levels were significant and

the potential failure to detect phenylbutazone in an EDTA plasma
sample when it would be detected in heparinized plasma sample must be
considered.

APPENDIX V
Preliminary high performance liquid chromatography
procedures and modifications used to determine if the
published method could be used in Experiment II

Preliminary studies were conducted to determine if the same
analysis method described by Taylor et al. (1981) could be success
fully used in this experiment to determine the concurrent concentra
tions of phenylbutazone in peripheral plasma and uterine secretions
of mares.
Standard solutions were prepared exactly as the published
method and injected several times into the HPLC system.

The standard

phenylbutazone concentration versus the peak height in centimeters
(cm) resulted in a linear relationship as reported.

Then, 10 pi of

the same standards were used to spike 2 ml aliquots of pooled mare
plasma collected in EDTA vacutainers.

The exact extraction procedure

was carried out, specifically removing the solvent in a stream of
nitrogen at room temperature as described.

A relatively linear rela

tionship resulted for aliquots with up to 15 yg phenylbutazone/ml
plasma.

These results indicated that the plasma procedure was

successful.
At this time it was decided to see if the same results could be
obtained by removing the solvent in a stream of air rather than ni
trogen because

(1) a limited supply of nitrogen was available at the

time; (2) nitrogen was too expensive to buy on a limited budget; (3)
1 extraction alone consumed about one half a nitrogen tank; (4) it
would be difficult to keep a large supply of nitrogen on hand consi
dering the number of samples to be analyzed for this experiment.
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Duplicate 2 ml aliquots of EDTA plasma were spiked with 10 pi of 4.0
mg/ml, 2.0 mg/ml or 0.4 mg/ml phenylbutazone standards.
dried with air and the other with nitrogen.

One set was

The results indicated

that there was little difference in peak height and that the possi
bility of using air instead of nitrogen should be further explored
(Table II).

Table II.

First results of plasma phenylbutazone (PBZ) standards
dried in either a stream of ^ or air

Peak Height (cm)
Plasma Std. Cone.
(ygPBZ/ml plasma)

20.0
10.0
2.0

Air
4.45
1.09
2.07

Nitrogen
5.45
1.06
2.07

Next, the lowest and highest standard phenylbutazone
concentrations were analyzed either dried in air or nitrogen (Table
III).
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Table III.

Second results of plasma phenylbutazone (PBZ) standards
dried in either a stream of air or

Peak Height (cm)
Plasma Standard Concentration
(ygPBZ/ml plasma)

Air_________ Nitrogen

2.0

1.60
1.65
1.95
1.75 *
deleted

1.50
1.15
1.15
1.20
1.10

Statistics
Mean
SEM
CV
t-test
df

=
1.74
=
0.15
=
8.91%
= 4.8808
= 7

1.22
1.61
13.20%
(P < 0.005)

Technical error

20.0

Mean
SEM
CV
t-test
df

4.80
4.15
5.30
5.00

4.70
4.50
5.10
5.35

=
4.81
=
0.49
=
10.10%
= -0.3225 (NS)
=
6

4.91
0.38
7.80%
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These results indicate that at the lower phenylbutazone
concentrations there is a significant difference between drying with
air and nitrogen, with the mean peak height of the air samples being
greater than the nitrogen samples.

At the higher phenylbutazone

concentrations, no significant difference between the 2 drying
processes was demonstrated.

Considering the circumstances and these

results, it was decided to air dry at room temperature all future
samples.
Another standard curve was run with all samples being dried in
a stream of air.

Two ml aliquots of pooled EDTA mare plasma were

spiked with 10 pi of the standard solutions.

The standards were made

in August, 1982, and this data was collected in December, 1982.

It

had been reported by previous researchers that the standards could be
kept in the refrigerator for at least a month without significant
degradation (Burns et al., 1953).

Even though peak height versus

phenylbutazone concentration resulted in a linear relationship (r =
0.9942) it was decided to avoid contamination and dilution effects
(caused by opening and closing the standard vials) by discarding
these standards and making new ones.

In the future, new standards

were to be made and used for only approximately a month.

192
APPENDIX VI

High performance liquid chromatography preliminary
procedure to determine if phenylbutazone concentrates in
supernatant or sediment of uterine fluids

Purulent yellow uterine flushing secretions collected from
control mares were pooled, measuring 250 ml.
stirred with a magnetic stirer for 20 minutes.

The solution was
Then, 800 pi of 0.05

mg/ml phenylbutazone standard was added and the mixture was stirred
for 30 minutes.

Then, it was centrifuged at 2800 rpm for 20 minutes.

The supernatant was poured off in 20 ml aliquots into 6 tubes.

The

sediment pellet was resuspended in the remainder of the supernatant,
measuring 125 ml.
The supernatant and resuspended sediment pellet solutions were
divided into 25 ml aliquots and were analyzed in duplicate as
described in Experiment II.

An unpaired Student's t-test comparing

chromatographic phenylbutazone peak heights of the supernatant and
the sediment determined that phenylbutazone concentrates in the
supernatant (P < 0.05) of uterine secretions.
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APPENDIX VII
High performance liquid chromatography interassay,
intrassay and limit of detection study

Determination of Reproducibility and Standard Curve
An interassay and intrassay study utilizing pooled plasma
spiked with the standard phenylbutazone solutions was conducted in
triplicate.

Discrepancies were minimized in each assay by taking all

samples from the same plasma pool, using only the fresh standards,
and running the whole set of samples from the same batch of mobile
phase.

Each time, the samples were extracted one day and allowed to

sit covered overnight at room temperature and were assayed the next
day.

Three sets of triplicate samples were assayed.

Two ml of

pooled EDTA mare plasma was spiked with 10 yl of standard solutions
of 0.00, 0.05, 0.10, 0.20, 0.40, 1.0, 2.0 or 4.0 mg phenylbutazone
/ml.

Three samples of each concentration were analyzed in each

assay.

Determination of Limits and Percent Recovery
The next study was to determine the extraction limit of
detection, the HPLC instrument limit of detection and the percent
recovery from both EDTA and heparin plasma samples.

All samples were

again extracted one day, and assayed the next day.
Both EDTA and heparin plasma samples were assayed together
under the same experimental conditions to compare results.
separate plasma assays were conducted.

Two

Each plasma sample contained

2 ml aliquots of pooled heparin or pooled EDTA plasma plus a known
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amount of a single, 0.1 mg/ml standard solution.

Both the EDTA and

heparin samples were run in duplicate spiked with 2, 4, 8, 10, 12,
14, 16, 20, 22, 25, 30, 40, 45 or 50 pi aliquots of 0.1 mg/ml
standard.

Hamilton syringes were used to spike the samples.

All

plasma residues were reconstituted with 150 pi tetrahydrofuran and 10
pi were injected into the HPLC instrument.

An instrument limit of

detection was conducted at the same time as the extraction limit of
detection in order to determine the percent recovery.

All samples in

each assay were run with the same batch of mobile phase.

Care was

taken to maintain the same experimental conditions for all plasma and
instrument samples within an assay.
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APPENDIX VIII
High performance liquid chromatography preliminary
uterine flushing study

The amount of uterine flushing from phenylbutazone-treated
mares necessary to elicit a positive response was determined by trial
and error.

A standard curve and a spiked uterine flushing sample

were run with each assay to confirm that the extraction procedure
worked.

Two, 3, 4 and 5 ml aliquots of uterine flushings were

assayed from mares giving a phenylbutazone positive plasma sample.
The uterine samples were extracted and analyzed the same as plasma.
All cloudy uterine samples from untreated mares were negative
for phenylbutazone.

Flushings from 2 treated mares which appeared

yellow and contained a sediment of purulent material were assayed in
duplicate using 1, 4 and 8 ml aliquots.

Plasma samples were phenyl

butazone positive, but all uterine flushings were negative.

Next,

six 25 ml aliquots of flushings classified as clear (2), cloudy (2)
or yellow purulent (2) were extracted.

The extraction procedure was

the same as plasma with the following exceptions

(1) 2 ml HCL was

used to deproteinize; (2) the residue was reconstituted with 50 yl
tetrahydrofuran.
zone positive.

All corresponding plasma samples were phenylbuta
The 4 clear or cloudy flushes were negative, but the

2 purulent yellow flushes were phenylbutazone positive, one eliciting
a phenylbutazone peak of approximately 40 parts per billion (ppb) and
the other 120 ppb.

It was then decided that all uterine flushings

would be extracted as above in 25 ml aliquots because a positive
response was obtained and it was a convenient size considering the

196
centrifuge and other laboratory equipment available.
The uterine flushing limit of detection and percent recovery
study was conducted with pooled uterine flushings from the control
mares.

Twenty-five ml aliquots of flushings were spiked with 2, 4,

8, 10, 14, 16, 20, 22, 25, 30, 35, 40, 45 or 50 yl of 0.1 mg/ml
standard solution.

The residue was reconstituted with 50 yl of

tetrahydrofuran and 10 yl of each sample were injected into the HPLC
machine.
Next, an interassay and intraassay coefficient of variation was
conducted on the uterine secretions.

Four separate assays were run

with 4 samples of 20, 25, 30 or 35 yl of 0.1 mg/ml standard solution
in 25 ml aliquots of pooled flushing.

Again, the residue was

reconstituted with 50 yl tetrahydrofuran and 10 yl of each sample was
injected into the HPLC instrument.
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